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Abstract 
 
Tina L Stevens: A Study of the Mechanisms of Diesel Exhaust Enhanced  
Allergic Lung Disease 
(Under the direction of Dr. M. Ian Gilmour) 
 
 
 
 Over the last several decades, epidemiologists have witnessed a rapid rise in the 
prevalence and severity of asthma. While the factors underlying this increase are clearly 
complex, environmental factors such as ambient particular matter (PM) appear to play a 
role. Diesel exhaust particles (DEP), a large contributor to vehicle derived PM, has been 
shown to act as an immunologic adjuvant when given with antigen; however, there is still 
a lack of understanding as to what component(s) are responsible for these effects and the 
underlying mechanisms through which they act. In this work, immunotoxic and genomic 
responses of three chemically distinct DEP samples were assessed in an ovalbumin 
(OVA) murine mucosal sensitization model. Immunotoxic endpoints in the lung after 
OVA challenge demonstrated C-DEP/OVA ≈ A-DEP/OVA > N-DEP/OVA with respect 
to adjuvancy. To elucidate possible mechanisms for these effects, global gene expression 
changes in the lung were assessed. While all three DEP/OVA treatments induced 
expression of cytokine and toll-like receptor pathways, only A- and C-DEP/OVA 
treatments altered expression of apoptosis pathways. In addition, C-DEP/OVA treatment, 
which induced the greatest TH2 response post-sensitization, altered expression of DNA 
damage pathways. This comprehensive approach using gene expression analysis to 
examine changes at a pathway level provides a clearer picture of the events occurring in 
 iii 
the lung after DEP exposure in the presence or absence of antigen. This work also 
explored immune responses in mice acutely exposed to moderate doses of DE in an OVA 
mucosal sensitization model and identified possible mechanisms using genomics. Mice 
exposed to DE/OVA induced a mild adjuvant response. Expression analysis 
demonstrated DE/OVA altered oxidative stress and metabolism pathways. Together these 
results demonstrate that exposure to even moderate doses of an air pollutant, such as DE, 
can enhance allergic sensitization through oxidative stress and inflammatory pathways. 
Overall the results demonstrate all three DEP samples and DE induced adjuvancy, the 
extent of which was not solely dependent on the extractable organic content, and gene 
expression analysis was a more sensitive indicator of early signaling events than the 
classical immunotoxic endpoints.   
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Introduction 
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1.1 Particulate Air Pollution 
 Epidemiological studies have demonstrated that exposure to ambient air 
particulate matter (PM) is positively associated with increases in mortality and morbidity 
due to respiratory illness [1-4].  While ambient PM can originate from natural sources 
such as volcanoes, forest fires, dust storms, and sea spray, a significant portion is 
generated from a variety of anthropogenic activity. These types of activities include 
agricultural operations, industrial processes, combustion of wood and fossil fuels, 
construction and demolition activities, and vehicle emissions.  Recognizing the 
detrimental respiratory as well as cancer and cardiovascular health effects of PM, through 
the Clean Air Act initiative, the Environmental Protection Agency (EPA) set National 
Ambient Air Quality Standards (NAAQS) regulating PM along with five other criteria 
pollutants. The 2006 revised standards limits particles with a mass median aerodynamic 
diameter (MMAD) of < 2.5 µm (PM2.5, fine) and those which are smaller than 10 µm 
but larger than 2.5 (PM10, coarse). The current 24-hour exposure standards are 35 µg/m3 
for PM2.5 and 150 µg/m3 for PM10. The annual fine particle exposure standard is 15 
µg/m3 and no annual PM10 exposure limit exists. In addition to PM10 and PM2.5 there is
also PM0.1 (ultra-fine). These are generally defined as having an MMAD < 0.1 µm and 
are not directly regulated by the NAAQS per se because they contribute very little mass
they are indirectly regulated through their presence in the PM2.5 and PM10 fractions [5].  
Coarse particles, consisting of inorganic minerals from wind erosion of crustal 
material (Al, Si, Ca, Fe, Ti), road dust (brake linings, tire residue), and bioaerosols 
(pollen, mold spores) [6], mainly deposit in the upper airways where they are removed by 
the body’s mucociliary clearance system resulting mainly in gastrointestinal exposure and 
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have been shown to induce pulmonary inflammation in rodents [7, 8]. Fine and ultra-fine 
particles, generated in combustion or formed from gases, can be more toxic to the lower 
airways because they are more readily inhaled [9], can reach the alveoli in a higher 
proportion than coarse where no cilia are present, and exhibit long atmospheric residence 
time [10].  
 In vitro and in vivo toxicology studies have demonstrated that ultra-fine carbon 
and titanium dioxide particles are more toxic than larger particles with the same 
chemistry with respect to pro-inflammatory and oxidative stress endpoints in A549 
human epithelial cells and a slower pulmonary clearance rate and greater inflammation in 
rats [9, 11] These effects have been attributed to the ultra-fine particles having a larger 
surface area and the ability to penetrate epithelial cells more readily than their larger 
counterparts. This in turn leads to a greater generation of reactive oxygen species on the 
surface [12], as well as better ability to activate signal transduction pathways important in 
inflammation, injury, and repair [13]. Researchers have used diesel exhaust particles 
(DEP) as a model PM pollutant to understand the impact of PM on the genesis and 
exacerbation of asthma. Several groups have demonstrated that DEP can act as an 
adjuvant when combined with an allergen, resulting in enhanced IgE antibody 
production, increased allergic inflammation and airway hyperresponsiveness (AHR) in 
mice [14-16]. 
 
1.2 Diesel Exhaust Characteristics 
Diesel Exhaust (DE) is produced after combustion of diesel fuel in compression-
ignition on road engines such as buses, trucks, and other heavy industrial transport 
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vehicles, as well as numerous off-road sources such as generators. It is a common 
contaminant of ambient air in urban and rural environments. DE comprises of particles 
and gases representing thousands of different chemical substances, of which at least 40 
are considered to be hazardous air pollutants by the Environmental Protection Agency 
(EPA). The chemical compounds in DE depend on the type and age of the engine, type of 
fuel and additives, type of emission control equipment, how the engine is maintained and 
operated, and after treatment.  
Although emissions have been reduced by improved control technologies, the use 
of diesel engines has continued to increase as indicated by EPA trends reports of vehicle 
miles traveled (http://www.epa.gov/OMS/fetrends.htm). DE contains approximately 20-
100 times more particles (DEP) than gasoline exhaust. About 90% of these particles are 
<1 µm and therefore are readily respirable and deposit in the lower respiratory tract. The 
particles consist of a carbon sphere surrounded by metals (i.e. iron, copper, chromium, 
and nickel) and thousands of organic constituents including various absorbed 
hydrocarbons such as aldehydes, benzene, nitrosamines, quinones, polycyclic aromatic 
hydrocarbons (PAHs; including phenanthrene, fluorenes, naphthalenes, pyrenes, 
fluoranthrenes), and nitro-PAHs.  The vapor and gaseous phase includes olefins (1,3-
butadiene), aromatics (benzene, ethylbenzene, toluene, and xylenes), alkanes, and 
aldehydes (formaldehyde and acetaldehyde) as well as oxides of nitrogen, carbon, and 
sulfur. After being emitted, diesel particles undergo “atmospheric ageing” (oxidation, 
nitration, or other chemical and physical changes) [17]. The atmospheric lifetime of the 
various compounds found in diesel exhaust is dependent on the particle size and can vary 
from hours to days. Particles smaller than 1 µm can remain in the atmosphere for up to 15 
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days and maybe transported over long distances. 
Human exposure to DEP ranges from 1.5 to 1700 µg/m3 depending upon 
proximity to source(s), ventilation rates, and dilution into surrounding air. The California 
Air Resources Board reported the average total DEP exposure for Californians to be 1.5 
µg/m3.  While the ambient DEP concentrations nationwide are relatively low, levels of 
DEP in certain urban areas can be considerably higher.  In 1996, PM2.5 was measured as 
a surrogate for DEP and found to be 37-47 µg/m3 at an intersection in the Harlem section 
of New York City [18]. Concentrations as high as  130 µg/m3 in a car following an urban 
transit bus making numerous stops were detected using real-time aethalometer carbon 
black measurements as an indicator of DEP concentrations [19].  Occupational exposure 
can be even greater.  The Health Effects Institute estimates average exposure over an 8 hr 
work day to be up to 100 µg/m3 for trucking and transportation occupations, 17-134 
µg/m3 for railroad locomotive shop workers, and 100-1700 µg/m3 for underground 
miners in proximity to diesel engines [20]. Those most likely to be exposed to diesel 
exhaust in occupational environments include mine workers, tunnel and loading dock 
workers, auto mechanics, toll booth collectors, truck and forklift drivers and others who 
work in areas where diesel powered vehicles are used, stored and maintained.  
Part of the difficulty in studying the health effects of DEP is the heterogeneous 
characteristic of the mixture. The chemical composition of DEP has been shown to alter 
its biological activity [21]. A study published in our laboratory compared the toxic effects 
of two DEP samples, one from an automobile DEP (A-DEP) and another from the 
National Institute of Standards Technology Standard Reference Material 2975 generated 
from a forklift engine (N-DEP).  The chemical properties of these samples were 
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dramatically different.  On a mass basis, A-DEP had more extractable organic material 
while the N-DEP was composed mostly of elemental carbon.  Intratracheal instillation of 
A-DEP in mice induced macrophage influx and stimulated an increase in cytokines 
interleukin (IL) -5, IL-6, TNFα, and MIP-2 while N-DEP enhanced neutrophil influx and 
IL-6.  These effects provided evidence for our hypothesis (discussed in more detail later) 
that DEP with different chemical profiles can have varied adjuvant potential in an allergic 
mouse model.  
 
1.3 Increased Prevalence of Asthma  
There has been a marked increase in the prevalence of allergic diseases such as 
asthma in industrialized countries over the last quarter of the 20th century [22, 23] with a 
trend toward more developed and westernized countries having higher asthma 
prevalence.  In the United States, allergic diseases affect 17% of the population and are 
the sixth leading cause of chronic illness [24]. An estimated 22 million Americans suffer 
from asthma, 6.5 million of which are children. According to National Health Interview 
Surveys, the asthma rate among US children more than doubled from 3.6% in 1980 to 
8.9% in 2005. The factors driving this increase are still not fully understood.  
Epidemiology studies have suggested that socioeconomic and ethnicity are risk 
factors for asthma development. Asthma prevalence is higher among families with lower 
incomes. Racial disparities are also evident in asthma prevalence. Respectively, 
American Indian or Alaska Native and black children have 25% and 60%, higher 
prevalence rates than white children. Social and environmental risk factors are 
highlighted by higher asthma rates in US-born Mexican populations than non-US born 
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Mexicans living in the US [25].  
Asthma and allergies have a strong hereditary and hence genetic component. 
Children with one parent who has asthma are three to six times more likely to develop the 
disease, and children with two parents with asthma are 10 times more at risk than those 
children whose parents do not have asthma. Over 100 genes have been associated with 
asthma , 25 of which are associated with asthma in six or more separate populations 
studies [26]. Many of these genes such as IL-4, STAT6, IL-13, TNFα, TGF-β, are related 
to the immune system or to modulating inflammation. While this does not prove a genetic 
cause it certainly reflects a modest effect of these genes on risk. Nevertheless, the rapid 
increase in the prevalence of asthma in the last decades is unlikely to be caused by 
genetic changes alone.  
Environmental factors appear to play a role. Many researchers have contributed 
the rise in asthma to our “western” lifestyle suggesting our diet [27], cigarette smoke 
[28], and inhalation of air pollution from indoor and outdoor sources [22, 29-31]. There is 
sufficient epidemiologic and animal data to suggest that some synergism exists between 
allergen exposure and exposure to air pollutants (primarily outdoor) in the induction of 
asthma in children and possibly adults [32, 33].While a combination of factors mentioned 
probably contribute to the increased allergy prevalence among individuals living in 
urbanized areas, this dissertation will focus on the effects of diesel exhaust and diesel 
exhaust particles on the development of allergic airway disease. 
 
1.4 Allergic Asthma 
 Asthma is a chronic inflammatory disease of the airways, characterized by 
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reversible airway obstruction and accumulation of lymphocytes and eosinophils in the 
lung. It can be divided into two sub-types, allergic and non-allergic asthma.  Of the nearly 
20 million Americans suffering from asthma, greater than 60% have allergic asthma [34].  
Allergic asthma is a TH2 lymphocyte mediated inflammatory disease which features high 
serum levels of allergen-specific IgE, and upon allergen challenge, results in airway 
eosinophilia, excess mucus production, and bronchoconstriction.  
 Allergy and allergic diseases like asthma normally develops in two phases. The 
first phase (induction) is induced when the susceptible individual initially encounters the 
allergen. A primary immune response is mounted that results in a state of heightened 
responsiveness to that particular antigen (specific sensitization). Subsequent exposures 
(challenge) of the now sensitized individual to the allergen evokes a more vigorous and 
accelerated secondary immune response. Overt outward adverse health effects are 
normally first recognized during this secondary immune response against the allergen and 
these symptoms present themselves as local tissue disruption and inflammation. 
With allergic asthma, symptoms are triggered by an allergic reaction after 
inhalation of common allergens, such as cockroach and dust mite feces, animal dander, 
molds, and seasonal pollens.  These environmental sensitizers have been ubiquitous as 
long as people have lived in the world, but in the last 50-100 years a growing and 
significant percentage of the population (particularly in developed countries) have 
developed an allergic response to these proteins [35].  This short timeframe suggests that 
environmental pollutant exposures are contributing to this increase as opposed to a 
significant change in the gene pool.  Changes in lifestyle including alterations in diet, 
activity patterns, medication use, housing conditions, and possibly other factors have 
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undoubtedly had an impact on the sensitization rate. Epidemiology studies have also 
shown that increases in ambient particle matter (PM) are correlated with increased 
hospitalizations due to respiratory illness including exacerbation of pre-existing asthma 
[3, 36, 37].  Furthermore, there is mounting evidence linking air pollution with an 
increased risk of developing asthma [38-40]. 
 
1.5 Molecular and Cellular Basis for the Inflammatory Events in Asthma 
 
1.5.1 T helper 1 (TH1) and T helper 2 (TH2) lymphocytes  
         In 1986, the existence of two CD4+ TH cell subsets was discovered in mice, and 
they were designated TH1 and TH2 [41]. Their identification has greatly improved 
understanding of the regulation of immune effector functions. These TH subsets are 
defined by the patterns of cytokines that they produce. TH1 cells secrete Interleukin (IL)-
2, IFNγ, IL-12 while TH2 secrete IL-4, IL-5, IL-6, IL-10, and IL-13. The differences in 
the cytokines secreted by these cell types determine their biological function. TH1 subset 
is responsible for many cell-mediated functions such as delayed-type hypersensitivity 
(DTH) and for the production of opsonization-promoting IgG antibodies.  TH2 cells 
stimulate eosinophil activation and differentiation, are more efficient B cell helpers, and 
promote the production of IgE and non-complement-activating IgG antibodies (in mice, 
IgG1). In addition, they cross-regulate by producing mutually antagonistic cytokines. For 
example, IFN-γ preferentially inhibits proliferation of the TH2 subset, and IL-4 and IL-10 
down-regulate secretion of IL-12. A shift in the predominant T cell population from TH1 
type to the TH2 type has been associated with asthma [42] (Figure 1.1) 
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1.5.2 Eosinophils  
Airway eosinophilic inflammation is a classical characteristic feature of allergic 
asthma. Eosinophils are regarded as effector cells responsible for much of the 
pathophysiology of asthma, playing a major role in the onset and maintenance of 
bronchial inflammation and tissue injury. They are known to be an indirect marker of 
asthmatic airway inflammation, the severity of which has been shown to be dependent on 
eosinophil accumulation and activation within the airways [43-45] 
A series of events occurs, directed by TH2 cells, to cause eosinophils to arrive in 
the airway and promote obstruction, injury, and bronchial hyperresponsiveness. These 
steps include proliferation and differentiation of eosinophils in the bone marrow, 
migration through the vascular endothelium into the lung tissue, and activation and 
release of toxic granules. 
Cytokines such as granulocyte monocyte colony stimulating factor (GM-CSF), 
IL-3, and IL-5 signal bone marrow progenitor cells to proliferate, differentiate into 
eosinophils, and release the cells into circulation [46].  IL-5 is the most selective for 
eosinophil differentiation, proliferation, and maturation within the bone marrow, as IL-3 
and GM-CSF can act on various other cell types [47].  
Eosinophil recruitment from the circulation into the lung tissue results from the 
complex mechanisms that involve vascular adhesion molecules, extracellular matrix 
proteins, and chemokines. The initial reversible tethering and rolling of eosinophils on 
the endothelium results from the formation of numerous weak reversible bonds between 
integrins expressed on eosinophils and endothelial adhesion molecules, such as very late 
activation antigen-4 (VLA-4) and vascular cell adhesion molecule-1 (VCAM-1), 
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respectively. The tethering and rolling of eosinophils is followed by chemokine mediated 
stable integrin-adhesion binding which firmly tethers the cells to the endothelium[48]. 
Integrinβ2 (Itgβ2) binds to intercellular adhesion molecule-1 (ICAM-1) on the 
endothelium resulting in firm cellular arrest that is critical for transmigration. Binding of 
CC chemokines (eotaxin, eotaxin-2, RANTES, and MCP-3) to their receptors (CCR3 and 
CCR5) on eosinophils leads to the formation and retraction of lamellipodia, which gives 
the cells “arms” and “feet” to migrate into the tissue. Transendothelial migration also 
requires the function of matrix metalloprotease-9 (MMP-9) which degrades membrane 
fibers, allowing eosinophils to penetrate the basement membrane [49].  
Once in the tissue, eosinophils can become activated and express a number of 
receptors for cytokines, as well as chemokines, immunoglobulins, and complement. The 
cytokines IL-3, IL-5, and GM-CSF prolong eosinophil survival, increase free oxygen 
radical production, and induce eosinophil degranulation.  
The proteins stored in eosinophil granules are major basic protein (MBP) eosinophil 
cationic protein (ECP), eosinophil peroxidase (EPO) and eosinophil derived neurotoxin 
(EDN). When released these granules directly cause mucosal injury and contribute to the 
disturbances in lung physiology. In addition, eosinophils generate lipid mediators, 
including platelet-activating factor, leukotrienes B4 and C4, as well as cytokines and 
chemokines, such as IL-5 and GM-CSF, which amplify the inflammatory response by 
recruiting and activating leukocytes and epithelial cells [50, 51].   
 
1.5.3 IgE and IgG1 antibodies     
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  IgE antibodies play a major role in allergy and asthma. These antibodies are 
primarily synthesized in the lymphoid tissue of the respiratory and gastrointestinal tracts. 
The regulation of IgE production appears to be a function of T cells. TH2 cytokines, in 
particular IL-4 and IL-13, stimulate B cells to switch to producing IgE antibodies [52]. 
Co-stimulatory interaction between CD40 ligand on the T cell surface and CD40 on the B 
cell surface is also essential for antibody class switching.  
  IL-4 further enhances IgE-mediated immune responses by up-regulation IgE 
receptors on the cell surface: the low-affinity IgE receptor (FcεRII or CD23) on B cells 
and mononuclear cells and the high-affinity IgE receptor (FcεRI) on mast cells and 
basophils[53]. Once an individual has become sensitized, the specific antigen binds to the 
IgE-Fc receptor complex and the cells release mediators such as histamine and secrete 
IL-4 [54].  
 In the mouse, mast cell activation induced by the interaction of IgE and mast cell 
FcεRI receptor is well characterized, however, the interaction of IgG1 and mast cell 
FcγRIII receptor can also induce mast cell activation and degranulation. Indeed, loss of 
the FcεRI alpha chain results in an enhancement of FcγRIII mast cell degranulation. It is 
important to note that while TH2 cells induce IgG1 and IgE in mice, in humans TH2 cells 
induce IgE and IgG4.  
 
1.5.4 Interleukin 4 (IL-4) 
IL-4 is a key cytokine in the development of allergic inflammation. Not only is it 
associated with induction of the ε isotype switch and secretion of IgE by B cells [52], but 
it also induces expression of vascular cell adhesion molecule-1 (VCAM-1), promotion of 
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eosinophil transmigration across endothelium, mucus secretion, and differentiation of T 
helper type 2 lymphocytes leading to cytokine release.  
IL-4 contributes to airway obstruction in asthma through the induction of mucin 
gene expression and the hypersecretion of mucus in mice and human cell lines [55], and 
increases the expression of eotaxin and other inflammatory cytokines from human lung 
fibroblasts that might contribute to inflammation and lung remodeling in chronic asthma 
[56]. 
An essential biological activity of IL-4 in the development of allergic 
inflammation is the ability to induce differentiation of naïve T helper type 0 (TH0) 
lymphocytes into TH2 lymphocytes [57, 58]. These TH2 cells then proceed to secrete IL-
4, IL-5, IL-10 and IL-13. The induction of TH2-like lymphocytes is a unique biological 
activity of IL-4 because IL-4 receptors and not IL-13 receptors are expressed on T cells 
[59].  
An important activity of IL-4 in promoting cellular inflammation in the asthmatic 
lung is the induction of vascular cell adhesion molecule (VCAM)-1 on vascular 
endothelium[60]. Through the interaction of VCAM-1, IL-4 is able to direct the 
migration of T lymphocytes, monocytes, basophils, and eosinophils to the site of 
inflammation. IL-4 also promotes eosinophilic inflammation by inducing eosinophil 
chemotaxis and activation through the increased expression of eotaxin. In addition, IL-4 
is important in allergic immune responses owing to its ability to prevent apoptosis of T 
lymphocytes and eosinophils.  
 
1.5.5 Interleukin 5 (IL-5) 
 14 
  The production of IL-5 by activated T cells is a key event in the induction of 
eosinophilic inflammation. Although  activated T-helper cell populations are the main 
source of IL-5, secretion from other cell types (eosinophils, mast cells, CD4+ and CD8+ T 
cells) have been reported [61]. IL-5 is the primary cytokine involved in activation and 
survival of eosinophils and marked proliferation and maturation of eosinophil precursors 
[62]. Transgenic mice in which IL-5 is constitutively expressed show a profound and 
lifelong eosinophilia. IL-5 has also been shown to augment airway hyperresponsiveness 
in asthma[63].  
 
1.5.6 Interleukin 13 (IL-13) 
IL-13 is produced by activated T cells, B cells and mast cells. In the mouse, 
almost exclusively TH2 clones express IL-13, however, in humans it can be expressed in 
both TH1 and TH2 cells [64].  IL-13 is a cytokine closely related to IL-4 and binds to IL-
4Rα receptors [65]. It is present in increased amounts in asthmatic airways and has very 
similar biological activities to IL-4 [66, 67]. IgE production and the induction of VCAM-
1 are activities shared with the related cytokine IL-4.  In addition both cytokines inhibit 
transcription of IFNγ and both α and β chains of IL-12. Thus, IL-13 may (like IL-4) 
suppress the development of TH1 cells through down-regulation of IFNγ and IL-12 
production by monocytes, favoring the generation of TH2 cells. There is a significant 
correlation between eosinophil BALF counts and levels of IL-13 in animal models of 
allergic asthma [68, 69]. Mice administered IL-13 exhibited goblet cell hyperplasia and 
mucus glycoprotein accumulation in the airways [70].  
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1.5.7 Interleukin 10 (IL-10) 
IL-10 is another TH2 cytokine, but its pathophysiological role in asthma has not 
been clearly elucidated. Some evidence suggests that IL-10 production is reduced in 
patients with asthma compared with nonasthmatic control subjects [71], and murine 
studies provide evidence that IL-10 suppresses development of eosinophilic inflammation 
in the airways. Robinson et al. [72] found IL-10 mRNA was increased in BALF cells in 
response to allergic sensitization and challenge.  
Administration of recombinant IL-10 reduced allergen-induced eosinophilic 
airway inflammation but increased airway hyperreactivity [73]. IL-10-induced airway 
reactivity may be linked to release of histamine. IL-10 has been shown to increase murine 
mast cell and basophil proliferation, differentiation, and degranulation [74] and stimulate 
MCP-1 production [75, 76]. MCP-1 suppresses monocyte production of IL-12 and is a 
potent stimulator of histamine release. Depletion of MCP-1 has been shown to reduce 
airway reactivity without attenuating eosinophilia [77]. Therefore IL-10 may induce 
airway hyperreactivity through MCP-1 production.  
 
1.5.8 Interleukin 1 (IL-1) 
The major cellular sources of the pro-inflammatory cytokine IL-1 are monocytes, 
macrophages, neutrophils, eosinophils, mast cells, platelets, lymphocytes, NK cells, 
endothelial cells, and airway smooth muscle cells. Nakae et al. [78] reported IL-1 plays 
important roles in the development of AHR. AHR, OVA-specific T cell proliferation, IL-
4 and IL-5 production by T cells, and IgG1 and IgE production by B cells were markedly 
reduced in IL-1 deficient mice compared with wild-type mice in an OVA-induced AHR 
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model. In addition, patients with symptomatic asthma showed increased levels of IL-1 in 
BAL fluid compared with patients with asymptomatic asthma [79]. IL-1 increased the 
expression of ICAM-1, E-selectin, and VCAM-1 in human bronchial tissue [80]. 
 
1.5.9 Tumor necrosis factor α (TNFα)  
TNFα is another pro-inflammatory cytokine that is present abundantly in 
asthmatic airways. It is produced by many cells including macrophages, T cells, mast 
cells, and epithelial cells, but the principal source is the macrophage. Like IL-1, TNFα 
also increased the expression of ICAM-1, E-selectin, and VCAM-1 in human bronchial 
tissue [80]. There is evidence that IgE triggering in sensitized lungs leads to increased 
expression in epithelial cells in both rat and human [81]. TNFα is present in the BAL 
fluid of asthmatic patients[82]. It is reported that TNFα is also released from alveolar 
macrophages of asthmatic patients after allergen challenge [83].  
 
1.5.10 Interleukin 6 (IL-6) 
The pro-inflammatory cytokine IL-6 is secreted by monocytes/ macrophages, T 
cells, B cells, fibroblasts, lung epithelial, and endothelial cells [84, 85]. IL-1 or TGFβ can 
increase IL-6 release from airway smooth muscle cells and fibroblasts [86, 87]. IgE-
dependent triggering stimulates the secretion of IL-6 from both blood monocytes and 
alveolar macrophages in vitro [88] Increased production of IL-6 was observed in the 
BALF of patients with allergic asthma at baseline compared to control subjects and a 
further increase was measured after challenge[89, 90].  
 
1.5.11 Granulocyte monocyte colony stimulating factor (GM-CSF)  
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GM-CSF is a pleiotropic cytokine that can stimulate and regulate growth, 
proliferation, maturation, and function of hematopoietic cells. Several airway cells 
produce GM-CSF, including macrophages, eosinophils, T-cells, fibroblast, endothelial 
cells, airway smooth muscle cell, and epithelial cells [91]. Elevated levels of GM-CSF 
have been well described in BALF, endobronchial biopsy, and sputum samples from 
asthmatics [92-94]. Elevated levels of GM-CSF, largely derived from epithelial cells, 
have been demonstrated to increase eosinophil activation and survival in asthmatics [95-
97]. GM-CSF not only influences eosinophils chemoattraction and activation but also 
participates in the etiology of bronchial hyperresponsiveness in mild asthma. Dendritic 
cells have been demonstrated to be essential for presenting inhaled Ag to previously 
primed TH2 cells, and thus for chronic eosinophilic airway inflammation [98, 99]. GM-
CSF is a critical factor for dendritic cell maturation, increased expression of accessory 
molecules such as ICAM-1, B7-1 (CD80), and B7-2 (CD86), and dendritic cell 
recruitment into the airway in murine models of asthma [99-101]   
 
1.5.12 Monocyte chemoattractant protein 1 (MCP1/CCL2)  
MCP-1 is a member of the cc family of chemokines. It was initially identified as a 
monocyte-specific chemoattractant, but now has also been shown to attract activated T 
cells, NK cells, and basophils. MCP-1 displays immunoregulatory functions and may be 
involved in TH2 differentiation. MCP-1 modulates the differentiation of monocytes into 
DCs. DCs generated in the presence of MCP-1 display a markedly reduced production of 
IL-12 and therefore may inhibit TH1 cell development  [102]. 
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1.5.13 Thymus and activation-regulated chemokine (TARC/CCL17) and macrophage-
derived chemokine (MDC/CCL22)  
TARC and MDC are CC chemokines which have recently been reported to play 
an important role in allergic airway disease. TARC and MDC are produced by DCs 
amongst other pulmonary cells and bind to the CC chemokine receptor 4 (CCR4), which 
is found on CD4+ TH2 cells.  Upon allergen challenge, bronchial epithelial cells release 
the cytokine TSLP which in turn stimulates dendritic cells to produce TARC and MDC, 
recruiting TH2 cells to the airways and ultimately perpetuating the disease [103, 104].   
  Studies have shown TARC and MDC are up-regulated in the airways and serum 
of human subjects with asthma after allergen challenge [105]. A mouse model of allergic 
airway inflammation has also shown antibody treatment against TARC can inhibit 
antigen-induced eosinophilia, TH2 cytokines, and bronchial hyperresponsiveness [105]. 
 
1.5.14 Transforming growth factor-β (TGF-β)  
TGF-β is a profibrotic cytokine which stimulates fibroblasts to promote the 
synthesis and secretion of many proteins of the extracellular matrix [106, 107]. Due to its 
function in promoting growth and repair, TGF-β is thought to play an important role at 
sites of wound healing and tissue remodeling and may play a role in the fibrotic changes 
occurring within asthmatic airways [108]. In addition, TGF-β is an immunomodulatory 
cytokine and a potent chemoattractant for several cell types including monocytes, 
fibroblasts, and mast cells [109-111]. Major sources of TGF-β are eosinophils, 
neutrophils, airway smooth muscle cells, fibroblasts, epithelial cells, and mast cells [112]. 
Expression of TGF-β mRNA and protein production by eosinophils in asthmatic subjects 
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has been correlated with the severity of asthma and the degree of subepithelial fibrosis 
[108].   
 
1.6 Effect of Particles on Allergic Immune Responses 
There is epidemiological evidence that certain air pollutants such as DE are 
associated with the development of allergic airway disease [113-117], and recent 
associations have been specifically linked to proximity to highways [118-120]. While 
these effects need to be confirmed with better personal exposure information, 
investigations in animals and in a few human clinical studies have reported that air 
pollutants may indeed contribute to the increased incidence of allergic disease and asthma 
[121-126].  
Animal experiments have demonstrated that many types of particles including 
ambient PM, DEP, residual oil fly ash (ROFA), carbon black particles (CB), and 
polystyrene particles (PSP) can act as immunologic adjuvants when administered with an 
antigen via intraperitoneal, intranasal, intratracheal, and inhalation routes of exposure 
[127-133].  In most cases the particles alone cause inflammation, but when administered 
during sensitization, they also promote the development of allergic immune responses (in 
the form of increased IgE antibody, TH2 cytokines, and airway hyperresponsiveness).  
Upon repeated challenge with antigen, these animals exhibit increased severity of allergic 
type disease (pulmonary eosinophils, airway hyperresponsiveness, increased mucus 
production, etc.) compared to control animals which received antigen exposure and 
vehicle control in the place of the pollutant.   
The relationship between particle exposure and increased allergic symptoms has 
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also been examined in limited human studies with both allergic and non-allergic subjects.  
Individuals with allergic rhinitis and mild asthma exposed intranasally to 0.3 mg of DEP, 
generated from an automobile, had significantly enhanced IgE antibody production in the 
nasal mucosa [134]. In a later study, atopic subjects given DEP prior to nasal 
immunization with a neoantigen, keyhole limpet hemocyanin (KLH), produced antigen-
specific IgG, IgA, and IgE as well as IL-4 in nasal lavage fluid [135], while subjects 
given KLH alone only produced  IgG and IgA, indicating that the DEP acted as an 
adjuvant to promote primary allergic sensitization.  
While these specific studies used a diesel particle highly enriched in organic 
constituents, another body of literature also shows that the carbonaceous core of the 
diesel as well as more inert particles like carbon black and polystyrene particles (PSP) 
can similarly induce adjuvant-like effects in rodents [136].  Rats instilled with 100 µg of 
fine (FCB) or ultrafine carbon black (UFCB) had some measure of allergic adjuvancy 
compared to DEP [137], while the adjuvant effects of PSP were directly related to the 
pro-inflammatory potential dictated by an increase in the surface area of ultrafine versus 
fine.  In contrast, instillation of DEP, “representative of heavy duty diesel engine 
particulate emissions” according to the National Institute of Standards and Technology, 
did not induce inflammatory or allergic responses in healthy or asthmatic subjects, 
suggesting chemistry plays an important role in the response [138]. 
 
1.7 Dendritic Cells 
Dendritic cells (DCs) are the most important antigen presenting cells in the lung 
and are located throughout the basement membrane of the airways, forming long 
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extensions or dendrites to sample the lumen on a continual basis. Antigen uptake during 
the presence of a “danger signal” (e.g. damage-associated molecular patterns; DAMPs) 
causes DC to process the antigen into the MHC complex, acquire a mature phenotype 
expressing co-stimulatory molecules (CD80/86), migrate to the draining lymph node, and 
present the antigen to naïve CD4+ T cells.  This “danger signal” could be induced by an 
allergen, microbial contaminant, or cytokines such as thymic stromal lymphopoietin 
(TSLP).  Depending on the signal type, maturation status, and the presence of other 
mediators, dendritic cells can preferentially polarize T lymphocytes to a TH1 or TH2 
response.   
Recent evidence shows airway DC populations are important in determining the 
induction of pulmonary immunity or tolerance. Two important subtypes of DCs are 
myeloid DC (mDC) and plasmacytoid DC (pDC). Both of these subtypes endocytose 
antigen in the lung and present processed peptides to naïve T cells in the draining lymph 
node.  Intratracheal instillation of OVA exposed bone-marrow-derived mDCs are 
sufficient to induce TH2 sensitization in mice, however pDCs have been shown to down-
regulate this effect [139, 140]. Depletion of pDCs during inhalation of protein allergens 
in mice results in the development of asthmatic symptoms such as airway eosinophilia, 
goblet cell hyperplasia, and TH2 cell cytokine production [141], while adoptive transfer 
of mDCs before sensitization results in an allergic phenotype [141].  It has also been 
shown that airway pDC are more abundant compared to mDC in the draining lymph node 
of tolerized mice compared to the profile seen in actively sensitized animals. Airway 
mDCs play a central role not only in initiating specific TH2 cell immune responses 
leading to asthmatic symptoms, but also in restimulating effector T cells during ongoing 
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airway inflammation and antigen challenge [142].  
 
1.8 Phase I and Phase II Metabolism 
The lung is a target organ for the toxicity of inhaled compounds (xenobiotics). 
The lung has the capability of metabolizing such compounds with the aim of reducing 
their potential toxicity. The metabolism of xenobiotics is often divided into two groups, 
called phase I and phase II. DEP or CB has been shown to significantly alter both phase I 
and phase II enzyme expression and activity in the lungs of rats [143]. 
Phase I introduces reactive and polar groups through a variety of enzymes. These 
reactions involve hydrolysis, reduction, and oxidation. Phase II reactions include 
glucuronidation, sulfonation, acetylation, methylation, and glutathione and amino acid 
conjugation. These reactions generally act in concert to detoxify xenobiotics and remove 
them from cells. In some instances, the biotransformation of a given compound can result 
in the generation of more reactive, and frequently more toxic, metabolites. Polycyclic 
aromatic hydrocarbons (PAHs) or N-nitrosamines are an example of pro-carcinogens 
which can be biotransformed into more reactive intermediates that more easily form 
DNA adducts than the parent compound. 
Diesel exhaust emissions contains fine and ultra-fine PM composed of carbon 
core surrounded by various adsorbed organic compounds, including PAHs, quinones, and 
nitro-PAHs [144]. Many of these organic compounds associated with diesel exhaust 
particles (DEP) are suspected to be mutagenic and carcinogenic [145]. Pathways involved 
in phase I metabolic activation of these compounds include formation of diol epoxides 
catalyzed by several cytochrome P450s [146-148], radical cations catalyzed by P450 
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peroxidases [149, 150], and reactive and redox active o-quinones catalyzed by 
dihydrodiol dehydrogenases (DD) [151, 152]. 
In phase I, a variety of enzymes introduce reactive and polar groups into their 
substrates such as -OH, -NH2, -SH, or -COOH. One of the most common modifications 
is hydroxylation catalysed by the cytochrome P-450-dependent mixed-function oxidase 
system. Cytochrome P450 monooxygenases (CYP) play an important role in the defense 
against inhaled toxicants, and are expressed in bronchial and bronchiolar epithelium, 
Clara cells, type II pneumocytes, and alveolar macrophages. CYP1A1, CYP1B1, 
CYP2A6, CYP2B6, CYP2E1, CYP2Cs, CYP2D, CYP3A4, CYP3A5 and CYP3A5 
mRNA expression has been detected in human lung cells. Exposure of rats to DEP or 
carbon black (CB) has been shown to induce changes in CYP1A1 and CYP2B1 protein 
levels in the lung. Recent studies have demonstrated that these enzymes are primarily 
responsible for the generation of intracellular ROS induced by DEP exposure [153] 
suggesting that CYP enzymes may contribute to both the inflammatory and genotoxic 
mechanisms of DEP carcinogensis. 
A widely accepted pathway of PAH activation involves formation of electrophilic 
diol epoxides. For benzo[a]pyrene (B[a]P), a representative PAH, are initially converted 
by CYP P450 to a variety of arene oxides that can bind covalently to DNA. One 
metabolite, benzo[a]pyrene-4,5-oxide is rapidly inactivitated by epoxide hydrolase. 
However, benzo[a]pyrene-7,8-dihydrodiol-9,10-oxide is not a substrate for epoxide 
hydrolase and is highly mutagenic to mammalian cells. 
A second pathway of PAH activation involves the formation of radical cations 
catalyzed by elevated levels of P450 peroxidase. The radical cations arise from one-
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electron oxidation at C6 on benzo[a]pyrene [149, 154]. The radical cations form 
predominantly depurinating adducts. PAH-derived DNA adducts, which may play a role 
in DEP-mediated mutagenicity and carcinogenicity, were found in rats after a short-term 
(12 weeks) exposure to DEP [155]. Elevated levels of PAH-derived DNA adducts have 
also been observed in white blood cells of humans following DEP exposure [156].  
Quinones can be reduced by two- or one-electron reduction to the hydroquinone 
or semiquinone form. Flavin-dependent quinone reductases and NAD(P)H quinone 
oxidoreductase 1 (NQO1) reduce quinones, via a two-electron reduction, to its 
hydroquinone form which can then be conjugated with glutathione or glucuronic acid and 
are rapidly excreted. The second pathway of quinone reduction is catalyzed by 
NAD(P)H-cytochrome P450 reductase, microsomal NADH-cytochrome b5 reductase, or 
mitochondrial NADH ubiquinone oxidoreductase, and results in the formation of the 
extremely unstable semiquinone radicals which subsequently undergo redox cycling, 
leading to the production of highly reactive oxygen species (ROS) in the presence of 
molecular oxygen. These reactive compounds induce oxidative damage and, 
consequently, tissue degeneration, and apoptotic cell death [60].  
The phase II enzymes, which include glutathione-S-transferases (GST), epoxide 
hydrolases, aryl sulfotransferases, and UDP-glucuronyltransferases, conjugate the 
activated xenobiotic metabolites with glutathione (GSH), glucuronides, sulfate ester, or 
amino acid derivatives to produce polar, readily excretable compounds. The induction of 
phase II enzymes has been shown to protect the lung from oxidative injury [157]. The 
GSTs, for example play a critical role in providing protection against electrophiles and 
products of oxidative stress. These enzymes facilitate the conjugation of glutathione with, 
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and subsequent elimination of, the electrophilic compounds including quinones and 
epoxides. 
 
1.9 Hierarchical Stress Response 
 The PM-induced oxidative stress response has been proposed to be a hierarchical 
event, which is characterized by the induction of antioxidant and phase II metabolism 
enzymes at lower tiers of oxidative stress and by pro-inflammatory followed by cytotoxic 
responses at higher levels of oxidative stress [158, 159] (Figure 1.2).  
In this proposed response, the first tier of oxidative stress, epithelial cells and 
macrophages respond by increasing expression of antioxidant and phase I and phase II 
metabolizing enzymes such as superoxide dismutase, catalase, glutathione peroxidase, 
glutathione reductase, glutathione S-transferase, NADPH quinone oxidoreductase, heme 
oxygenase 1 (HO-1). The transcription of these enzymes is mediated in part by the 
transcription factor nuclear regulatory factor 2 (Nrf2) which binds to the antioxidant 
response element (ARE) in the promoter of these genes [160].  
If the antioxidant and detoxification pathways fail to neutralize the oxidative 
stress response, pro-inflammatory cytokines are produced (tier 2). DEP and DEP extracts 
have been shown to activate the mitogen-activated protein (MAP) kinase and NFκB 
signaling cascades in epithelial cells and macrophages [161, 162]. Activation of these 
pathways leads to the production of IL-4, IL-5, IL-10, IL-13, TNFα, MCP-1, GM-CSF, 
ICAM-1, and VCAM-1 [163]. These cytokines, chemokines, and adhesion molecules 
play important roles in the pathogenesis of asthma and therefore it has been suggested to 
be the mechanism by which DEP exerts its adjuvant effects[125]. In addition to the 
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original oxidative stress insult, these signaling molecules lead to inflammation and 
further oxidative stress.  
The third tier of oxidative stress involves mitochondrial perturbation, which can 
lead to apoptosis, apoptosis-necrosis, and superoxide generation [164]. Reactive species 
generated from phase I metabolism can disrupt the mitochondrial transmembrane 
potential by interfering with the electron transport chain. Uncoupling of oxidative 
phosphorylation interrupts ATP production which decreases mitochondrial membrane 
potential leading ultimately to apoptosis and necrosis. The quinone-enriched polar 
fraction of DEP extract decreased of membrane potential and mitochondrial membrane 
mass, and induced of apoptosis in RAW 264.7 cells [165]. In addition, ultra-fine particles 
have been observed lodged inside the damaged mitochondria suggesting direct 
mitochondrial damage [166].   
 
1.10 Genomic Analysis 
The human genome project, along with the sequencing of DNA from many other 
organisms, has led to a dramatic increase in knowledge about gene structure and function 
over the last two decades. Through this knowledge and the development of new 
technologies for monitoring genetic sequences, genetic variation, and global gene 
expression analysis, the field of genomics was created. Broadly speaking genomics is the 
study of how genes interact and influence biological pathways, networks, and cellular 
physiology [167, 168].  Toxicogenomics, a new sub-discipline in the field of toxicology, 
takes this one step farther by examining how environmental and xenobiotic exposures 
alter these interactions. 
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Toxicogenomics, combining conventional toxicological research and functional 
genomics, is based on the fact that most relevant toxicological effects of a compound also 
alter gene expression, directly or indirectly. Toxicogenomics data offers additional 
insights into cellular mechanisms of toxicity beyond those derived from traditional 
toxicological endpoints based on whole organ pathology or survival curves. Molecular 
profiling of toxicants through microarray technology enhances our basic understanding of 
some of the underlying mechanisms that cause toxicity.  
Several experimental studies have employed microarray technology to study the 
biological effects of DEP exposures. Arrays containing a limited number of genes were 
used to study gene expression changes in vivo in rat lung. Reynolds and Richards [169] 
assessed the effects of intranasal instillation of DEP in rats with rat stress arrays. 10 genes 
out of the 207 stress-related rat genes tested, were up-regulated. These included mitogen-
activated protein kinase 2, calcium-binding protein 2, 94 kDa glucose-regulated protein, 
G1/S-specific cyclin D1, prothymosin-alpha, MAP kinase kinase 5, M-phase inducer 
phosphatase 2, and nucleoside diphosphate kinase A, which are involved in the lung’s 
damage response.  Sato et al. [170]exposed rats to DE and surveyed cDNA expression 
arrays with only 588 rat cDNAs to identify genes that may be involved in DE-induced 
carcinogenesis.  Six genes, heat-shock protein 47, superoxide dismutase, proliferating cell 
nuclear antigen, retinoblastoma, A-raf, and K-ras, were up-regulated in the lungs of 
exposed rats.  
In vitro microarray studies investigating the effects of DEP extract were also 
conducted. Koike et al. [171] investigated the effects of DEP extract on rat primary 
alveolar macrophages by examining changes in gene expression levels after a 6 hr 
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exposure using a toxicology array containing 450 rat cDNAs. Six genes, heme oxygenase 
(HO)-1 and -2, thioredoxin peroxidase 2, glutathione S-transferase P subunit, NAD(P)H 
dehydrogenase, and proliferating cell nuclear antigen (PCNA) were up-regulated. The 
first five are involved in antioxidant response while PCNA is involved in DNA damage 
repair. In addition, Koike et al [172] also exposed epithelial cells to DEP extract and 
evaluated gene expression changes using a 10,000 gene spotted array. The 6 hr DEP 
extract exposure increased expression of HO-1 and 50 other genes associated with drug 
metabolism, antioxidant response, cell cycle/proliferation/apoptosis, 
coagulation/fibrinolysis, and expressed sequence tags. In addition, 20 genes including 
type II transglutaminase (TGM-2), a regulator of coagulation, were decrease. The authors 
concluded HO-1 and TGM-2, genes with the highest differential responses, were good 
biomarkers for PM exposure. 
A microarray study by Verheyen et al. [173] exposed human alveolar 
macrophages for 6 or 24 hrs to DEP. Oxidative metabolism, transcription regulation, 
transport, signal transduction, as well as cell cycle, DNA repair, and immune response 
genes were altered. CYP1B1, IL-1, thrombomodulin, integrinβ 7, similar to S. cerevisiae 
Sec6p, TNF receptor superfamily member 1B, leupaxin, CGI-41 protein, and BTG family 
member 2 genes were up-regulated at both time points. In addition peroxiredoxin 1, 
collagen type 1 receptor, protein kinase cAMP-dependent catalytic beta, butyrobetaine 2-
oxoglutarate dioxygenase 1, CDC-like kinase 1, stathmin 1, and high-mobility group 
protein 2 were down-regulated at both time points. The authors concluded a multitude of 
biological processes are involved in DEP toxicity. 
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1.11 Scope of this Dissertation 
 The studies performed in this dissertation were focused on elucidating the 
mechanisms by which diesel exhaust (DE) enhances allergic lung disease. Chapter 2 
evaluates the relative potency of three chemically distinct DE particles (DEP) on allergic 
airway inflammation in a murine ovalbumin (OVA) sensitization model. In addition to 
the post-challenge adjuvant effects, this chapter also assesses early immunologic changes 
in lungs after exposure to DEP. This chapter has been submitted to Toxicological 
Sciences for publication.  In chapter 3 genomic microarray technology was utilized to 
identify altered pathways in the lung that were associated with the effects found in 
chapter 2. This chapter identifies common and unique pathways associated with exposure 
to the three DEP samples. Chapter 4 had two goals: 1) to investigate the adjuvant effects, 
post antigen challenge, of a short term inhalation exposure to moderate doses (500 and 
2000 µg/m3) of DE; and 2) to identify global gene changes associated with altered 
immune function.  To this end immunologic endpoints were examined in mice acutely 
exposed by whole-body inhalation to moderate doses of DE in an ovalbumin mucosal 
sensitization model.  In addition, microarray analysis was utilized to determine global 
lung gene expression changes associated with the effects of DE exposure alone and with 
antigen. The text and data in this chapter was published in April 2008 in Toxicological 
Sciences.  
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Figure 1.1 TH2 differentiation and allergic sensitization.  Antigen presenting cells 
(APC) present antigen to naïve T helper cells (TH0) inducing activation and 
differentiation into a TH2 or TH1 subset, depending on the cytokines present.  
Differentiation into TH1 cells occurs under the influence of IL-12. TH1 cells produce high 
levels of IL-2 and IFNγ.  TH2 differentiation occurs under the influence of IL-4 and these 
cells produce IL-4, IL-5, and IL-13, which are cytokines known for their role in allergic 
airway inflammation. Both TH cell sub-types are mutually antagonistic; IL-4 and IL-10 
down-regulate IL-12 and IFNγ down-regulates IL-4. 
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Figure 1.2 Hierarchical stress responses. At a low level of oxidative stress (Tier 1), 
antioxidant enzymes and phase I and II metabolizing enzymes are up-regulated to protect 
the cell from oxidative damage. At an intermediate level of oxidative (stress), the cells 
protective responses are overwhelmed and inflammation ensues. At a high level of 
oxidative stress (tier 3), the cell responds by inducing apoptosis or apoptosis/necrosis 
pathways. (Adopted from Li et al. [174, 175]) 
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Differential Potentiation of Allergic Lung Disease in Mice Exposed to 
Chemically Distinct Diesel Samples 
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Abstract 
 
Numerous studies have demonstrated that diesel exhaust particles (DEP) 
potentiate allergic immune responses however the chemical components associated with 
this effect and the underlying mechanisms are not well understood. This study 
characterized the chemical composition of three chemically distinct DEP samples and 
compared post-sensitization and post-challenge inflammatory allergic phenotypes in 
BALB/c mice. Mice were instilled intranasally with saline or 150 µg of NIST (N-DEP), 
automobile (A-DEP), or compressor (C-DEP) with or without 20 µg of ovalbumin 
(OVA) on days 0 and 13, and were subsequently challenged with 20 µg of OVA on days 
23, 26, and 29. Mice were necropsied 18 hrs post-sensitization and 18 and 48 hrs post-
challenge. N-DEP, A-DEP, and C-DEP contained 1.5%, 68.6%, and 18.9% extractable 
organic material (EOM), respectively. The post-challenge results showed that DEP given 
with OVA induced a gradation of adjuvancy as follows: C-DEP ≈ A-DEP > N-DEP. The 
C- and A-DEP/OVA exposure groups had significant increases in eosinophils, OVA-
specific IgG1, and airway hyperresponsiveness. In addition the C-DEP/OVA exposure 
increased the TH2 chemoattractant chemokine, thymus and activation-regulated 
chemokine (TARC), and exhibited the most severe perivascular inflammation in the lung 
while A-DEP/OVA increased IL-5 and IL-10. In contrast, N-DEP/OVA exposure only 
increased OVA-specific IgG1 post-challenge. Analysis of early signaling showed that C-
DEP induced a greater number of TH2 cytokines compared to A-DEP and N-DEP. The 
results demonstrate that immune potentiation was not solely related to the amount of 
organic material and suggest that a balanced combination of carbon and EOM was the 
most effective adjuvant. 
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2.1 Introduction 
 
Epidemiology studies have shown that the incidence of asthma has almost 
doubled in industrialized countries over the past 20 years [176-182]. Increases in ambient 
particulate matter (PM) have been correlated with a rise in hospitalization associated with 
respiratory illnesses such as asthma [118, 183]. Diesel exhaust particles (DEP) are an 
important component of ambient air PM. Several animal and limited human studies have 
shown that DEP can act as an immunological adjuvant to increase the severity of allergen 
induced asthma [114, 115, 123, 128, 134, 184-186], however, the physical and chemical 
composition of DEP responsible for this effect and a detailed understanding of early 
cellular signaling events are not well understood.  
DEP are a complex mixture of organic and inorganic compounds that vary 
depending on factors such as type of engine, load characteristics, and method of 
collection.  Two well studied DEP samples, an automobile derived DEP (A-DEP) and the 
National Institute of Standards Technology Standard Reference Material 2975 DEP (N-
DEP) sample generated from a forklift engine, have been extensively studied for their 
pulmonary inflammatory effects [187] and mutagenicity [188], respectively. When 
compared, these particles were found to have contrasting physical and chemical 
properties and involuntary aspiration in mice showed distinct pulmonary toxicity profiles 
indicating that not all DEP are the same [21].  
Animal studies have shown DEP exert allergic airway effects when given with an 
antigen [128, 137, 185, 189, 190].  These effects include increased TH2 cytokines, 
eosinophils, and airway hyperresponsiveness upon antigen challenge.  Studies have 
attributed this adjuvant effect to the organic components or the particles themselves by 
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examining either a DEP rich in organics and DEP organic extractable material [191, 192] 
or carbon black, synthetic model particles [193-195], or DEP stripped of its organics 
(washed DEP) [196], respectively.  However, comparisons among the different studies 
are complicated by the variability in the sensitization and challenge regime as well as the 
methods of particle preparation.  
The present study was conducted to evaluate the relative potency of three 
different DEP samples, N-DEP, A-DEP, and C-DEP (generated from a diesel engine used 
to power an air compressor) on allergic airway inflammation in a murine ovalbumin 
(OVA) mucosal sensitization model. In addition to adjuvant effects after antigen 
challenge, pulmonary responses post-sensitization were characterized to improve 
understanding of the relationship between the physical and chemical components of DEP 
and early signaling involved in the enhanced development of allergic immune response.  
 
2.2 Materials and Methods 
 
2.2.1 Animals 
Female BALB/C mice (8-10 weeks old) were obtained from Charles River 
Laboratories (Raleigh, NC) and allowed to acclimate for a minimum of one week prior to 
dosing.  Mice were randomly assigned to treatment groups and housed in an AAALAC-
approved animal facility at the US-EPA.  All animal procedures were reviewed and 
approved by the US-EPA’s Institutional Animal Care and Use Committee. Housing 
environment conditions include a 12-h light/dark cycle at an ambient temperature of 
22±1ºC and relative humidity of 55±5ºC. Mice were provided water and mouse chow ad 
libitum. Additional mice from each facility were routinely monitored serologically for 
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Sendai, mouse pneumonia, mouse hepatitis, and other murine viruses, as well as 
mycoplasma.  
 
2.2.2 Particle samples 
Standard Reference Material (SRM) 2975 diesel exhaust particle sample (N-DEP) 
was purchased from National Institute of Standard Technology (NIST) (Gaithersburg, 
MD). The reported mean diameter of these particles was 11.2 ±0.1 µm by area 
distribution, and the surface area, as determined by nitrogen adsorption, was 91µm2/g.  
The certified analysis contains 11 certified concentrations and 28 reference 
concentrations for selected PAHs found in the DEPs.  The DEP was generated by a 
heavy-duty forklift diesel engine and collected under “hot” conditions without a dilution 
tunnel (Table 2.1).  
Automobile DEP (A-DEP) was generated and collected under conditions 
previously described [187, 197].  Briefly, the sample was generated by a light-duty 
(2740cc), 4-cylinder Isuzu diesel engine. DEP was collected under “cold” (50 ºC) 
conditions onto glass-fiber filters and on steel duct walls in a constant-volume sampling 
system fitted at the end of a dilution tunnel (Table 2.1).   
Compressor DEP (C-DEP) was generated in-house as described by Cao et al 
[198] at EPA-RTP using a 30 kW (40 hp) 4-cylinder Deutz BF4M1008 diesel engine 
connected to a 22.3 kW Saylor Bell air compressor to provide 20% load.  The generated 
particles were collected under “hot” conditions in a baghouse (Table 2.1). 
 
2.2.3 Particle analysis 
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Organic carbon (OC) and elemental carbon (EC) were analyzed using a thermal-
optical carbon analyzer with transmittance-based pyrolysis correction (Sunset 
Laboratory, Inc., Tigard, OR) using method 5040 found in the National Institute for 
Occupational Safety and Health (NIOSH) Manual of Analytical Methods (NIOSH 1994). 
DEP were extracted to determine mass distribution of initial extractable organic matter 
(EOM) and sub-fractions. Bulk samples of 2 g of each DEP were loaded in glass fiber 
thimbles and extracted with dichloromethane (DCM) using soxhlets overnight. Extracts 
were subsequently concentrated under nitrogen, and aliquots were dried on aluminum 
pans and weighed. Another aliquot of each DCM extract was further concentrated to 150 
µL and readjusted to 12 mL with hexane. The hexane-insoluble fraction of the extract 
remained as a precipitate, and the other soluble fractions were applied to a DCM-rinsed 
neutral silica gel column. The EOM was then eluted serially with hexane, 50:50 
hexane:DCM, DCM, and methanol. Each fraction was concentrated, and the mass was 
determined.  
 
2.2.4 Experimental design 
Following the protocol of Steerenberg et al [199], DEP samples (N-, C-, A-DEP) 
were suspended at a concentration of 3 mg/ml in saline alone or with 0.4 mg/ml of 
ovalbumin.  Particles were sonicated using a Microson Ultrasonic Cell Disruptor 
(Micromix) for 10 min. Mice were randomly divided into 8 treatment groups, 
anesthetized with isofluorane, and exposed to saline, 20 µg OVA, 150 µg DEP, or DEP + 
OVA by intranasal instillation on Days 0 and 13.  Mice were either necropsied 18 hrs 
later or went on to be challenged with 20 µg of ovalbumin on days 23, 26, and 29, and 
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necropsied 18 or 48 hrs after the last challenge (Figure 2.1).  
 
2.2.5 Necropsy 
Mice were euthanized with sodium pentobarbital and bled by cardiac puncture.  
The chest wall was opened and the trachea cannulated.  The left lung lobe was clamped 
off and the right lobes lavaged with three 0.6 ml volumes of warmed Hanks balanced salt 
solution (HBSS) (Invitrogen, Grand Island, NY) and immediately cooled on ice.  The left 
lung lobe was inflated with 10% buffered formalin and used for histopathological 
analysis. 
 
2.2.6 Bronchoalveolar lavage fluid and characterization 
The bronchoalveolar lavage fluid (BALF) was centrifuged (800rpm, 15 min, 4 ºC) 
and the supernatant was stored at 4 ºC for biochemical analysis or -80 ºC for cytokine 
detection.  The pelleted cells were resuspended in 1 ml of RPMI 1640 (Gibco, Carlsbad, 
CA) containing 2.5 % fetal bovine serum (FBS; Gibco, Carlsbad, CA). Total cell counts 
in the lavage fluid of each mouse were obtained with a Coulter Counter (Beckman 
Dickson, Hialeah, FL).  Each sample (200 µl) was centrifuged in duplicate onto slides 
using a Cytospin (Shandon, Pittsburgh, PA) and subsequently stained with Diff Quik 
solution (American Scientific, McGraw Park, PA) for cell differentiation determination, 
with at least 200 cells counted from each slide.   
 
2.2.7 Biochemical analysis 
BALF supernatant was analyzed using commercially available kits adapted for 
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automated analysis using a Cobas Fara II centrifugal spectrophotometer (Hoffman-La 
Roche, Branchburg, NJ).  All assays were modified for use on the Konelab 30 clinical 
chemistry analyzer (Espoo, Finland). Microalbumin (MIA) levels were determined using 
a MALB SPQ kit (INCSTAR, MN) with a standard curve prepared with bovine serum 
albumin (BSA). N-acetyl-B-D-glucosaminidase (NAG) was measured using a 
commercially prepared kit containing sodium 3-cresolsulfonphthaleinyl-N-acetyl-B-D-
glucosinamide, which can be hydrolyzed by NAG, releasing 3-cresolsulfonphthalein 
sodium salt (3-cresol purple), and standards from Roche Diagnostics (Mannheim, 
Germany).  BALF supernatants were assayed for total protein using Pierce Coomassie 
Plus Protein Assay Reagent (Pierce Biotechnology, Inc, Rockford, IL).  Concentrations 
were determined from a standard curve using BSA standards obtained from Sigma 
Chemical Co. (St. Louis, MO).  Supernatants were also assayed for LDH activity using a 
commercially prepared kit and controls from Sigma Chemical Co.  Both assays were 
modified for use on a KONELAB 30 clinical chemistry spectrophotometer analyzer 
(Thermo Clinical Lab Systems, Espoo, Finland). 
 
 2.2.8 Cytokine analysis 
Cytokine proteins in cell supernatants were assessed using the Luminex 100 
(Luminex Corp., Austin, TX) and LINCOplex kits (Linco Research, Inc., St. Charles, 
MO) for simultaneous detection and measurement of cytokines IL-4, IL-5, IL-6, IL-10, 
IL-12, IL-13, IL-15, IL-17, TNF-α, GM-CSF, IFN-γ, and a monocyte chemotactic protein 
(MCP-1). The limits of detection of the Luminex assays were 0.3, 0.6, 0.7, 10.3, 3.7, 4.7, 
9.3, 1.7, 0.9, 4.6, 0.7, and 6.3 pg/ml, respectively. Enzyme-linked immunosorbent assays 
 40 
(ELISA) for thymus and activation-regulated chemokine (TARC) were conducted using a 
commercially available kit (R&D systems, Minneapolis, MN) following manufacturer’s 
protocol. The limit of detection was 15 pg/ml. 
 
2.2.9 Antigen-specific serum IgE and IgG1 
Antigen-specific IgE and IgG1 serum immunoglobulin production was measured 
by sandwich ELISA.  Serum was prepared and kept frozen at -80 ºC until assay. Briefly 
96 well flat bottom plates are coated with 100 µl/well of ovalbumin (OVA) (Sigma-
Aldrich, St. Louis, MO) at a concentration of 100 µg/ml in PBS and incubated overnight 
at 4 ºC. The following day, after a blocking step and washing, 100 µl of each serum 
sample (IgE-neat and IgG1-diluted 1:10000) and 7 2-fold serial dilutions of mouse anti-
OVA IgE (beginning at 1000 ng/ml; Serotec, Raleigh, NC) and IgG1 (beginning at 100 
ng/ml; Zymed, San Francisco, CA) was added in duplicate wells to the plates.  After an 
overnight incubation at 4 ºC and washing, the plates were treated successively with 100 
µl/well of biotinylated IgE or IgG1 and horseradish peroxidase-streptavidin (diluted 
1:1000; Zymed, San Francisco, CA), with washes and incubation for 1hr at room 
temperature between each of these steps.  Tetramethylbenzidine substrate (TMB; DAKO 
Corp., Carpinteria, CA) was added (20 min, RT), the reaction was stopped using 2 M 
H2SO4, and absorbance was measured at 450 nm and compared between treatment 
groups. Optical density was read on a Spectramax 340PC Plate Reader (Molecular 
Devices Corp., Menlo Park, CA).  Softmax Pro version 2.6.1 Software (Molecular 
Devices Corp.) was used for data collection and conversion from optical density to 
antibody concentration was calculated with reference to standard curves of the known 
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amounts of each antibody.   
 
2.2.10 Histopathology 
The left lung lobe of the lung was inflated and fixed with 10% buffered formalin, 
immersed in 10% buffered formalin for 24 hrs then transferred into 70% ethanol.  
Samples were sent to Experimental Pathology Laboratories (Research Triangle Park, NC) 
for processing and histopathological evaluation by a board certified veterinary 
pathologist. Lung sections were stained with hematoxylin and eosin (H&E) to determine 
inflammatory changes. Specifically, lung sections were scored for perivascular and 
peribronchial inflammation: 0-normal, 1-minimal, 2-mild, 3-moderate or 4-severe. The 
total scores for each group (n=3) were averaged. Statistical analysis of the data was not 
performed, but the data were assessed for any immediately obvious trends.  
 
2.2.11 Airway hyperresponsiveness (AHR) 
 
Nonspecific airway responsiveness to increasing concentrations of aerosolized 
methacholine (Mch) in unrestrained mice in a 12-chamber whole-body plethysmograph 
system (Buxco Electronics, Troy, NY) was measured on Day 31, 48 h after intranasal 
challenge. Pressure signals were analyzed with BioSystem XA software (SFT3812, 
version 2.0.2.4, Buxco Electronics) to derive whole-body flow parameters that were used 
to calculate enhanced pause (Penh).  Penh was used as an index of airflow obstruction, 
which has been correlated with changes in airway resistance [200]. After measuring 
baseline parameters for 7 min, an aerosol of saline or Mch in increasing concentrations 
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(6.25, 12.5, and 25 mg/ml) was nebulized through an inlet of the chamber. The recorded 
Penh values were averaged during the baseline periods and the Mch challenges to obtain 
mean values for each event and were represented as change from the mean during the 
baseline period to the mean during each Mch challenge.  
2.2.12 Statistical analysis 
The data were analyzed using a two-way analysis of variance (ANOVA) model.  
The two independent variables were OVA (at levels present and absent) and treatment (at 
levels A-DEP, C-DEP, N-DEP and Saline).  Pair-wise comparisons were performed as 
subtests of the overall ANOVA, subsequent to a significant main or interactive effect.  If 
the usual ANOVA assumptions were not satisfied, either the data were transformed so as 
to satisfy the assumptions or, in cases where the assumptions could not be satisfied, a 
distribution free test was substituted for the ANOVA.  The level of significance was set at 
0.05.  No adjustment was made to the significant level as a result of multiple 
comparisons. 
 
2.3 Results 
 
2.3.1 Chemical characteristics of diesel exhaust particles (DEP) 
 
From the OC/EC ratios, the A-DEP comprised six times the amount of organic 
carbon compared to elemental carbon, while the C-and N-DEP contained more elemental 
carbon.  The significant enrichment of organics in A-DEP was also shown by the amount 
of DCM-extracted organics (approximately 70% of particles mass), which was much 
larger than the 19% and 1.5% for C-DEP and N-DEP, respectively (Table 2.1). However, 
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the mass distribution of sub-fractions of EOM of A-DEP and C-DEP were found to be 
similar, showing that the EOM of A-and C-DEP were mostly hexane soluble (less polar; 
58-74% in organic extracts), while the EOM of N-DEP was soluble in hexane or 
methanol (more polar) at the same degree (Table 2.1). A previous study [201] suggested 
that A-DEP comprised a large amount of unburned fuel, which was indicated by GC/MS 
as a large amount of aliphatic hydrocarbons. GC/MS analysis on C-DEP also showed a 
similar organic composition with A-DEP, with a large amount of alkanes by single 
chemical quantitative identification analyses (data not shown), suggesting that organics in 
C-DEP could also result from incomplete combustion of diesel fuel, albeit at a lower 
degree.    
 
 
2.3.2 Post-challenge results 
BALF cell differential counts   
 Mice were given either saline or DEP alone (non-sensitized) or with OVA 
(sensitized) on days 0 and 13, challenged with OVA on days 23, 26, and 29, and 
necropsied 18 and 48 hrs later (Figure 2.1). The C-DEP + OVA group at 18 hrs had a 
significantly greater number of macrophages than all groups (Table 2.2).  At the 48 hr 
time point the total cell numbers in the BALF of all sensitized mice exposed to DEP was 
increased compared to saline or DEP alone treatments, of which macrophages and 
eosinophils were the predominant cell type (Table 2.3).  Statistical analysis revealed an 
interactive effect of DEP exposure combined with antigen with respect to the number of 
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eosinophils in the BALF at 48 hrs for the A- and C-DEP + OVA exposures. Eosinophils 
in all DEP + OVA treated mice were significantly greater than saline and DEP alone at 
the 48 hr time point, however A- and C-DEP + OVA treated mice had a significantly 
greater amount of eosinophils compared to the OVA control and N-DEP + OVA groups. 
OVA control and non-sensitized A-DEP groups exhibited a significant increase in 
eosinophils at the 48 hr time point compared to saline and N- and C-DEP alone. 
Neutrophil and lymphocyte infiltration was highest in the C-DEP + OVA treatment for 
both time points (Table 2.2 & 2.3). A significant interactive effect from the combined 
DEP and OVA exposures, with respect to the number of lymphocytes in the BALF, was 
apparent for both N- and C-DEP + OVA exposures at both time points and the A-DEP + 
OVA exposure at the 48 hrs. Only the C-DEP + OVA exposure demonstrated a 
synergistic effect with respect to neutrophil infiltration at both time points. These data 
show that after DEP + OVA sensitization and allergen challenge, (a) mice had increased 
airway inflammatory cell influx compared with saline, OVA, and DEP alone; (b) the 
magnitude of inflammatory cell influx was greater at the 48 hr time point; (c) while C- 
and A-DEP + OVA mice displayed the strongest inflammatory response at 48 hrs, this 
response was initially stronger in C-DEP + OVA; and (d) at the 48 hr time point OVA 
and A-DEP alone also resulted in a significant increase in inflammatory cells.  
BALF biochemical analyses 
To determine if the increased lung inflammation present in DEP + OVA exposed 
mice after allergen exposure was accompanied by changes in alveolar epithelial 
permeability, BALF total protein and microalbumin (MIA) were measured. Protein 
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(Figure 2.2) and MIA levels (data not shown) in non-sensitized DEP treated mice were 
not significantly different from each other or saline control. In sensitized mice, only C-
DEP + OVA displayed an increase in both biomarkers at the early time point. However, 
by 48 hrs protein both protein and MIA levels in A- and C-DEP + OVA groups were 
significantly greater than saline, OVA, all non-sensitized DEP, and N-DEP + OVA 
exposed groups, suggesting that increased epithelial permeability accompanied the 
inflammatory process (Figure 2.2).  
To explore whether the allergen-induced inflammation in mice was accompanied 
by increased lysosomal enzyme release, we measured BALF NAG, an established marker 
of alveolar macrophage activation[202]. A- and C-DEP + OVA sensitized mice exhibited 
a significant increase in BALF  NAG at the 48 hr time point compared with saline, OVA, 
and DEP alone (data not shown). LDH levels in the BALF were measured as an index of 
cellular toxicity. C-DEP + OVA exposed mice had a significant increase in LDH levels at 
both points compared to saline, OVA, and non-sensitized N- and A-DEP (Figure 2.3). 
The A-DEP + OVA exposure induced a significant increase in LDH compared to saline 
and non-sensitized N- and C-DEP at the 48 hr time point (Figure 2.3b). These results 
suggest that the increased inflammation in mice was associated with increased alveolar 
epithelial permeability, release of lysosomal enzymes from activated macrophages, and 
cellular toxicity. 
Serum antibody levels 
To evaluate the influence of DEP exposure on sensitization, OVA specific IgE 
and IgG1 serum levels were measured 18 and 48 hrs post-challenge.  Saline and non-
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sensitized DEP exposed mice had undetectable levels of OVA specific IgE and IgG1. 
There were no significant changes in IgE levels across all groups (data not shown). OVA 
specific IgG1 antibody titers in the serum of all DEP + OVA sensitized mice were 
significantly increased compared to saline control for both time points (Figure 2.4).  Only 
N- and C-DEP + OVA at 18 hrs and N-DEP + OVA at 48 hrs had a significant increase 
in IgG1 antibodies compared to OVA control.  
BALF cytokine analyses 
To determine the effects of DEP on TH2 polarization, local production of TH1 (IL-
12 and IFN-γ) and TH2 cytokines and chemokines (IL-4, 5, 6, 10, 13, 15, and 17, TNF-α, 
GM-CSF, MCP-1, TARC) in BALF was quantified 18 hrs post-challenge. Although an 
increase was seen in the OVA treatment group, all DEP + OVA exposures did not 
enhance IL-4, 6, 12, 13, 15, 17, TNF-α, GM-CSF, IFN-γ, or MCP-1 above OVA control 
concentrations (data not shown).  A-DEP + OVA treatment resulted in a significant 
increase in IL-5 and IL-10 compared to saline, OVA, and N-DEP + OVA (Figure 2.5a + 
b). IL-10 was also significantly greater than C-DEP + OVA (Figure 2.5b). Thymus and 
activation-regulated chemokine (TARC) levels were significantly increased compared to 
saline, OVA, and N- and A-DEP + OVA in C-DEP + OVA exposed mice (Figure 2.5c). 
Airway hyperresponsiveness 
Airway hyperresponsiveness (AHR) to methacholine was measured by whole 
body plethysmography. Forty-eight hrs after the last OVA challenge, all mice had similar 
baseline readings but OVA and all DEP + OVA exposures resulted in an overall 
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increased Penh for all methacholine challenges (Figure 2.6) compared to saline and DEP 
alone exposures (data not shown). Intranasal instillation of A- and C-DEP + OVA and 
OVA control significantly increased Penh in response to 6 mg/ml of methacholine 
compared to saline controls (Figure 2.6). In addition, A- and C-DEP + OVA had a 
significantly greater PenH than saline in response to 12 and 25 mg/ml of methacholine. 
Histopathology 
Histology specimens from all animals were scored for the degree of perivascular 
and peribronchial inflammation, with a score of 1 indicating mild to a score of 4 
indicating severe change. Where appropriate, airways were identified as being mainstem 
bronchus versus secondary airways. Lung sections from non-sensitized mice given DEP 
demonstrated minimal to mild perivascular inflammation. In contrast, all DEP + OVA 
exposures appeared to mildly potentiate the inflammatory response above that observed 
with OVA sensitization alone. Specifically C-DEP + OVA groups had the highest scores 
for all measurements with perivascular inflammation (3.67) being the highest at 48 hrs 
(Table 2.4).  
 
2.3.3 Post-sensitization 
BALF cell counts 
To elucidate early cellular mechanisms that lead to the development and intensity 
of allergic inflammation seen after antigen challenge, cellular profiling of the BALF was 
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investigated. Mice were given either saline or DEP with or without OVA on days 0 and 
13 and necropsied 18 hrs later. As shown in Table 2.5, non-sensitized A-DEP exposed 
mice had a significant increase in the number of macrophages in the BALF (Table 2.5). 
Eosinophils were significantly increased in C-DEP + OVA exposed mice compared to 
OVA control, A-DEP, C-DEP, and A-DEP + OVA. Non-sensitized N-DEP and C-DEP + 
OVA mice had a significantly greater number of neutrophils in the BALF.  In addition, 
C-DEP + OVA exposure induced a significant increase in lymphocytes in the BALF 
compared to all groups. Statistical analysis indicated a synergistic effect from the 
combined exposure of C-DEP and OVA with respect to eosinophil and lymphocyte lung 
infiltration. 
BALF biochemical analyses 
To determine if the DEP exposure with or without antigen directly induced 
cellular lung injury and toxicity, the BALF was analyzed for total protein, MIA, NAG, 
and LDH. MIA levels were unchanged across all groups (data not shown). Only the non-
sensitized N-DEP exposure induced a significant increase in NAG compared to saline 
and OVA control (data not shown). In the context of antigen, significant increases in 
LDH compared to OVA control were measured in A- and N-DEP + OVA exposures. C- 
and N-DEP + OVA exposures significantly increased BALF NAG levels. Total protein 
levels were also elevated in A-DEP + OVA exposure compared to OVA control (data not 
shown) 
BALF cytokine analysis 
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To determine the effects of DEP given with antigen on early cell signaling events, 
TH2 cytokines (IL-4, 5, 10, 13, 15, and 17) and chemokines (TARC, and MCP-1), and 
proinflammatory cytokines (IL-6 and TNF-α) concentrations in BALF post-sensitization 
were quantified. All DEP + OVA exposures increased the production of IL-5 compared 
to saline and OVA controls, however this increase was only significant in N- and C-DEP 
+ OVA exposed mice (Figure 2.7a). Instillation of C-DEP + OVA significantly increased 
the concentration of the TH2 cytokine IL-4 above saline and OVA controls (Figure 2.7b). 
The TH2 chemoattractant chemokine TARC was significantly increased in all DEP + 
OVA exposures (Figure 2.7c). Monocyte chemoattractant protein (MCP-1) protein levels 
were only significantly greater in C-DEP + OVA compared to all groups (Figure 2.7d).  
The proinflammatory cytokine IL-6 was greatly increased in response to C-DEP + OVA 
exposure compared to all treatment groups (data not shown). OVA and C-DEP + OVA 
exposure significantly decreased the concentration of the TH1 cytokine IL-12 (Figure 
2.8). In contrast, N- and A-DEP + OVA exposures increased the production IL-12 
compared to OVA, however this increase was not significant.  
 
2.4 Discussion 
Studies in humans and animals have shown diesel exhaust particles (DEP) can act 
as an immunological adjuvant to enhance the development of allergic lung disease, and 
this effect is influenced by the chemical composition of the DEP.  The chemical 
components of DEP associated with allergic adjuvancy and the underlying mechanisms 
are not well understood. Furthermore, the heterogeneous nature of DEP samples adds to 
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the difficulty in determining what effects are common among all DEP samples versus 
specific characteristics of a particular sample. Previous studies have shown the organic 
components such as polycyclic aromatic hydrocarbons (PAHs) as well as the particles 
themselves can induce allergic adjuvancy [191-195].  The present study investigated the 
relative adjuvant potency of three different DEP samples, N-DEP, A-DEP, and C-DEP 
which differed in the percentage of DCM extractable organic material (1.5%, 68.6%, and 
18.9%, respectively) in a mucosal sensitization model adopted from Steerenberg et al. 
[199]. This study demonstrated a synergistic effect from the combined exposure of DEP 
and antigen with respect to injury and inflammation. Overall the results showed that on a 
comparative mass basis, the three samples induced a gradation of post-challenge 
adjuvancy and this was not solely dependent on the organic content. The inflammatory 
component characterized by increased numbers of eosinophils, neutrophils, and 
lymphocytes was significantly increased in OVA, A-DEP alone, and all DEP + OVA 
treatment groups, with the C- and A-DEP + OVA groups exhibiting the most robust 
responses. Recruitment of these inflammatory cells was accompanied by increases in 
alveolar epithelial permeability, macrophage activity, and general cellular toxicity as 
measured by protein and MIA, NAG, and LDH levels, respectively. AHR and histology 
results were in overall agreement with these findings.  
Antigen-specific IgE antibodies have been shown to increase in response to DEP 
when given with antigen [128, 189, 190].  In the present study, all DEP + OVA induced a 
significant increase in OVA-specific IgG1 serum antibodies after antigen challenge, but 
not OVA-specific IgE. However, other indicators of allergic airway disease such as 
eosinophilic airway inflammation and airway hyperresponsiveness were present in mice 
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exposed to A- and C-DEP + OVA. In addition it has previously been reported that 
antigen specific IgG1, but not IgE, induced eosinophil degranulation ex vivo in the sera 
from ragweed pollen sensitive asthmatics [203]. Furthermore, late asthmatic reactions are 
correlated with high IgG1 but not IgE antibodies [204]. Therefore, antigen-specific IgG1 
appears to be an important indicator of adjuvancy in this model. 
Human and rodent studies have shown DEP induced allergic asthma is 
characterized by recruitment of T helper 2 (TH2) lymphocytes and subsequent production 
of TH2 cytokines like IL-4, IL-5, IL-10, and IL-13, which perpetuate the inflammatory 
response.  The importance of TH2 cells in allergic asthma is underlined by a study in 
which adoptive transfer of these cells into naïve mice led to an allergic asthma phenotype 
[205]. Conversely, removal of these cells prevented induction of asthma in sensitized 
mice. Thymus activation regulated chemokine (TARC), mainly produced by dendritic 
cells, selectively induces the migration of CCR4-expressing TH2 cells [206, 207] and is 
thought to play a crucial role in allergic asthma. Elevated TARC levels have been 
observed in the BALF of patients with allergic asthma after allergen challenge [208], and 
rodent studies have shown that neutralization of this chemokine attenuates OVA induced 
lung eosinophilia, TH2 cytokine expression, and associated increases in bronchial 
responsiveness after antigen challenge [209]. In the present study, TARC levels post-
challenge in the BALF were significantly increased in C-DEP + OVA exposed mice 
compared to all groups and this was accompanied by a significant increase in 
lymphocytes.  
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We and others have shown A-DEP alone and with antigen induces the TH2 
cytokine IL-5 in the BALF of mice and humans [124, 201, 210]. In agreement with these 
studies, IL-5 levels in the BALF of mice exposed to A-DEP + OVA were significantly 
increased above saline and OVA controls post-challenge. IL-5 is an important factor in 
the proliferation and activation of eosinophils and may explain the eosinophilia seen in 
those mice.  IL-10 is described as a TH2 cell factor that inhibits cytokine synthesis by TH1 
cells [211, 212]. Although others have found IL-10 to down-regulate IL-5 production 
[213-215], in this study IL-10 was increased along with IL-5 in the BALF of mice 
exposed to A-DEP + OVA providing more evidence for their cooperative effect. 
While most reports on PM-induced adjuvancy have focused on immune effects 
post-challenge, we were also interested in assessing early signaling events caused by 
DEP alone or in the context of antigen sensitization. The direct injury and 
proinflammatory effects of intranasal instillation of  DEP with or without OVA on the 
airways was assessed by analyzing biochemistry, cell differential counts, and cytokine 
profiling of the BALF 18 hours after the last DEP exposure. All DEP exposures alone 
caused no changes in the biochemical indicators of injury which suggests no direct local 
airway damage. The molecule NAG was also measured as an indicator of macrophage 
activation. Although A-DEP exposure increased the number of macrophages and N-DEP 
increased neutrophil influx, NAG levels were significantly elevated in the BALF of N-
DEP exposed mice.  C-DEP alone had no direct effect on lung injury, NAG, or cellular 
infiltration.  
In the context of antigen sensitization, N-DEP + OVA induced a slight increase in 
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LDH and NAG levels. This cellular injury and macrophage activation was accompanied 
by an increase in lymphocytes and the TH2 chemokines MCP-1 and TARC in the BALF.  
This mild TH2 phenotype post-sensitization was followed by a low level of adjuvancy 
post-challenge. Exposure to A-DEP with antigen induced a significant increase in LDH 
and protein levels but exhibited no significant cellular influx or cytokine production 
compared to OVA control, although this treatment group led to a robust adjuvant 
response post-challenge. On the other hand, C-DEP + OVA was a strong adjuvant post-
challenge and  induced a significant increase in NAG, eosinophils, neutrophils, and 
lymphocytes, as well as IL-4, 5, 6, MCP-1 and TARC post-sensitization. This indicates 
an early induction of a TH2 phenotype in C-DEP + OVA exposure.  
In the present study, C-DEP + OVA exposure induced the strongest TH2 response 
post-sensitization although this sample was more balanced with respect to organic and 
elemental carbon levels compared to the N-DEP and A-DEP, which contained very low 
or very high OC/EC ratios, respectively. This immune skewing induced by C-DEP + 
OVA exposure was followed by a robust adjuvant effect post-challenge. On the other 
hand, the organic rich A-DEP did not display a TH2 response when given with antigen 
but did in fact induce a strong adjuvant effect post-challenge. This suggests that the 
kinetics of the response or the mechanism may be different for inducing the post-
challenge adjuvant response in the A-DEP + OVA exposure.  
There is much evidence that the organic chemical compounds, such as PAHs, 
quinones, and nitro-PAHs, absorbed on the surface of DEP play a role in ROS production 
which in turn causes oxidative stress. If the level of oxidative stress exceeds the cells 
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natural antioxidant defense mechanisms then inflammatory cytokines and chemokines, 
which may contribute to the adjuvant effect of DEP, are produced. The amount of DCM 
extractable organic material present in the A-DEP sample was about 3.5 times greater 
than C-DEP; however, both samples when given with allergen induced similar degrees of 
adjuvancy post challenge. An alternate explanation for these effects induced by exposure 
to the different DEP samples is the presence of particular species of compounds in the 
organic fraction, rather than the overall amount, could be responsible for the toxic effects. 
Xia et al [165] demonstrated the quinone-enriched polar fraction of DEP was more potent 
than the PAH-enriched aromatic fraction in ROS production suggesting a greater ability 
to cause oxidative stress. Further chemical analysis of the compounds present in the 
fractionated DCM EOM of the DEP samples is needed. 
This research highlights the capacity of different diesel particles to modulate the 
induction of an immune response. On an equal mass basis all three particle samples could 
enhance allergic sensitization as measured by antigen-specific IgG1 antibodies in the 
BALF after antigen challenges; however, the effects were more pronounced with the C-
DEP and A-DEP samples which are composed of a higher percentage of extractable 
organic material. The adjuvant effects can be summarized as follows: C-DEP ≈ A-DEP 
>> N-DEP.  To date investigations of underlying mechanisms have mainly focused on 
ROS production. Since these studies have investigated a single DEP sample a 
comparative study analyzing different samples using a global inspection approach of 
transcriptional regulation is needed. This study identifies the importance of chemical 
composition when studying heterogeneous mixtures. The expanding knowledge of the 
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immune effects of DEP could ultimately have wider implications for unraveling the 
mechanisms of air pollution enhanced allergic lung disease. 
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Tables 
Table 2.1 Characteristics of A-DEP, C-DEP, and N-DEP 
Compound A-DEP C-DEP N-DEP 
Source  4-cylinder 4JB1 
type Isuzu 
automobile, Light 
duty (2740cc); on-
road 
30 kW (40hp) 4-
cylinder Deutz 
BF4M1008 diesel 
engine used to 
power a 22.3 kW 
Saylor Bell air 
compressor; 
stationary 
Industrial 
forklift; off-
road 
Collection method Dilution tunnel 
terminus onto 
glass fiber filter 
(GD-100R, 
203×254mm) at 
50°C, Particles 
were scraped off 
from the filter 
Diluted, cooled to 
35°C, and directed 
to a small baghouse 
(Dusyex model T6-
3.5-9 150 ACFM 
pyramidal baghouse) 
Diesel 
exhaust filter 
system, 
under hot 
conditions 
Collection Date Early 1990’s October 2004 Late 1980’s 
Organic carbon 
(OC)/Elemental carbon 
(EC)mass ratio 
5.56 0.33 0.08 
DCM EOM (% of DEP) 68.6 18.9 1.5 
Sub-fractions of EOM 
 (% of EOM) 
   
Hexane 57.3 73.6 37.9 
Hexane/DCM 3.2 7.1 4.4 
DCM 0.7 1.1 1.5 
Methanol 6.6 10.4 30.2 
Precipitates  
(hexane-insoluble) 
32.3 7.9 26.0 
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Table 2.2 Differential cell counts in the BALF 18 hrs after OVA challenge 
Group Macrophages 
(x104/ml BALF) 
Eosinophils 
(x104/ml BALF) 
Neutrophils 
(x104/ml BALF) 
Lymphocytes 
(x104/ml BALF) 
Saline 24.27 ± 2.01 0.13 ± 0.05 4.61 ± 1.16 0.49 ± 0.14 
OVA 32.19 ± 5.03 8.33 ± 4.67 6.62 ± 2.01 1.90 ± 1.00 
NDEP 35.51 ± 6.54 2.49 ± 2.46 7.61 ± 3.63 1.96 ± 1.52 
ADEP 28.68 ± 3.99 2.45 ± 0.93 5.54 ± 1.72 1.35 ± 0.33 
CDEP 32.82 ± 6.47 0.22 ± 0.19 9.71 ± 2.05 2.16 ± 0.57 
OVA + NDEP 39.11 ± 5.28 25.67 ± 13.18*,a,c 19.68 ± 6.64 10.68 ± 4.41*,#,a,b 
OVA + ADEP 38.09 ± 8.61 29.24 ± 15.12*,a,c 17.31 ± 5.15 7.35 ± 2.59* 
OVA + CDEP 68.54 ± 10.15*,#,a,b,c,d,e 38.01 ± 17.82*,a,b,c 36.16 ± 9.79*,#,a,b,c 19.42 ± 5.39*,#,a,b,c 
*P<0.05: significantly greater than saline control. #P<0.05: significantly greater than 
OVA control. aP<0.05: significantly greater than N-DEP. bP<0.05: significantly greater 
than A-DEP. cP<0.05: significantly greater than C-DEP. dP<0.05: significantly greater 
than N-DEP/OVA. eP<0.05: significantly greater than A-DEP/OVA. 
 
 
Table 2.3 Differential cell counts in the BALF 48 hrs after antigen challenge 
Group Macrophages 
(x104/ml BALF) 
Eosinophils 
(x104/ml BALF) 
Neutrophils 
(x104/ml 
BALF) 
Lymphocytes 
(x104/ml BALF) 
Saline 21.97 ± 3.53 0.40 ± 0.28 0.19 ± 0.09 0.25 ± 0.09 
OVA 29.38 ± 4.38 12.37 ± 4.67*,a,c 0.62 ± 0.18 3.62 ± 1.01*,a,c 
NDEP 25.52 ± 2.99 0.00 ± 0.00 0.64 ± 0.08 0.50 ± 0.15 
ADEP 30.18 ± 6.37 11.32 ± 5.31*,a,c 4.32 ± 2.62*,c 3.41 ± 2.35* 
CDEP 31.49 ± 1.70 0.23 ± 0.15 0.40 ± 0.08 0.57 ± 0.22 
OVA + NDEP 43.79 ± 6.62* 28.42 ± 5.72*,a,b,c 2.67 ± 1.13*,c 13.86 ± 3.94*,#,a,b,c 
OVA + ADEP 81.66 ± 11.09*,#,a,b,c,d 77.74 ± 12.29*,#,a,b,c,d 4.11 ± 1.22*,#,a,c 19.82 ± 2.66*,#,a,b,c 
OVA + CDEP 
83.72 ± 12.86*,#,a,b,c,d 81.96 ± 14.52*,#,a,b,c,d 11.47 ± 3.98*,#,a,c 
43.41 ± 
13.83*,#,a,b,c,d 
 
*P<0.05: significantly greater than saline control. #P<0.05: significantly greater than 
OVA control. aP<0.05: significantly greater than N-DEP. bP<0.05: significantly greater 
than A-DEP. cP<0.05: significantly greater than C-DEP. dP<0.05: significantly greater 
than N-DEP/OVA. 
 
 
 
 58 
Table 2.4 Histopathology scores 18 and 48 hrs after challenge 
 
 18 hrs 48 hrs 
Group Perivascular 
Inflammation 
Peribronchial 
Inflammation 
Perivascular 
Inflammation 
Peribronchial 
Inflammation 
Saline 0.33 0.33 0.33 0.00 
OVA 1.00 0.33 1.67 0.00 
NDEP 1.00 0.33 0.00 0.00 
ADEP 1.33 1.00 2.00 0.33 
CDEP 0.00 0.00 0.33 0.00 
OVA + NDEP 2.00 0.33 3.33 1.33 
OVA + ADEP 2.33 1.33 2.00 1.33 
OVA + CDEP 2.33 1.67 3.67 1.67 
 
 
 
Table 2.5 Differential cell counts in the BALF 18 hrs after sensitization 
 
Group Macrophages 
(x104/ml 
BALF) 
Eosinophils 
(x104/ml BALF) 
Neutrophils 
(x104/ml 
BALF) 
Lymphocytes 
(x104/ml BALF) 
Saline 5.32 ± 2.26 0.15 ± 0.13 5.53 ± 2.50 0.28 ± 0.13 
OVA 9.12 ± 2.70 0.03 ± 0.03 9.27 ± 3.13 0.21 ± 0.06 
NDEP 6.81 ± 1.34 0.16 ± 0.07 31.89 ± 3.70*,# 0.07 ± 0.06 
ADEP 14.16 ± 2.39*,c 0.00 ± 0.00 23.44 ± 6.40 0.06 ± 0.05 
CDEP 5.62 ± 1.61 0.00 ± 0.00 16.89 ± 1.72 0.03 ± 0.03 
OVA + NDEP 6.97 ± 1.60 0.09 ± 0.05 13.85 ± 2.86 0.39 ± 0.03a,b,c 
OVA + ADEP 6.25 ± 1.31 0.03 ± 0.03 13.85 ± 4.00 0.17 ± 0.07 
OVA + CDEP 7.72 ± 1.14 1.60 ± 0.80#,b,c,e 25.51 ± 7.02* 0.72 ± 0.07*,#,a,b,c,d,e 
*P<0.05: significantly greater than saline control. #P<0.05: significantly greater than 
OVA control. aP<0.05: significantly greater than N-DEP. bP<0.05: significantly greater 
than A-DEP. cP<0.05: significantly greater than C-DEP. dP<0.05: significantly greater 
than N-DEP/OVA.. . eP<0.05: significantly greater than A-DEP/OVA. 
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Figures 
 
 
 
 
Figure 2.1 Schematic of exposure regime. BALB/c mice were intranasally instilled 
with saline or 150 µg of N-, A-, or C-DEP, with or without 20 µg of OVA on days 0 and 
12.  Mice were challenged with an intranasal instillation of 20 µg of OVA on days 23, 26, 
and 29 and necropsied 18 or 48 hrs later.   
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Figure 2.2 Protein concentrations in the BALF after challenge.  Protein levels @ 18 
hrs (A) and 48 hrs (B). *P<0.05: significantly greater than saline control. #P<0.05: 
significantly greater than OVA control. aP<0.05: significantly greater than N-DEP. 
bP<0.05: significantly greater than A-DEP. cP<0.05: significantly greater than C-DEP. 
dP<0.05: significantly greater than N-DEP/OVA.  
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Figure 2.3 LDH levels in the BALF after challenge.  LDH levels @ 18 hrs (A) and 48 
hrs (B). *P<0.05: significantly greater than saline control. #P<0.05: significantly greater 
than OVA control. aP<0.05: significantly greater than N-DEP. bP<0.05: significantly 
greater than A-DEP. cP<0.05: significantly greater than C-DEP. dP<0.05: significantly 
greater than N-DEP/OVA.  
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Figure 2.4 Kinetic development of OVA-specific IgG1 serum antibodies in mice 
exposed to diesel exhaust during allergic sensitization. Mice were intranasally instilled 
with 20 µg of OVA alone or in combination with 150 µg of N-, A-, or C-DEP on days 0 
and 12.  Mice were challenged with 20 µg of OVA on days 23, 26, and 29 and necropsied 
after 18 or 48 hrs. OVA-specific IgG1 antibody levels were measured in the serum by 
ELISA. *P<0.05: significantly greater than saline control. #P<0.05: significantly greater 
than OVA control.  
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Figure 2.5 IL-5, IL-10, and TARC production levels in the BALF 18 hrs after 
challenge. Mice were intranasally instilled with saline, 20 µg of OVA alone or in 
combination with 150 ug of N-, A-, or C-DEP on days 0 and 12.  Mice were challenged 
with 20 µg of OVA on days 23, 26, and 29 and necropsied after 18 hrs. IL-5 (A), IL-10 
(B), and TARC (C) levels were measured in the BALF by ELISA. *P<0.05: significantly 
greater than saline control. #P<0.05: significantly greater than OVA control. aP<0.05: 
significantly greater than N-DEP + OVA. bP<0.05: significantly greater than A-DEP + 
OVA. cP<0.05: significantly greater than C-DEP + OVA.  
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Figure 2.6 Airway hyperresponsiveness in mice 48 hrs after OVA challenge. Mice 
were intranasally instilled with saline, 20 µg of OVA alone or in combination with 150 
ug of N-, A-, or C-DEP on days 0 and 12.  Mice were challenged with 20 µg of OVA on 
days 23, 26, and 29 and Airway hyperresponsiveness (AHR) was measured 48 hrs after 
the last challenge. AHR was determined by an increase in enhanced pause (Penh) in 
response to increasing concentrations to methacholine. *P<0.05: significantly greater than 
saline control.  
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Figure 2.7 TH2 cytokine and chemokine levels in the BALF 18 hrs after sensitization. 
Mice were intranasally instilled with saline, 20 µg of OVA alone or in combination with 
150 ug of N-, A-, or C-DEP on days 0 and 12 and necropsied 18 hrs later. IL-5 (A), IL-4 
(B), TARC (C), and MCP-1 (D) levels were measured in the BALF by ELISA. *P<0.05: 
significantly greater than saline control. #P<0.05: significantly greater than OVA control. 
aP<0.05: significantly greater than N-DEP + OVA. bP<0.05: significantly greater than A-
DEP + OVA.  
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Figure 2.8 IL-12 production levels in the BALF 18 hrs after sensitization. Mice were 
intranasally instilled with saline, 20 µg of OVA alone or in combination with 150 ug of 
N-, A-, or C-DEP on days 0 and 12 and necropsied 18 hrs later. IL-12 levels were 
measured in the BALF by ELISA. *P<0.05: significantly less than saline control.  
 
 
 
 
Chapter 3 
 
 
 
 
Differential Transcriptional Changes in Mice Exposed to Chemically 
Distinct Diesel Samples 
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Abstract 
Epidemiological studies have linked ambient particulate matter with exacerbation 
of asthmatic symptoms and pulmonary inflammation. Diesel exhaust particles (DEP) are 
a predominant source of vehicle derived ambient PM and experimental studies have benn 
shown to be an allergic adjuvant when given with an antigen. We previously assessed the 
effects of three chemically distinct DEP samples: N-DEP, A-DEP, and C-DEP in a 
murine ovalbumin (OVA) mucosal sensitization model. The present study exposed mice 
to these DEP samples with and without OVA on days 0 and 13 and analyzed gene 
expression changes in the lungs 18 hrs after the last exposure.  Transcription expression 
profiling demonstrated DEP altered cytokine and toll-like receptor pathways regardless of 
the sample or combination with antigen. Further analysis of DEP exposure with OVA 
demonstrated the C-DEP/OVA treatment to induce the greatest number of altered genes. 
While all three DEP/OVA treatments induced cytokine and toll-like receptor pathways to 
a greater extent than DEP alone, only A- and C-DEP/OVA treatments induced 
differential expression of apoptosis pathways. The induction of apoptosis pathways by 
these treatments was associated with a strong adjuvant response post-challenge in the 
previous study. In addition, the C-DEP/OVA treatment, which had the greatest TH2 
response post-sensitization in the previous study, altered expression of DNA damage 
pathways. This comprehensive approach using gene expression analysis to examine 
changes at a pathway level provides a clearer picture of the events occurring in the lung 
after DEP exposure in the presence or absence of antigen. 
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3.1 Introduction  
 
Epidemiology studies have reported an association between rises in ambient 
particle matter (PM) levels and increases in hospital rates due to respiratory illnesses 
including asthma [216]. Diesel exhaust particles (DEP) are an important contributor to 
ambient PM and many studies have focused on DEP as a model anthropogenic pollutant. 
These particles consist of a carbon core surrounded by various amounts of adsorbed 
organic compounds, including polycyclic aromatic hydrocarbons (PAHs), quinones, and 
nitro-PAHs [144]. Human and rodent studies have shown DEP to induce allergic lung 
disease when given with an antigen [15, 121, 217, 218]. Although the biologic 
mechanisms associated with the adverse health effects of DEP are not well understood, it 
is likely to involve oxidative stress and inflammation.  
 The composition of DEP varies greatly depending on the type of engine, load, 
and method of collection, which in turn can alter its biological function. Singh et al. [201] 
investigated the chemical characteristics and pulmonary toxicity of two different 
particles, an automobile derived DEP (A-DEP) and National Institute of Standard 
Technology standard reference material 2975 (N-DEP) generated from a heavy forklift. 
The two particle samples exhibited disparate pulmonary toxicity which reflected their 
dissimilar chemical composition. 
We previously assessed the effects of N-DEP, A-DEP, and C-DEP (generated 
from a diesel engine used to power a compressor) in a murine ovalbumin (OVA) mucosal 
sensitization model [219].  These samples differed in their percentage of dichloromethane 
(DCM) extractable organic material (EOM); N-DEP, C-DEP, and A-DEP contained 
1.5%, 18.9%, and 67%, respectively. Immune and inflammatory endpoints showed that  
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the potency of C-DEP/OVA ≈ A-DEP/OVA >> N-DEP/OVA with respect to post-
challenge adjuvancy as measured by eosinophilic inflammation and TH2 cytokines in the 
BALF, serum OVA-specific IgG1 antibodies, and airway hyperresponsiveness. C-
DEP/OVA, consistent with the strong degree of adjuvancy post-challenge, increased the 
influx of eosinophils, neutrophils, and lymphocytes, increased the production of TH2 
cytokines, and decreased the production of the TH1 cytokine IL-12 in the BALF, 18 hrs 
after sensitization. On the other hand, post-sensitization differential cell counts and 
production of TH1 and TH2 cytokines were not significantly different for the organic rich 
A-DEP/OVA compared to OVA control although this group induced a strong adjuvant 
effect post-challenge. The relatively elemental carbon rich N-DEP/OVA exposures 
induced a mild TH2 phenotype post-sensitization followed by a mild adjuvant effect post-
challenge. This suggests either the kinetics or the mechanism by which A-DEP/OVA 
induces allergic lung disease differs from the other DEP samples. The results also 
demonstrated the degree of adjuvancy was not solely dependent on organic content.   
While in vitro and in vivo microarray studies have been conducted to identify 
potential mechanisms for the adverse health effects of DEP, there are no reports of global 
transcriptional changes induced by DEP given with an allergen.  In addition, there have 
not been studies comparing the transcriptional profiles of chemically distinct DEP 
samples. The present study used microarray analysis of whole-lung RNA to elucidate the 
pathways and networks involved in the effects of N-DEP, A-DEP, and C-DEP given with 
or without allergen in BALB/C mice.   
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3.2 Materials and Methods 
 
3.2.1 Animals 
Female BALB/C mice (8-10 weeks old) were obtained from Charles River 
Laboratories (Raleigh, NC) and allowed to acclimate for a minimum of one week prior to 
dosing.  Mice were randomly assigned to treatment groups and housed in an AAALAC-
approved animal facility at the US-EPA.  All animal procedures were reviewed and 
approved by the US-EPA’s Institutional Animal Care and Use Committee. Housing 
environment conditions include a 12-h light/dark cycle at an ambient temperature of 
22±1ºC and relative humidity of 55±5ºC. Mice were provided water and mouse chow ad 
libitum. Additional mice from each facility were routinely monitored serologically for 
Sendai, mouse pneumonia, mouse hepatitis, and other murine viruses, as well as 
mycoplasma.  
 
3.2.2 Particle samples 
Standard Reference Material (SRM) 2975 diesel exhaust particle sample (N-DEP) 
was purchased from National Institute of Standard Technology (NIST) (Gaithersburg, 
MD). The reported mean diameter of these particles was 11.2 ±0.1 µm by area 
distribution, and the surface area, as determined by nitrogen adsorption, was 91µm2/g.  
The certified analysis contains 11 certified concentrations and 28 reference 
concentrations for selected PAHs found in the DEPs.  The DEP was generated by a 
heavy-duty forklift diesel engine and collected under “hot” conditions without a dilution 
tunnel.  
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Automobile DEP (A-DEP) was generated and collected under conditions 
previously described [187, 197].  Briefly, the sample was generated by a light-duty 
(2740cc), 4-cylinder Isuzu diesel engine. DEP was collected under “cold” (50 ºC) 
conditions onto glass-fiber filters and on steel duct walls in a constant-volume sampling 
system fitted at the end of a dilution tunnel.   
Compressor DEP (C-DEP) was generated in-house as described by Cao et al 
[198] at the EPA using a 30 kW (40 hp) 4-cylinder Deutz BF4M1008 diesel engine 
connected to a 22.3 kW Saylor Bell air compressor to provide 20% load.  The generated 
particles were collected under “hot” conditions in a baghouse. 
 
3.2.3 Experimental design 
DEP samples (N-, C-, A-DEP) were suspended at a concentration of 3 mg/ml in 
saline alone or with 0.4 mg/ml of ovalbumin.  Particles were sonicated using a Microson 
Ultrasonic Cell Disruptor (Micromix) for 10 min. Mice were randomly divided into 8 
treatment groups, anesthetized with isofluorane, and exposed to saline, 20 µg OVA, 150 
µg DEP, or DEP + OVA intranasal instillation on Days 0 and 13 and necropsied 18 hrs 
later.  
 
3.2.4 Necropsy and RNA isolation 
Mice were euthanized with sodium pentobarbital and bled by cardiac puncture.  
The chest wall was opened and the left lung lobe was removed, quick frozen in liquid 
nitrogen, and stored at -80° C. RNA from frozen lung tissue was isolated using RNeasy 
(Qiagen, Valencia, CA) following manufacture’s protocol.  Quantity and quality of the 
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RNA was measured using a Nanospot and Agilent Bioanalyzer (Agilent Technologies, 
Palo Alto, CA), respectively.  
 
3.2.5 Microarray 
RNA samples were prepared, processed, and hybridized to the Affymetrix Mouse 
430A gene chip at Expression Analysis (Durham, NC), as described in the GeneChip 
Expression Analysis Manual (Affymetrix; Santa Clara, CA).  The hybridized probe array 
was stained with streptavidin phycoerythrin conjugate and scanned by the GeneChip® 
Scanner 3000 (Affymetrix; Santa Clara, CA). The amount of light emitted at 570 nm is 
proportional to the bound target at each location on the probe array. 
The Mouse 430A Genome chip contains over 22,000 probe sets representing over 
14,000 well-characterized mouse genes.  A detailed description can be found at 
http://www.affymetrix.com/products/arrays/specific/mouse430.affx. A total of 24 gene 
chips representing lung samples from 24 individual mice (8 treatments, N=3) were used 
in this study.   
 
3.2.6 Overall data analysis strategy 
The analysis approach of this data set, consisting of 2 controls and 6 treatment 
groups, was to use a binary comparison approach of each treatment group compared to its 
respective control: N-DEP and saline, A-DEP and saline, C-DEP and saline, N-
DEP/OVA and OVA, A-DEP/OVA and OVA, and C-DEP/OVA and OVA.  The analysis 
of these data sets consisted of: 1) evaluating the data quality; 2) performing principal 
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components analysis (PCA) for a global inspection of within group sample 
correspondence and to examine model and dose effects; 3) performing Gene Set 
Enrichment Analysis (GSEA) to determine differentially expressed gene sets between 
treatment groups and controls; 4) extracting core genes responsible for a particular gene 
set identified as significant from the GSEA analysis; 5) determining common genes 
across treatment groups; 6) mapping core genes to functional pathways using KEGG 
pathways and MetaCore GENEGO® to identify altered pathways and networks unique or 
in common among the treatments. 
 
3.2.7 Principal component analysis (PCA) 
 PCA transforms microarray data from all gene chips to a new coordinate system 
using an orthogonal linear transformation, which reduces the data to a 3 dimensional 
coordinate system while retaining those characteristics of the data set that contribute most 
to the variance. This analysis was employed to survey the data for within-group outliers 
and model and dose effects using Rosetta Resolver (Rosetta Inpharmatics, Agilent 
Technologies, Palo Alto, CA) following linear weighting normalization (p<0.001). Each 
individual gene chip or gene expression profile was represented by a single data point and 
the variance between each gene chip was comparable to the distance between the data 
points whereby two similar gene expression profiles were projected as two adjacent 
points and vice versa. This analysis was employed as a visual tool to initially inspect the 
data for within group and across group similarities and dissimilarities.  
 
3.2.8 Gene set enrichment analysis (GSEA)   
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GSEA is a powerful computational method that utilizes an a priori defined set of 
genes to determine statistically significant, concordant differences between two 
phenotypes. For this analysis, raw data from 24 gene chips were quantile normalized 
using Robust Multichip Average (RMA) in Gene Pattern (www.genepattern.org) to 
generate estimated expression summaries. The RMA values were imported into GSEA to 
determine gene sets associated with each diesel treatment group compared to its 
respective control.  The molecular signature database (MSigDB) C2 provided on the 
website http://www.broad.mit.edu/gsea/msigdb/msigdbindex.html, which contains 1687 
gene sets, was queried for association with a particular treatment in each pairwise 
comparison (N-DEP/OVA and OVA, A-DEP/OVA and OVA, C-DEP/OVA and OVA, 
N-DEP and saline, A-DEP and saline, and C-DEP and saline). Only gene sets with a 
minimal gene set size of 15 genes per pathway and a maximum of 90 were queried.  We 
acknowledge our use of GSEA software and Molecular Signature Database (MSigDB) 
(http://www.broad.mit.edu/gsea/) [220].  
 
3.2.9 Pathway level analysis 
The gene sets with an FDR q-value of < 0.01 were used to create a core gene list. 
The core gene list comprised of genes responsible for a gene set being considered 
significant.  These genes were exported and then applied to two pathway analysis 
programs, KEGG Pathway Analysis (http://gather.genome.duke.edu/) and MetaCore 
GENEGO® (http://www.genego.com/metacore), which maps genes to pathways and 
determines significance. All pathways with a p-value of <0.001 and at least 5 or more 
differentially expressed genes were reported. 
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3.3 Results 
 
3.3.1 Principle component analysis (PCA) 
PCA was applied to provide a multidimensional gene expression profile of each 
gene chip in a 3 dimensional space to reveal clusters in the experimental data.  All data 
from the 24 gene chips were analyzed with each dot representing a gene chip (Figure 
3.1a). After analysis the gene chips were then highlighted in either blue (OVA treatment) 
or red (saline control). Good separation of the two groups was observed illustrating a 
model effect between antigen and saline.  The saline group appeared to be more tightly 
clustered than OVA indicating low within group variability.   To determine if exposure to 
chemically different DEP samples induces diverse genetic profiles, the gene chips were 
highlighted according to diesel sample (purple- A-DEP and A-DEP/OVA, blue- C-DEP 
and C-DEP/OVA, green- N-DEP and N-DEP/OVA, and yellow- saline and OVA) 
(Figure 3.1b).  The plot reveals a separation of the saline and OVA treatment groups from 
DEP treated groups. In addition, clustering of the A-DEP exposed mice regardless of 
antigen is seen while the N-DEP and C-DEP exposures were clustered separately from N- 
and C-DEP/OVA groups.  
 
3.3.2 Gene set enrichment analysis (GSEA) 
GSEA was developed to overcome the limitations of relatively small individual 
differential gene expression changes and small sample size. In contrast to conventional 
microarray analysis programs, the algorithm employed by GSEA derives its power by 
focusing on gene sets with biological relevance rather than individual genes. [220, 221]. 
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To test for sets of related genes that were altered in the lungs of mice exposed to the 
various treatments, we employed GSEA.  The arrays were separated into 6 binary groups; 
N-DEP/saline and saline, A-DEP/saline and saline, C-DEP/saline and saline, N-
DEP/OVA and OVA, A-DEP/OVA and OVA, and C-DEP/OVA and OVA. The C2 
collection of curated gene sets from the MSigDB were queried and a detailed description 
of each gene set can be found on the website 
http://www.broad.mit.edu/gsea/msigdb/msigdb_index.html. Gene sets with a false 
discovery rate (FDR) q-value of < 0.001 were considered significant. The number of 
significant gene sets associated with N-DEP, A-DEP, and C-DEP, as determined by the 
pairwise comparisons (DEP exposure and saline control), was 101, 90, and 98, 
respectively. In the context of antigen, 60, 68, and 113 gene sets were associated with N-, 
A-, and C-DEP/OVA, respectively.  The complete list of the significant gene sets is 
found in Appendices 1-6.  
  
3.3.3 Venn analyses 
 Venn analyses were performed to identify the common genes to all DEP 
exposures. The core genes (those genes responsible for a gene set being considered 
significant with a FDR q-values of <0.001) were extracted from the significant gene sets 
associated with each diesel exposure identified by GSEA. A venn diagram was 
constructed to identify genes common among the 3 DEP/saline exposure pairwise 
comparisons (Figure 3.2a). ADEP/saline exposure resulted in the greatest number of 
differentially expressed genes (545). 200 genes were common among all 3 DEP 
treatments. Similarly a venn diagram was constructed for the genes associated with each 
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DEP/OVA exposure (Figure 3.2b).  CDEP/OVA exposure resulted in greatest number of 
differentially expressed genes (800). 236 genes were found common to all DEP + OVA 
exposures. The two sets of common genes were applied to another venn diagram to 
identify the 117 common genes among all DEP exposures (Figure 3.2c). 
 
3.3.4 KEGG pathway analyses 
To understand the biological significance of the common genes associated with 
the 3 DEP/saline exposures, the 200 genes were imported into the gene annotation tool, 
Gather (http://gather.genome.duke.edu/), and the genes were mapped to KEGG pathways, 
using the criteria that pathways must have 5 or more differentially expressed genes and 
be overrepresented based on a hypergeometric test with p-value <0.001. Cytokine-
cytokine receptor interaction and toll-like receptor signaling pathway were common to all 
DEP/saline exposures (Table 3.1). The 236 genes common among the 3 DEP/OVA 
exposures also significantly populated the cytokine-cytokine receptor interaction and toll-
like receptor signaling pathway as well as the KEGG apoptosis pathway (Table 3.2). 
Table 3.3, representing the 117 common genes for all DEP/saline and DEP/OVA 
exposures, contains all but 3 of the genes found in the 2 pathways common to the 
DEP/saline (Table 3.1).  These genes included common proinflammatory cytokines and 
chemokines such as IL1, IL6, Ccl2, 3, 4, 6, 7, 8, 9, 11, 17, and 22. 
To understand the effects of the individual DEP/OVA exposures, the extracted 
core genes were mapped to KEGG pathways and the results represented in Tables 3.4-
3.6. CDEP/OVA altered the most number of pathways. All 3 exposures populated the 
cytokine-cytokine receptor pathway similarly with 56, 56, and 51 genes for NDEP/OVA, 
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ADEP/OVA, and CDEP/OVA, respectively. Additionally, the toll-like receptor pathway 
contained similar amounts of genes with 23, 26, and 28 genes for NDEP/OVA, 
ADEP/OVA, and CDEP/OVA, respectively. This pathway contained toll-like receptors 
as well as many proinflammatory cytokines and transcription factors. N-DEP/OVA and 
C-DEP/OVA altered the expression of genes in the neuroactive ligand-receptor 
interaction pathway. ADEP/OVA and C-DEP/OVA altered the apoptosis pathway. 
Pyrimidine metabolism and aminoacyl-tRNA biosynthesis pathways were unique to C-
DEP/OVA exposures.   
 
3.3.5 GeneGo analysis 
The C-DEP/OVA exposure gave the highest transcriptional changes based on the 
numbers of significant gene sets, extracted core genes, and the KEGG pathways, 
however, these analyses were not specific enough to allow an inference as to why or how 
C-DEP was able to elicit a stronger TH2 response post-sensitization. We therefore 
mapped the 3 sets of genes to GeneGo curated databases and the results can be found in 
Figures 3.3 and 3.4.  Figure 3.3 depicts the significance of the top 20 differentially 
affected GeneGo process networks for all 3 DEP/OVA exposures (N-DEP/OVA-blue; A-
DEP/OVA-red; C-DEP/OVA-orange). Using this approach the similarities and 
differences of the groups are clear. All groups significantly altered networks related to 
antigen presentation, inflammation, and cell adhesion.  In addition the C-DEP/OVA 
exposure also altered cell cycle, DNA damage, and protein degradation networks. 
Differentially affected GeneGo analysis on a pathway level revealed the common 
pathways were associated with MHC class I antigen presentation, inflammation, and 
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other pathways related to the innate immune response. The A-DEP/OVA and C-
DEP/OVA common pathways were involved with TNF mediated apoptosis pathways 
whereas C-DEP/OVA alone also induced altered expression of FAS, IAP, and 
mitochondrial mediated apoptosis and cell cycle regulation pathways (Figure 3.4).  
 
3.4 Discussion 
It has been established that DEP can act as an immunologic adjuvant when given 
with antigen [15, 121, 217, 218]; however, there is still a lack of understanding as to what 
component or components are responsible for these effects and the underlying 
mechanisms through which they act.  The organic extractable material (EOM) as well as 
the particle itself has been shown to be responsible for the inflammatory and adjuvant 
effects [131, 133, 222]. In addition, it has been demonstrated that the physicochemical 
composition of DEP influences its biological function [1].   
We recently reported the adjuvant effects of three DEP samples with different 
amounts of dichloromethane (DCM) EOM (N-, A-, and C-DEP samples contained 1.5, 
67, and 18.9%, respectively) in a murine mucosal sensitization model [219].  The results 
demonstrated A-DEP/OVA and C-DEP/OVA exposures induced strong allergic 
responses after antigen challenge, while N-DEP, when given with OVA, was a mild 
adjuvant. To understand the mechanism behind these responses, we examined changes in 
the BALF 18 hrs after the last sensitization. The results were C-DEP/OVA > N-
DEP/OVA > A-DEP/OVA with respect to cellular influx and TH2 cytokine production 
[219].  
The present study was designed to identify the global transcriptional changes in 
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the lung after exposure to the three chemically distinct DEP samples (N-, A-, and C-DEP) 
with or without OVA. While it is important to identify individual genes that are 
associated with a toxic response, most toxicity occurs through interactions of multiple 
genes. Therefore, our approach was to identify pathways common and unique to the 
DEP/OVA exposures and to associate their transcriptional responses to their allergic 
phenotype. 
It is known that DEP exposure induces lung inflammation. DE and DEP have 
been shown to induce pulmonary inflammation manifested by neutrophil infiltration and 
elevated levels of total protein, albumin, LDH, and ROS in the lung as well as up-
regulation of inflammatory pathways [201, 217, 219, 223, 224]. Based on these 
observations, it was no surprise that the cytokine-cytokine receptor pathway was a 
significantly altered pathway common to all DEP/saline exposures. The genes in this 
pathway included inflammatory, TH1, and TH2 cytokines and chemokines, but the 
majority of them were associated with neutrophil signaling in the DEP/saline exposures. 
In agreement with these findings, all three DEP/saline samples induced an increase in 
neutrophils in the BALF at this time point, although the increase was not significant 
[219].  
  Toll-like receptor signaling was also altered in all DEP/saline exposures. Toll-like 
receptors (TLRs) play important roles in the initiation of both innate and adaptive 
immune responses [225, 226]. Their activation is usually associated with viral or bacterial 
exposure; however, TLRs can also signal in response to endogenous molecules and 
environmental pollutants.  NO2 adjuvant effects are dependent on TLR2 [227], and 
airway hyperresponsiveness, induced by chronic ozone exposure, is dependent on TLR4 
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[228]. In addition, Zhou et al. [229] reported heat shock induced increases in TLR2 and 
TLR4 mRNA and protein expression in monocytes. Furthermore, DEP has been shown to 
induce TLR4 expression in the lung [230] and TLR4 deficient mice develop airway 
inflammation to a lesser degree in response to DEP compared to control [231]. Our 
results demonstrated that the toll-like receptor interaction pathway was altered by all 
three DEP/saline exposures, providing further evidence that the TLR pathway is involved 
in DEP induced inflammatory responses.  
The cytokine-cytokine receptor interaction and toll-like receptor signal pathways 
were also common pathways associated with all three DEP/OVA exposures but with a 
greater enrichment of genes in both pathways. In addition, GeneGo pathway analysis 
revealed significantly altered immune response, inflammatory, and apoptosis pathways. 
We have previously shown all three DEP/OVA exposures induced allergic adjuvancy 
after antigen challenge suggesting the pathways presented here may be important early 
signaling pathways in DEP induced allergic disease.   
Li et al. [174] proposed a hierarchical oxidative stress model to explain DEP 
induced effects whereby low levels of oxidative stress induce antioxidant defense 
mechanisms to restore redox balance in the cell (tier 1). Intermediate levels of oxidative 
stress (tier 2) activate MAPK and NF-κB cascades, which induce inflammation, while 
high levels of oxidative stress (tier 3) activate apoptosis and apoptosis/necrosis pathways 
[174]. The study presented here confirmed similar effects in vivo.  Antioxidant 
transcription factor and enzymes such as Nrf2, heme oxygenase 1 (HO-1), and 
superoxide dismutase 2 (SOD2) were up-regulated in response to all three DEP/OVA 
exposures indicative of the tier 1 response. The tier 2 responses were also up-regulated: 
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MAPKs, NF-κB, as well as inflammatory, TH1, and TH2 cytokines and chemokines. In 
addition, A- and C-DEP/OVA exposures altered apoptosis (tier 3) pathways; however, C-
DEP/OVA significantly altered the greatest number of these pathways. Furthermore, the 
apoptosis pathway representation appears to coincide with the combined phenotypic 
allergic responses of the three DEP/OVA. Although ROS production was not measured, 
the results suggest that C-DEP/OVA, according to the hierarchical stress model, induced 
high levels of oxidative stress. 
It has been established that DEP organic compounds can generate reactive oxygen 
species (ROS) [232] and excessive ROS production can lead to a variety of cellular 
responses including DNA damage [233]. In fact, oxidative DNA damage (8-
hydroxydeoxyguanosine) has been detected in mouse lung DNA after DEP exposure 
[234].  Although the A-DEP sample contained the greatest amount of DCM EOM, in the 
present study, C-DEP/OVA exposure was unique in significantly altering cell cycle and 
DNA damage pathways.  Global transcriptional analysis of lung tissue revealed up-
regulation of cell cycle control genes including 6 cyclin genes, 7 cell division cycle 
genes, 7 members of the family of MAP kinases, 2 cyclin-dependent kinases, RAS p21 
protein activator 3 (Rasa3),  and 5 other RAS related proteins.  
In conclusion mice exposed to all three DEP samples with or without OVA had 
altered cytokine and toll-like receptor pathways suggesting these responses are a DEP 
chemical class signature rather than an effect of a particular component of DEP (i.e. the 
percentage of DCM EOM). All DEP/OVA exposures increased transcription of genes 
involved in the hierarchical stress response model described by Li et al. [166, 174, 175]. 
CDEP/OVA exposure significantly altered the most number of apoptosis pathways as 
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well as cell cycle and DNA damage pathways suggesting the C-DEP is the most bioactive 
sample. This comprehensive approach using gene expression analysis to examine 
pathway changes at a transcriptional level provides a clearer picture of the events 
occurring in the lung after DEP exposure in the presence or absence of antigen. Genomic 
analysis revealed a wide range of altered pathways suggesting this method may be more 
sensitive and can be used for identifying mechanisms involved in adverse effects of 
inhaled pollutants. 
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Tables 
 
Table 3.1 KEGG pathways mapped from the 200 common genes associated with 
DEP/saline exposure 
 
KEGG Pathway # Genes p Value 
Cytokine-cytokine receptor interaction 28 < 0.0001 
       Ccl17 Ccl2 Ccl22 Ccl3 Ccl4 Ccl6 Ccl7 Ccl8 Ccl9 Ccr1 Ccr2 Csf2    
       Csf2rb1 Cxcl1 Cxcl10 Cxcl13 Cxcl2 Cxcl5 Ifngr2 Il1b Il1r2 Il8rb  
       Inhba Ltb Osmr Tnf Tnfrsf1b Tnfrsf9  
Toll-like receptor signaling pathway 11 < 0.0001 
       Ccl3 Ccl4 Cd14 Cxcl10 Il1b Nfkb2 Nfkbia Pik3cd Rac2 Tlr2 Tnf    
   
 
 
 
Table 3.2 KEGG pathways mapped from the 236 genes common to all DEP/OVA 
exposure 
 
KEGG Pathway # Genes p Value 
Cytokine-cytokine receptor interaction 40 < 0.0001 
       Ccl11 Ccl17 Ccl2 Ccl22 Ccl3 Ccl4 Ccl6 Ccl7 Ccl8 Ccl9 Ccr1 Ccr2    
       Ccr5 Csf1 Csf2 Csf2ra Csf2rb1 Csf2rb2 Csf3r Cxcl1 Cxcl10 Cxcl11    
       Cxcl13 Cxcl2 Cxcl5 Cxcl9 Ifngr2 Il1a Il1b Il1r1 Il1r2 Il2rg Il6 Il8rb    
       Osmr Tgfb1 Tnf Tnfrsf1b Tnfrsf5 Tnfrsf9   
Toll-like receptor signaling pathway 17 < 0.0001 
       Ccl3 Ccl4 Cd14 Cxcl10 Cxcl11 Cxcl9 Ikbke Il1b Il6 Lbp Nfkb1    
       Nfkb2 Pik3cd Rac2 Stat1 Tlr2 Tnf   
Apoptosis 11 0.0002 
       Birc3 Cflar Csf2rb1 Csf2rb2 Il1a Il1b Il1r1 Nfkb1 Nfkb2 Pik3cd Tnf    
   
   
 
   
Table 3.3 KEGG pathways mapped from the 117 genes common to both DEP/OVA and 
DEP/saline exposure 
 
KEGG Pathway # Genes p Value 
Cytokine-cytokine receptor interaction 26 < 0.0001 
       Ccl17 Ccl2 Ccl22 Ccl3 Ccl4 Ccl6 Ccl7 Ccl8 Ccl9 Ccr1 Ccr2 Csf2    
       Csf2rb1 Cxcl1 Cxcl10 Cxcl13 Cxcl2 Cxcl5 Ifngr2 Il1b Il1r2 Il8rb    
       Osmr Tnf Tnfrsf1b Tnfrsf9    
Toll-like receptor signaling pathway 10 < 0.0001 
        Ccl3 Ccl4 Cd14 Cxcl10 Il1b Nfkb2 Pik3cd Rac2 Tlr2 Tnf    
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Table 3.4 KEGG pathway mapped from the 526 genes associated with N-DEP/OVA 
exposure 
 
KEGG Pathway # Genes p Value 
Cytokine-cytokine receptor interaction 56 < 0.0001 
       Ccl11 Ccl17 Ccl2 Ccl22 Ccl3 Ccl4 Ccl6 Ccl7 Ccl8 Ccl9 Ccr1    
       Ccr2 Ccr5 Ccr6 Ccr7 Csf1 Csf1r Csf2 Csf2ra Csf2rb1 Csf2rb2   
       Csf3r Cxcl1 Cxcl10 Cxcl11 Cxcl13 Cxcl2 Cxcl5 Cxcl9 Ifnar1    
       Ifnar2 Ifngr2 Il10ra Il15 Il18rap Il1a Il1b Il1r1 Il1r2 Il2 Il2ra Il2rg   
       Il3ra Il6 Il7r Il8rb Ltb Osmr Tgfb1 Tnf Tnfrsf10b Tnfrsf13c     
       Tnfrsf1b Tnfrsf5 Tnfrsf9 Tnfsf9   
   
Toll-like receptor signaling pathway 23 < 0.0001 
       Ccl3 Ccl4 Cd14 Cd86 Cxcl10 Cxcl11 Cxcl9 Fos Ifnar1 Ifnar2    
       Ikbke Il1b Il6 Lbp Nfkb1 Nfkb2 Nfkbia Pik3cd Rac2 Stat1 Tlr2  
       Tlr7 Tnf   
   
Neuroactive ligand-receptor interaction 6 0.0002 
       Adora2b C3ar1 Ctsg Fpr1 P2ry6 Ptger4    
 
 
 
 
Table 3.5 KEGG pathways mapped from the 483 genes associated with A-DEP/OVA 
exposure 
 
KEGG Pathway # Genes p Value 
Cytokine-cytokine receptor interaction 56 < 0.0001 
       Ccl11 Ccl17 Ccl2 Ccl22 Ccl3 Ccl4 Ccl6 Ccl7 Ccl8 Ccl9 Ccr1 Ccr2    
       Ccr4 Ccr5 Csf1 Csf2 Csf2ra Csf2rb1 Csf2rb2 Csf3r Cxcl1 Cxcl10    
       Cxcl11 Cxcl13 Cxcl2 Cxcl5 Cxcl9 Ifnar2 Ifnb1 Ifng Ifngr2 Il12a    
       Il12b Il12rb1 Il1a Il1b Il1r1 Il1r2 Il2 Il2rg Il4 Il5 Il6 Il8rb Inhba    
       Osmr Tgfb1 Tgfbr1 Tnf Tnfrsf1a Tnfrsf1b Tnfrsf5 Tnfrsf9 Tnfsf10      
       Tnfsf13 Tnfsf13b   
   
Toll-like receptor signaling pathway 26 < 0.0001 
       Ccl3 Ccl4 Cd14 Cxcl10 Cxcl11 Cxcl9 Ifnar2 Ifnb1 Ikbke Il12a Il12b   
       Il1b Il6 Lbp Map3k7ip1 Mapk13 Myd88 Nfkb1 Nfkb2 Nfkbia    
       Pik3cd Rac2 Stat1 Tlr1 Tlr2 Tnf    
   
Apoptosis 19 < 0.0001 
       Bax Birc3 Capn1 Casp3 Cflar Csf2rb1 Csf2rb2 Il1a Il1b Il1r1    
       Myd88 Nfkb1 Nfkb2 Nfkbia Pik3cd Ripk1 Tnf Tnfrsf1a Tnfsf10    
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Table 3.6 KEGG pathways mapped from the 800 genes associated with C-DEP/OVA 
exposure 
 
KEGG Pathway # Genes p Value 
Apoptosis 28 < 0.0001 
       Apaf1 Bax Bid Birc2 Birc3 Casp3 Casp7 Casp8 Cflar Chuk    
       Csf2rb1 Csf2rb2 Dffa Ikbkb Il1a Il1b Il1r1 Il3ra Irak1 Myd88    
       Nfkb1 Nfkb2 Pik3cd Ripk1 Tnf Tnfrsf1a Tradd Traf2    
   
Cytokine-cytokine receptor interaction 51 < 0.0001 
       Ccl11 Ccl17 Ccl2 Ccl22 Ccl3 Ccl4 Ccl6 Ccl7 Ccl8 Ccl9 Ccr1    
       Ccr2 Ccr5 Csf1 Csf2 Csf2ra Csf2rb1 Csf2rb2 Csf3r Cxcl1 Cxcl10   
       Cxcl11 Cxcl13 Cxcl2 Cxcl5 Cxcl9 Ifngr2 Il10ra Il1a Il1b Il1r1   
       Il1r2 Il2rb Il2rg Il3ra Il6 Il7r Il8rb Inhba Ltb Osmr Tgfb1 Tgfbr1   
       Tnf Tnfrsf1a Tnfrsf1b Tnfrsf25 Tnfrsf5 Tnfrsf9 Tnfsf13b Tnfsf9    
   
Aminoacyl-tRNA biosynthesis 13 < 0.0001 
       Aars Cars Fars1 Farslb Gars Iars Kars Nars Rars Tars Vars2    
       Wars Yars    
   
Toll-like receptor signaling pathway 28 < 0.0001 
       Casp8 Ccl3 Ccl4 Cd14 Chuk Cxcl10 Cxcl11 Cxcl9 Ikbkb Ikbke    
       Il1b Il6 Irak1 Lbp Ly96 Map2k4 Map3k7 Mapk13 Myd88 Nfkb1    
       Nfkb2 Pik3cd Rac2 Stat1 Tlr2 Tlr4 Tlr7 Tnf    
   
Pyrimidine metabolism  21 < 0.0001 
       Ctps Dck Dtymk Dut Ecgf1 Nme1 Nme2 Pola2 Pold1   
       Pold2 Pole2 Polr2g Polr2h Polr3k Prim1 Rrm2 Txnrd1 Umpk    
       Umps Upp1    
   
Neuroactive ligand-receptor interaction 7 < 0.0001 
       Adora2b Bzrp C3ar1 Grik5 Gzma P2ry6 Ptger4    
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Figures 
 
 
 
Figure 3.1 Principle component analysis plot from microarray data. PCA plots were 
created in Rosetta Resolver. Each plot contains gene chips from all mice and each dot 
represents a gene chip. Gene chips were highlighted according to the immunization 
protocol (blue-OVA treatment or red-saline treatment) (A) or the diesel exposure 
(yellow- saline and saline/OVA, pink- A-DEP and A-DEP/OVA, blue- C-DEP/saline and 
C-DEP/OVA, and green- N-DEP/saline and N-DEP/OVA) (B). 
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Figure 3.2 Venn analyses. Venn analyses of the core genes from significantly altered 
gene sets associated with each exposure  
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Figure 3.3 Results of GeneGo mapping of differentially affected networks. 
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Figure 3.4 Results of GeneGo mapping of differentially affected pathways. 
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Abstract 
Diesel exhaust (DE) has been shown to enhance allergic sensitization in animals 
following high dose instillation or chronic inhalation exposure scenarios.  The purpose of 
this study was to determine if short term exposures to diluted DE enhance allergic 
immune responses to antigen, and identify possible mechanisms using microarray 
technology. BALB/c mice were exposed to filtered air or diluted DE to yield particle 
concentrations of 500 or 2000 µg/m3 4 hr/day on days 0-4.  Mice were immunized 
intranasally with ovalbumin (OVA) antigen or saline on days 0-2, challenged on day 18 
with OVA or saline, and all mice were challenged with OVA on day 28. Mice were 
necropsied either 4 hrs after the last DE exposure on day 4, or 18, 48, and 96 hrs after the 
last challenge.  Immunological endpoints included OVA-specific serum IgE, biochemical 
and cellular profiles of bronchoalveolar lavage (BAL), and cytokine production in the 
BAL. OVA-immunized mice exposed to both concentrations of DE had increased 
eosinophils, neutrophils, lymphocytes, and IL-6 post-challenge compared to OVA 
control, while DE/saline exposure yielded increases in neutrophils at the high dose only.  
Transcriptional microarray analysis 4 hrs after the last DE exposure demonstrated distinct 
gene expression profiles for the high dose DE/OVA and DE/saline groups. DE/OVA 
induced oxidative stress and metabolism pathways while DE in the absence of 
immunization modulated cell cycle control, growth and differentiation, G-proteins, and 
cell adhesion pathways.  This study shows for the first time early changes in gene 
expression induced by the combination of diesel exhaust inhalation and mucosal 
immunization, which resulted in stronger development of allergic eosinophilia. 
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4.1 Introduction 
The prevalence of allergic asthma has risen over the last 4 decades and has been 
linked to increased urbanization and exposure to airborne pollutants [235-237].  Recent 
studies have shown that the actual incidence of asthma could be related to residential 
highway proximity [238, 239] or average ozone exposure concentrations [240, 241].  A 
large contributor to urban air pollution and ambient particulate matter (PM) is diesel 
exhaust (DE).  Human occupational exposures to DE range from 1-100 µg/m3 (eight-
hour averages) in the trucking and transportation industry, average  225 µg/m3 (time-
weighted average with adjustment for background levels) for Boston and New York 
firefighters, and 100-1700 µg/m3 for  underground miners [242, 243]. Experiments in 
mice have shown that inhalation of fresh DE or intrapulmonary instillation of diesel 
exhaust particles (DEPs) results in adjuvant activity that increases the sensitization to 
allergens [14, 15, 244].  Most of these studies used high dose instillation or chronic 
inhalation exposure scenarios to demonstrate this detrimental health effect while some 
limited instillation studies showed similar effects in humans [122, 135].  
The mechanisms by which DE acts as an adjuvant are complex.  The adjuvant 
potential of DE has been attributed to the generation of reactive oxygen species (ROS) by 
pro-oxidative organic chemical compounds on the surface of the particles [158, 164, 165, 
245].  There is good evidence, however, that the carbon core of DEPs also imparts 
adjuvant activity through ROS production, as can accompanying gases such as NO2 [123, 
189, 246-248]. ROS generation by any of these components of DE may lead to a 3 tier 
hierarchical oxidative stress response described by Li and co-workers (2003). Initial 
responses to oxidative stress first lead to the induction of antioxidant and detoxification 
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mechanisms which restore cellular homeostasis (tier 1). If the capacity of these systems is 
overwhelmed, the ensuing inflammation (tier 2) leads to apoptosis (tier 3) [174].   The 
importance of oxidative stress in promoting allergic immune responses is supported by 
reversal of these effects with thiol anti-oxidants [158, 249].  
After DE exposure in the context of antigen, components of the immune response 
responsible for allergic sensitization, such as IL-4, IL-5 and IL-13, are upregulated.  This 
immune skewing results in a bias towards T-helper 2 immune activity, and increased 
development of IgE antibodies [42].  Following antigen challenge there are subsequent 
increases in clinical indicators of asthma such as eosinophilic lung inflammation, airway 
hyperresponsiveness, and airway mucous production [42].  While the chemical 
components of DE that cause these adjuvant effects under high dose conditions are 
diverse, demonstrating significant affects with more realistic inhalation exposure 
scenarios has been challenging because resultant changes in response are much smaller in 
magnitude.  
Inhalation exposure studies are important from a dosimetry perspective for risk 
assessment calculations.  Because low levels of DE exposure cause minimal changes in 
disease over short exposure periods, we sought to investigate more sensitive measures of 
altered immune function and early signaling pathways. The field of toxicogenomics has 
allowed simultaneous comparison of thousands of genes following experimental 
perturbations.  Accompanying data sets and analytical software packages have been 
critical in identifying pathways as opposed to comparing single genes [250].  While some 
in vitro genomic studies of DEPs have been reported, no data are currently available for 
in vivo inhalation exposures.  Furthermore, the interaction with antigen sensitization has 
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not been studied with a broad toxicogenomic pathway analysis approach.  
In this study mice were exposed by whole-body inhalation to filtered air or DE 
diluted to yield 500 or 2000 µg/m3 of DEP.  Exposures were conducted for 4 hr/day over 
5 consecutive days (days 0-4).  On days 0, 1, and 2, mice were intranasally instilled with 
100 µg of OVA or saline. Day 18 mice were either challenged with OVA or saline and all 
mice were challenged with OVA on day 28.  Effects were assessed after the 2° challenge 
to confirm that mild adjuvancy was accomplished.  Lung tissues taken 4 hrs after the last 
DE exposure on day 4 were assessed for alterations in global gene expression as an 
indicator of changes associated with later development of clinical disease.  
 
 
4.2 Materials and Methods 
 
4.2.1 Animals 
Pathogen-free BALB/c female mice, 10-12 wk old, weighing 17-20 g, were 
purchased from Charles River (Raleigh, NC).  All of the animals were housed in 
AAALAC-approved animal facilities with high-efficiency particulate air filters and 
received access to food and water ad libitum.  The studies were conducted after approval 
by the laboratory’s Institutional Animal Care and Use Committee. 
 
4.2.2 Diesel Exhaust Exposure and Monitoring 
Diesel exhaust was generated in-house using a 30 kW (40 hp) 4-cylinder Deutz 
BF4M1008 diesel engine connected to a 22.3 kW Saylor Bell air compressor to provide a 
load.  Diesel fuel was purchased from a local (Research Triangle Park, NC) service 
station and stored in drums.  Replicate analysis (ultimate, elemental, heating value, and 
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specific gravity) of multiple batches of fuel purchased over time indicated consistent fuel 
properties and composition (data not shown).  Engine lubrication oil (Shell Rotella, 15W-
40) was changed before each set of exposure tests.  The engine and compressor were 
operated at steady-state to produce 0.8 m3/min of compressed air at 400 kPa.  This 
translates to approximately 20% of the engine’s full-load rating.  From the engine 
exhaust, a small portion of the flow (14 L/min) was educted by an aspirator (3:1 dilution) 
to a second cone diluter (10:1 dilution), and then through approximately 15 m of flexible 
food grade polyvinyl chloride (PVC) tubing (7.62 cm inside diameter) to two stainless 
steel 0.3 m3 Hinners inhalation exposure chambers housed in an isolated animal exposure 
room.  The dilution air used was drawn from the animal exposure room through a high 
efficiency particulate air (HEPA) filter.  Target DEP concentrations in the two chambers 
were 2000 µg/m3 (high) and 500 µg/m3 (low).  Control animals were housed in a third 
chamber supplied with the same HEPA filtered room air.  DEP concentrations in the low 
(500 µg/m3) chamber were achieved by additional dilution using HEPA filtered room air 
just prior to entering the chamber.  All three chambers were operated at the same flow 
rate (142 L/min) which resulted in 28 air exchanges per hour. 
Integrated 4 h filter samples (14.1 L/min) were collected once daily from each 
chamber and analyzed gravimetrically to determine particle concentrations.  In addition, 
8 and 20 min quartz filter samples (14.1 L/min) were collected from the high and low 
chambers, respectively, and analyzed using a thermal/optical carbon analyzer (Sunset 
Laboratory Inc., model 107, Tigard, OR) to determine organic carbon/elemental carbon 
(OC/EC) partitioning of the collected DEP.  Continuous emission monitors (CEMs) were 
used to measure chamber concentrations of PM by tapered element oscillating 
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microbalance (TEOM, Rupprecht and Patashnick Co., series 1400, Albany, NY); oxygen 
(O2, Beckman Corp., model 755, La Habra, CA); and carbon monoxide (CO., model 48, 
Franklin), nitric oxide and nitrogen dioxide (NO and NO2, model 42c., Franklin), and 
sulfur dioxide (SO2, model 43c, Franklin) by Thermo Electron Corp., Franklin (Waltham, 
MA).  Samples were extracted through fixed stainless steel probes in the exposure 
chambers. Gas samples were passed through a particulate filter prior to the individual gas 
analyzers.  Dilution air was adjusted periodically to maintain target PM concentrations as 
measured by the TEOM.  Particle size distributions were characterized using a scanning 
mobility particle sizer (SMPS, TSI Inc., model 3080/3022a, St. Paul, MN) and an 
aerodynamic particle sizer (APS, TSI Inc., model 3321, St. Paul, MN).  Chamber 
temperatures, relative humidity, and noise were also monitored, and maintained within 
acceptable ranges.   
 
4.2.3 Experimental Design 
Figure 4.1 depicts the exposure regimen utilized for diesel exhaust exposure and 
intranasal ovalbumin (OVA) immunization and challenge. Mice were exposed to HEPA 
filtered air or DE at a particle concentration of 500 or 2000 µg/m3 4 hr/day for 5 
consecutive days. The intranasal antigen exposure regimen used was a modification of 
that used by Farraj et al. [251]. Mice were anesthetized in a small plexiglass box using 
vaporized isofluorane (Webster Veterinary Supply Inc., Sterling, MA).  Anesthetized 
mice were treated with an intranasal instillation (IN) of 100 µg of ovalbumin (OVA; 
Sigma-Aldrich Inc, St. Louis, MO) in 20 µl of sterile saline (Hospira Inc., Lake Forest, 
IL) or saline only (as negative control) divided evenly between each nare.  The 
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immunization phase consisted of a single instillation of OVA or saline once per day, 40 
min after DE exposure, for 3 consecutive days (days 0-2). Immunized mice were 
challenged on days 18 and 28 with the same volume and concentration of antigen as the 
instillations during the immunization phase and naïve mice were instilled with saline on 
day 18 and OVA on day 28. Mice were either necropsied 4 hrs after the final chamber 
exposure on day 4, or 18, 48, or 96 hrs after the 2° OVA challenge.  
 
4.2.4 Bronchoalveolar lavage fluid  
Mice from each treatment group were euthanized with sodium pentobarbital and 
the trachea was exposed, cannulated, and secured with suture thread.  The left mainstem 
bronchus was isolated and clamped with a microhemostat.  The right lungs lobes were 
lavaged 3 times with a single volume of warmed Hanks balanced salt solution (HBSS) 
(Invitrogen, Grand Island, NY) (35ml/kg).  The resulting lavage was centrifuged (717 x 
g, 15 min, 4◦ C) and 150 µl was stored at 4◦ C (for biochemical analysis) or -80◦ C (for 
cytokine measurement).  The pelleted cells were resuspended in 1 ml of RPMI 1640 
(Gibco, Carlsbad, CA) containing 2.5 % fetal bovine serum (FBS; Gibco, Carlsbad, CA).  
Total cell counts in the lavage fluid of each mouse were obtained with a Coulter Counter 
(Beckman Dickson).  Each sample (200 µl) was centrifuged in duplicate onto slides using 
a Cytospin (Shandon, Pittsburgh, PA) and subsequently stained with Diff Quik solution 
(American Scientific, McGraw Park, PA) for cell differentiation determination, with at 
least 200 cells counted from each slide.  The left lobe was removed for RNA isolation at 
the 4 hr time point post immunization. 
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4.2.5 Cytokine measurements 
Macrophage inflammatory protein-2 (MIP-2), IL-4, IL-5, IL-6, IL-10, IL-12, and 
TNFα concentrations in bronchoalveolar lavage fluid (BALF) were measured by enzyme-
linked immunosorbent assay (ELISA) with commercially available paired antibodies per 
manufacturer’s instructions (Pharmingen, Franklin Lakes, NJ). 
 
4.2.6 Cellular biochemistry 
Lactate dehydrogenase (LDH) and total protein were modified for use on a 
Konelab 30 clinical chemistry analyzer (Thermo Clinical Lab systems Espoo, Finland).  
Activity for LDH was determined using a commercially available kit from Thermo DMA 
Corp (Cincinnati, OH).  Total protein concentrations were determined with the 
Coomassie plus protein Reagent (Pierce Chemical, Rockford, IL) with a standard curve 
prepared with bovine serum albumin from Sigma-Aldrich (St. Louis, MO).   
 
4.2.7 Antigen-specific serum IgE 
Antigen-specific serum IgE production was measured by enzyme-linked 
immunosorbent assay (ELISA). Briefly, 96 well flat-bottom ELISA plates were coated 
with 100 µl of OVA at a concentration of 2 µg/ml and incubated overnight at 4°C. The 
following day, after a nonspecific protein blocking step using bovine serum albumin 
(BSA) and washing, 100µl of each serum sample and an OVA-specific IgE antibody 
(Serotec, Ltd., Oxford, UK) for the standand control was added in duplicate wells to the 
plates.  Following an overnight incubation at 4°C and washing, the plates were treated 
successively with 100 µl/well of biotinylated rat anti-mouse IgE  (Serotec, Ltd., Oxford, 
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UK), horseradish peroxidase-streptavidin (diluted 1:1500), with washes and incubation 
for 1 hr at room temperature between each of these steps.  Finally, 100 µl/well TM Blue 
(Dako Corporation, Carpinteria, CA) was added as a substrate for horseradish peroxidase 
and reactions were allowed to develop at room temperature for at least 10 minutes.  Plates 
were read at 650 nm by a Spectromax ELISA plate reader (Molecular Devices, Menlo 
Park, CA). 
 
4.2.8 RNA isolation 
RNA from frozen lung tissue was isolated using RNeasy (Qiagen, Valencia, CA) 
following manufacture’s protocol.  Quantity and quality of the RNA was measured using 
a Nanospot and Agilent Bioanalyzer (Agilent Technologies, Palo Alto, CA), respectively.  
 
4.2.9 Microarray 
RNA samples were prepared, processed, and hybridized to the Affymetrix Mouse 
430A gene chip at Expression Analysis (Durham, NC), as described in the GeneChip 
Expression Analysis Manual (Affymetrix; Santa Clara, CA).  The Mouse 430A Genome 
chip contains over 22,000 probe sets representing over 14,000 well-characterized mouse 
genes.  A detailed description can be found at 
http://www.affymetrix.com/products/arrays/specific/mouse430.affx. A total of 24 gene chips 
representing 4 hr samples from 24 individual mice (6 treatments, N=4) were used in this 
study. The microarray data have been deposited at Genome Expression Omnibus 
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database (http://www.ncbi.nlm.nih.gov/geo/) and are accessible through GEO series 
accession number GSE9383. 
  
4.2.10 Statistical analysis of inflammatory, biochemical, and immune endpoints 
The data were analyzed using a two-way analysis of variance (ANOVA) model.  
The two independent variables were exposure (DEP at levels 0, 500, and 2000 µg/m3) 
and treatment (at levels saline and OVA).  Pair-wise comparisons were performed as 
subtests of the overall ANOVA, subsequent to a significant main or interactive effect.  If 
the usual ANOVA assumptions were not satisfied, either the data were log transformed 
so as to satisfy the assumptions or a distribution free test was substituted for the ANOVA.  
The level of significance was set at 0.05.  No adjustment was made to the significance 
level as a result of multiple comparisons. 
 
4.2.11 Overall data analysis strategy 
The analysis of this data set consisted of 6 groups (filtered air, 500 µg/m3 [low], 
or 2000 µg/m3 [high] DE with or without OVA).  Steps were made to: 1) evaluate the 
data quality; 2) perform principal components analysis (PCA) for a global inspection of 
within group sample correspondence and to examine model and dose effects; 3) perform 
Gene Set Enrichment Analysis (GSEA) to determine differentially expressed gene sets 
between groups; 4) extract core genes responsible for a particular gene set identified as 
significant from the GSEA analysis; and 5) map core genes to functional pathways using 
MetaCore GENEGO® to identify altered pathways unique or in common among the 
treatments. 
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4.2.12 Principal component analysis (PCA) 
 PCA transforms microarray data from all gene chips to a new coordinate system 
using an orthogonal linear transformation, which reduces the data to a 3 dimensional 
coordinate system while retaining those characteristics of the data set that contribute most 
to the variance. This analysis was employed to survey the data for within-group outliers 
and model and dose effects using Rosetta Resolver (Rosetta Inpharmatics, Agilent 
Technologies, Palo Alto, CA) following linear weighting normalization (p<0.001). Each 
individual gene chip or gene expression profile was represented by a single data point and 
the variance between each gene chip was comparable to the distance between the data 
points whereby two similar gene expression profiles were projected as two adjacent 
points and vice versa. This analysis was employed as a visual tool to initially inspect the 
data for within group and across group similarities and dissimilarities.  
 
4.2.13 Gene set enrichment analysis (GSEA)   
GSEA is a powerful computational method that utilizes an a priori defined set of 
genes to determine statically significant, concordant differences between two phenotypes. 
For this analysis, raw data from 24 gene chips were normalized using Robust Multichip 
Average (RMA) in Gene Pattern (www.genepattern.org) to generate estimated expression 
summaries. The molecular signature database (MSigDB) C2 provided on the website 
http://www.broad.mit.edu/gsea/msigdb/msigdbindex.html, which contains 1687 gene 
sets, was queried for association with a particular treatment in each pairwise comparison 
(low DE/OVA vs. air/OVA, high DE/OVA vs. air/OVA, high DE/saline vs. air/saline, 
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air/OVA vs. air/saline, low DE/OVA vs. low DE/saline, and high DE/OVA vs. high 
DE/saline). Only gene sets with a minimal gene set size of 15 genes per pathway and a 
maximum of 500 were queried.  To determine the significance of a gene set for each 
pairwise comparison, GSEA ranked all genes according to the difference in expression 
using a signal-to-noise metric.  A running sum statistic termed the enrichment score (ES) 
was determined for each gene set and the maximum ES (MES) over all gene sets in the 
actual data was recorded. The ES reflects the degree to which a gene set is 
overrepresented at the top or bottom of the ranked genes.  To determine the significance 
of the MES, a comparison was made between the actual MES and that seen in 1000 
permutations that shuffled the gene set labels creating a null distribution.  In addition the 
data were normalized based on the size of the gene set (normalized expression set 
[NES]).  A false discovery rate (FDR) was calculated corresponding to each NES. Gene 
sets with a FDR of <25% were considered significant.  Heatmaps were generated from 
the top 50 genes that were most strongly associated with the DE or DE/OVA treatment. 
GSEA software and Molecular Signature Database (MSigDB) are available at 
http://www.broad.mit.edu/gsea/[220].  
 
4.2.14 Pathway level analysis 
The gene sets with an FDR of <25% were used to create a core gene list. The core 
gene list comprised genes responsible for a gene set being considered significant.  These 
genes were then applied to a pathway analysis program called MetaCore GENEGO® 
(http://www.genego.com/metacore), which maps genes to pathways and determines 
significance. All pathways with a p-value of <0.01 were reported.   
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4.3 Results 
 
 
 
4.3.1 Diesel exposures 
 
Table 4.1 shows a summary of the 5 day average exposure data for the low (500 
µg/m3) and high (2000 µg/m3) DE concentrations.  These target chamber concentrations, 
determined and adjusted based on continuous TEOM measurements were achieved with 
relatively low variability either within a particular 4 hr exposure or between different 
days.   Chamber particle concentrations determined gravimetrically from integrated filter 
samples (one 4 hr sample per exposure day), agreed with the TEOM measurements 
within 10%.  CO, NO, NO2, and SO2 concentrations in the high chamber averaged 4.3, 
9.2, 1.1, and 0.2 ppm, respectively.  Concentrations in the low chamber were below 
detection limits, as indicated.  Particle number concentrations were relatively high, and 
corresponded to particle size distributions (PSDs) with a well established accumulation 
mode and little evidence of notable nuclei or coarse modes.  Geometric median number 
and volume (assuming spherical particles) diameters of 86 and 195 nm, respectively, 
were measured in both chambers.  OC/EC wt ratios of 0.7 from both chambers indicate 
that approximately 41% of the DEP was comprised of organic carbon. 
 
4.3.2 Post-challenge  endpoints 
Ovalbumin specific IgE antibodies 
 Mice exposed to the low and high DE during local immunization produced 
increasing OVA-specific IgE antibodies over time.  Mice exposed to the high dose of DE 
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(2000 µg/m3) had a mild but non-significant increase (relative to OVA control) in these 
antibodies at the 48 hr time point (Figure 4.2).  In the absence of immunization with 
OVA, OVA-specific IgE antibodies were not detected (data not shown).  
Bronchoalveolar lavage cell differential counts 
 To evaluate the effect of DE exposure with or without OVA immunization on 
airway inflammation post-challenge, the cellular profile of BALF fluid 18, 48, and 96 hrs 
after OVA challenge was assessed.  Cell profiles at the 18 and 96 hr time points did not 
differ across treatment groups. At the 48 hr time point however, eosinophils, neutrophils, 
and lymphocytes were statistically increased in ova immunized mice exposed to both 
concentrations of DE (Figure 4.3).  With DE exposure alone, only neutrophils were 
statistically increased in the high DE concentration.  
Cytokine production in the bronchoalveolar lavage fluid 
To characterize the role of local cytokine production on the effects of DE in an 
ovalbumin immunization model, the production of macrophage inflammatory protein-2 
(MIP-2), IL-4, IL-5, IL-6, IL-10, IL-12, and TNFα were quantified.  IL-6 production was 
significantly increased in mice exposed to the high dose DE (2000 µg/m3) at the 96 hr 
time point (Figure 4.4A).   Although not significant, IL-10 was seen to increase in mice 
exposed to the high dose DE for the 48 and 96 hr time points (Figure 4.4B).  All other 
cytokines measured were unchanged compared to controls. 
 
4.3.3 Post-immunization endpoints 
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Pulmonary inflammation and lung injury 
 Mice were exposed to filtered air or diesel exhaust (DE) at a concentration of 500 
or 2000 µg/m3 on days 0-4, given an intranasal instillation of either saline or 100 µg of 
ovalbumin (OVA) 40 min after the chamber exposure on days 0-2, and necropsied 4 hrs 
after the last chamber exposure as depicted in Figure 1.  Cell differential counts in the 
BALF were quantified to assess pulmonary inflammation.  No differences among the 
groups were observed for macrophage, lymphocyte, neutrophil, and eosinophil counts 
(data not shown). Protein and LDH levels were quantified to determine if DE and/or 
antigen exposure induced cellular lung injury.  These biomarkers were not found to be 
increased in BALF of any group (data not shown).   
Principle component analysis (PCA) 
PCA was applied to provide a multidimensional gene expression profile of each 
gene chip in a 3 dimensional space to reveal clusters in the experimental data.  All data 
from the 24 gene chips were analyzed with each dot representing a gene chip (Figure 
4.5). The first 3 PCs combined reflected approximately 40% of the variance among all 
samples.  After analysis the gene chips were then highlighted in either blue (OVA 
treatment) or red (saline control). Good separation of the two groups was observed 
reflecting different expression profiles illustrating a model effect between antigen and 
saline (Figure 4.5A).  To determine if there was a diesel dose effect, the gene chips were 
highlighted according to diesel concentrations (blue- air/saline and air/OVA, red-500 µg 
DE/m3/saline and 500 µg DE/m3/OVA, green- 2000 µg DE/m3/saline and 2000 µg 
DE/m3/OVA) (Figure 4.5B).  The plot was rotated to reveal clustering among the 2000 
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µg/m3 DE exposure groups.  
Gene set enrichment analysis (GSEA) 
To test for sets of related genes that might be altered in the lungs of mice exposed 
to the various treatments we employed GSEA.  In contrast to conventional microarray 
analysis programs, the algorithm employed by GSEA derives its power by focusing on 
gene sets with biological relevance rather than individual genes. [220, 221]. Pairwise 
comparisons revealed significant gene set differences between high DE/saline vs. 
air/saline and high DE/OVA vs. air/OVA. For each comparison, a heatmap was 
constructed of the top 50 genes associated with the treatment of interest. The degree of 
correlation in each chip is represented by a range of colors reflecting the strength of 
correlation (red: high, pink: moderate, light blue: low, and dark blue: lowest). Visual 
inspection of the high DE/saline heatmap (Figure 4.6) showed striking contrast of the top 
50 genes between the diesel and air treatments. A similar map was also constructed for 
the high DE/OVA vs. air/OVA comparison, where the top 50 genes associated with DE 
in the context of OVA are shown (Figure 4.7).  While the contrast was less strong in this 
comparison, a binary response was still evident.  For both heat maps there was good 
consistency across each of the 4 animals per group represented by individual gene chips 
(individual animals). 10 genes from the top 50 genes, 1190003K14RIK, CD14, CXCL1, 
CXCL5, IFITM1, LCN2, PIGR, PROM1, REG3G, and RETNLA, were in common 
between both heat maps.  
The C2 collection of curated gene sets from the MSigDB were queried and a 
detailed description of each gene set can be found on the website 
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http://www.broad.mit.edu/gsea/msigdb/msigdb_index.html. A table was contructed for 
the high DE/saline vs. air/saline comparison of the top 20 gene sets associated with the 
DE phenotype, as ranked by normalized enrichment scores (Appendix 7).  The core genes 
in these gene sets are involved in cellular proliferation and inflammatory effects. The top 
20 gene sets associated with the DE/OVA phenotype generated from the high DE/OVA 
vs. air/OVA comparison (Appendix 8) contained genes involved in oxidative stress 
responses.  The gene set WANG_MLL_CBP_VS_GMP_UP was associated with both 
high DE/saline and high DE/OVA phenotypes. 
Pathway analysis 
A total of 49 enriched gene sets with a FDR < 25% were identified in the high 
DE/saline compared to air/saline.  The combined 619 core genes from these significant 
gene sets were extracted and imported into a pathway analysis program MetaCore 
GENEGO®. The list of pathways significantly altered by DE compared to air in the 
absence of antigen was clearly related to immune function and cell signaling pathways 
(Table 4.2). Specifically pathways included those for cell adhesion, cell cycle control, 
apoptosis, growth and differentiation, and cytokine signaling among others. 
The pairwise comparison of high DE/OVA vs. air/OVA yielded 23 enriched gene 
sets with a FDR < 25%.  The 412 core genes were imported into the MetaCore pathway 
program.  The pathways associated with the high DE/OVA phenotype were distinct from 
those associated with the DE/saline phenotype.  The majority of these pathways could be 
functionally classified under metabolic processes with oxidative stress systems including 
oxidative phosphorylation, mitochondrial and peroxisomal oxidation, ubiquinone, 
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glutathione, vitamin E, and PPAR regulation of lipid metabolism being very prominent 
(Table 4.3).   
 
4.4 Discussion 
Diesel exhaust has been shown to act as an adjuvant for allergic inflammation in 
animals and humans but the precise signaling pathways are not clear. Many studies have 
used instillation boluses of DEP or DEP extracts to explore the mechanisms of diesel 
enhanced allergic immune responses. While these methods are simpler and cheaper than 
inhalation, and can be used for hazard identification, they are not representative of real 
world exposures.  Previous inhalation studies have used chronic exposures, between 5-34 
weeks, and antigen administration has often been systemic or in combination with 
adjuvants such as alum.  These studies have shown increases in neutrophils and 
eosinophils in the BALF [14, 252] but it is not clear if short term, moderate dose 
exposures would have the same effect on mucosal immunization. Moreover, these 
inhalation studies have not investigated the signaling mechanisms responsible for 
increased immunity and clinical disease. The present study had two goals: 1) to 
investigate the adjuvant effects, post antigen challenge, of a short term inhalation 
exposure to moderate doses (500 and 2000 µg/m3) of DE; and 2) to identify global gene 
changes associated with altered immune function.  Our data demonstrate for the first time 
that even short term inhalation exposure to moderate concentrations of DE, when given 
with an antigen, can induce allergic lung disease after antigen challenge.  Furthermore, 
these adjuvant effects were associated with changes in gene expression 4 hrs after DE 
exposure in mice given antigen that were distinct from changes in animals exposed to DE 
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alone.  
The post-challenge results demonstrate DE exposure with antigen resulted in mild 
adjuvancy as evidenced by significant increases in eosinophils, neutrophils, lymphocytes, 
and IL-6 in the BALF. Saline and OVA control mice did not induce an asthma phenotype 
after the 2° OVA challenge and DE alone only increased neutrophils, indicating the 
combination exposure of DE and antigen was essential to promote the development of 
allergic lung disease. In life measures showed that none of the animals lost weight or 
experienced any indicators of the lung injury.  
For the second goal, microarray analysis was employed to examine global gene 
changes 4 hrs after the last DE exposure to understand the mechanisms involved in 
promoting adjuvancy.  While cellular and biochemical measures showed no changes in 
clinical indicators of inflammation, principal component analysis (PCA) of the gene 
expression data revealed a model (OVA) and a high dose DE (2000 µg/m3) effect.  Gene 
set enrichment analysis (GSEA) was applied to further investigate gene changes 
associated with adjuvancy.  The pairwise comparison of air/OVA vs. air/saline yielded no 
significant gene sets.  A plausible explanation for this is the last OVA dose was given on 
day 2 while the lungs were harvested for gene expression analysis on day 4 (figure 1) 
when the mild immune stimuli could have subsided. The GSEA comparison of low DE 
(500 µg/m3)/OVA vs. air /OVA resulted in no significant gene sets associated with the 
low DE/OVA treatment.  Comparison of the high (2000 µg/m3) DE/OVA vs. air/OVA 
however showed significant changes in 23 gene sets.  For this reason subsequent analyses 
were focused on the high DE/OVA vs. OVA comparison and the high DE/saline vs. 
saline comparison.  
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DE inhalation has been shown to induce lung inflammation in humans [253] and 
in rodents [14, 254]. In vitro studies have demonstrated DEP exposure induced release of 
inflammatory cytokines, IL-1β, IL-8, and granulocyte-macrophage colony-stimulating 
factor (GM-CSF) [216, 217, 255, 256].   Here the diesel exposures caused an up-
regulation of neutrophil homing chemokines genes (CCL4, CXCL1, -5, and -6) and 
inflammatory cytokines (IL-1β, CXCL2 [mouse equivalent to IL-8], and GMCSF).  In 
addition, 32 other signaling molecules were also associated with diesel exposures 
including numerous interleukins and TNF subtypes, and an array of CC and CXC 
chemokines.   
Chronic DE exposures induce epithelial cell proliferation in the airways and 
alveoli, and increase the number of resident macrophages [257-259].  An in vitro study 
reported that serum starved A549 cells proliferated in response to a low dose (up to 10 
µg/ml) DEP exposure [260]. Analysis of diesel exposed lungs revealed increases in 
growth and differentiation pathways such as IGF-RI and PDGF signaling, and 
granulocyte development. Jak-STAT cascades involved in cell growth and survival, as 
well as genes in G1/S transition cell cycle control were also altered.  While cell cycle 
control genes such as cyclin E2, cell division cycle associated 7, cyclin-dependent kinase 
8, E2F transcription factor 5, mitogen-activated protein kinase kinase kinase 5 
(MAP3K5), and mitogen-activated protein kinase 6 (MAPK6), retinoblastoma 1 (Rb1) 
were increased, we also observed up-regulation of several genes up-stream of this 
pathway such as Jun-B oncogene (JunB), trans-acting transcription factor 1 (Sp1), and 
early growth response 1 (Egr1) that could be driving this proliferative response.   
A substantial amount of evidence has shown that PM including DEP acts as an 
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adjuvant when given with antigen. The proposed mechanism is a hierarchical model 
whereby low levels of oxidative stress induce antioxidant defense mechanisms to restore 
redox balance in the cell. Intermediate levels of oxidative stress activate MAPK and NF-
κB cascades, which induce inflammation, while high levels of oxidative stress disrupt the 
mitochondrial permeability transition pore and electron transport chain resulting in cell 
death [174]. In vitro studies have shown that DEP extracts and ultrafine particles (UFPs) 
induce ROS production and oxidative stress by interfering with the mitochondrial 
electron transport chain [165, 166].  The study presented here confirmed similar effects in 
vivo.  Global transcriptional analysis of lung tissue from mice in the high DE/OVA 
treatment group expressed increased transcription of 45 genes involved in the NADH and 
FADH2 respiratory chain located in the inner membrane of the mitochondria.  These 
include 6 ATP synthases, 6 ATPases, 8 cytochrome c oxidases, 20 NADH 
dehydrogenases, and 2 ubiquinol-cytochrome c reductases, the majority of which were 
up-regulated.  The genomic profile for the DEP/OVA group also altered a significant 
number of genes reflecting phase I metabolism, including cytochrome P450s, 
dehydrogenases, carboxylesterases, and reductases, and a consistent induction of phase II 
transferases. These data confirm in vitro findings that have shown polycyclic aromatic 
hydrocarbons (PAH) induce oxidative stress indirectly, through biotransformation by 
cytochrome P450, expoxide hydrolase, and dihydrodiol dehydrogenase to generate redox 
active quinones [261]. 
In conclusion mice exposed to high DE alone had altered inflammatory, cell cycle 
control, growth and proliferation, and cell adhesion pathways.  Consistent with the Li et 
al premise, DE exposure in the context of antigen immunization induced oxidative stress 
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pathways, possibly through disruption of the inner mitochondrial membrane. These 
effects were associated with mild adjuvancy as evidenced by increases in eosinophils, 
neutrophils, and lymphocytes as well as IL-6 post-challenge. Genomic alterations in lung 
tissues after both high DE/saline and high DE/OVA exposures are more likely to reflect 
molecular changes within the resident lung cell population rather than the infiltration of 
new cells because the cell differential counts were unchanged compared to saline and 
OVA controls at that time point. This comprehensive approach using gene expression 
analysis to examine changes at a cellular and molecular level combined with more 
traditional immunotoxicity endpoints provide a clearer picture of the events occurring in 
the lung after DE exposure in the presence or absence of antigen. The results show that 
relatively short exposures to DE, at concentrations seen in severe occupational 
environments, cause mild increases in immunologic sensitization to allergen.  Genomic 
analysis revealed a wide range of altered pathways suggesting this method may be more 
sensitive and can be used for identifying mechanisms involved in adverse effects of 
inhaled pollutants. 
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Tables 
 
Table 4.1 Summary of concentrations and characteristics of the diesel exhaust particles 
and gases within the animal exposure chambersa 
 
Constituent Units Low exposure High exposure 
Particle mass 
concentration (TEOM) 
 
µg/m3 
 
561±9 
 
2136±63 
Particle mass 
concentration (filter)b 
µg/m3 546±29 1983±55 
 
Particle number 
concentrationc 
#/cm3 
  5.6×105 
±4.1×103 
  2.0×106 
±9.9×103 
Oxygen (O2) % 20.7±0.11 20.3±0.07 
Carbon monoxide (CO) ppm <1.0 4.3±0.07 
Nitric oxide (NO) ppm <2.5 9.2±0.30 
Nitrogen dioxide (NO2) ppm <0.25 1.1±0.05 
Sulfur dioxide (SO2) ppm <0.06 0.2±0.10 
Number median Dpd nm 80±2 86±2 
Volume median Dpd nm 184±2 195±2 
OC/ECe wt ratio 0.7±0.05 0.7±0.05 
 
aTapered element oscillating microbalance (TEOM), O2, CO, NO, NO2, and SO2 data 
represent mean values from continuous measurements taken over the five day exposure ± 
SE. 
bFilter data represent mean values from one measurement per day taken over the five day 
exposure ± SE. 
cParticle number concentration data represent mean values from two measurements (low 
exposure) and three measurements (high exposure) taken over one representative 
exposure day ± SE. 
dDp indicates particle geometric number and volume median diameters for a single 
representative particle size distribution ± geometric standard deviation.  Note that volume 
information is calculated from number based mobility diameters and assume spherical 
particles. 
eOC/EC (organic carbon to elemental carbon ratio) data represent mean values from one 
measurement per day taken over the five day exposure ± SE. 
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Table 4.2 Significantly altered pathways by high DE/saline compared to air/saline 
   
Pathway p-Value Genes 
Cell Adhesion   
Chemokines and adhesion  6.98E-05 18/153 
Cytoskeleton remodeling  7.32E-03 15/177 
FAK signaling  2.43E-03 9/70 
PLAU signaling  3.14E-03 7/47 
Cell Cycle Control    
Regulation of G1/S transition (p.1)  4.08E-03 8/62 
Cell Death/Apoptosis    
FAS signaling cascades  9.45E-03 6/44 
Cell Survival   
EPO-induced Jak-STAT pathway  7.37E-04 7/37 
Cyto/chemokines   
CXCR4 signaling pathway  1.68E-03 8/54 
IL4 - antiapoptotic action  1.20E-03 7/40 
IL6 signaling pathway  2.18E-03 6/33 
G-proteins    
A3 receptor signaling  1.60E-03 10/79 
A2B receptor: action via G-protein alpha s  9.23E-03 7/57 
cAMP signaling  9.29E-04 13/114 
CREB pathway  9.48E-03 10/101 
M-RAS regulation pathway  7.07E-03 4/19 
RAB5A regulation pathway  6.97E-03 3/10 
Regulation of CDC42 activity  2.74E-03 5/24 
Growth and Differentiation   
IGF-RI signaling  7.54E-06 13/72 
Membrane-bound ESR1: interaction with G-proteins signaling  2.96E-03 9/72 
PDGF signaling via STATs and NF-kB  5.91E-03 6/40 
Leptin signaling via JAK/STAT and MAPK cascades  6.45E-03 5/29 
Membrane-bound ESR1: interaction with growth factors signaling  7.53E-03 6/42 
TPO in cell process  4.83E-05 10/52 
Transcription regulation of granulocyte development  4.84E-04 8/45 
PIP3 signaling in cardiac myocytes  1.19E-03 10/76 
Growth factors   
Prolactin receptor signaling  4.08E-03 8/62 
Hormones   
Androgen Receptor nuclear signaling  1.19E-03 10/76 
Insulin signaling:generic cascades  7.61E-03 7/55 
Non-genomic (rapid) action of Androgen Receptor  2.43E-03 9/70 
Kinases    
AKT signaling  2.39E-03 8/57 
Metabolism - Lipid    
Insulin regulation fatty acid metabolism  2.29E-04 9/51 
Insulin regulation of glycogen metabolism  9.23E-03 7/57 
Metabolism - Regulators   
Transcription regulation of aminoacid metabolism  2.96E-04 8/42 
Insulin receptor signaling pathway  1.86E-03 7/43 
Neuroscience   
Regulation of CDK5 in CNS  1.30E-03 6/30 
GDNF signaling  3.31E-03 5/25 
Phosphatases    
PTEN pathway  4.13E-04 9/55 
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Transcription Factors    
PPAR Pathway  7.58E-04 8/48 
Translation Regulation   
Insulin regulation of the protein synthesis  7.61E-03 7/55 
Regulation activity of EIF2  8.39E-03 7/56 
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Table 4.3 Significantly altered pathways by high DE/OVA compared to air/OVA   
          
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Pathway p-Value Genes 
Cell Cycle Control  
  
Role of Brca1 and Brca2 in DNA repair  1.60E-06 9/40 
Metabolism - Aminoacid 
  
Leucune, isoleucine and valine metabolism p.1 4.00E-04 4/13 
Leucune, isoleucine and valine metabolism p.2 4.92E-06 7/25 
Phenylalanine metabolism  1.12E-05 7/28 
TCA  8.99E-07 7/20 
Metabolism - Carbohydrates  
  
Glycolysis and gluconeogenesis (short map)  3.55E-03 5/36 
Glycolysis and gluconeogenesis  5.53E-03 3/13 
Propionate metabolism p.1  5.48E-04 4/14 
Propionate metabolism p.2  1.88E-06 7/22 
Pyruvate metabolism  5.39E-03 4/25 
Metabolism - Energy  
  
Oxidative phosphorylation  7.31E-36 40/99 
Metabolism - Lipid  
  
Mitochondrial long chain fatty acid beta-oxidation  2.57E-10 9/17 
Mitochondrial unsaturated fatty acid beta-oxidation  2.46E-09 8/15 
Mitochondrial ketone bodies biosynthesis and metabolism  4.41E-06 5/10 
Peroxisomal branched chain fatty acid oxidation  1.55E-05 6/20 
Peroxisomal straight-chain fatty acid beta-oxidation  5.48E-04 4/14 
PPAR regulation of lipid metabolism  3.02E-09 10/28 
Regulation of fatty acid synthesis 1.77E-03 3/9 
Metabolism - Nucleotide  
  
ATP metabolism  1.66E-03 7/60 
ATP/ITP metabolism  1.79E-08 14/73 
CTP/UTP metabolism  1.75E-15 20/67 
dATP/dITP metabolism  6.99E-04 7/52 
dCTP/dUTP metabolism  3.05E-06 9/43 
dGTP metabolism  9.40E-04 6/40 
GTP-XTP metabolism  1.41E-07 12/61 
TTP metabolism  1.04E-05 8/38 
Metabolism - Vitamin and Cofactor  
  
Glutathione metabolism  7.64E-13 14/37 
Heme metabolism  8.48E-03 5/44 
Ubiquinone metabolism  3.30E-18 23/73 
Vitamin E (α-tocopherol) metabolism  9.16E-05 5/17 
Regulation of Transcription 
  
Ligand-Dependent Transcription of Retinoid-Target genes  4.24E-03 10/129 
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Figures 
 
 
 
 
Figure 4.1 Schematic of exposure regime. BALB/c mice were exposed to filtered air, 
500, or 2000 µg/m3 of DE on days 0-4.  After the first three days of exposure, mice were 
treated with an intranasal instillation of 100 µg in 20 µl of saline or saline alone.  Mice 
were challenged with the same dose and concentration of either OVA or saline alone on 
day 18 and all mice were challenged with OVA on day 28.  Necropsies were either 4 hrs 
(n=4) after the last air or DE exposure or 18, 48, or 96 hrs (n=6-8) after the last challenge. 
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Figure 4.2 Kinetic development of OVA-specific serum antibodies in mice exposed 
to diesel exhaust during allergic immunization. Mice were exposed to filtered air or 
DE at a particle concentration of 500 or 2000 µg/m3 on days 0-4 for 4 hr/day, intranasally 
instilled with OVA on days 0, 1, 2, 18, challenged with OVA on day 28, and necropsied 
18, 48, and 96 hrs later. OVA-specific IgE antibody levels were measured in the serum 
by ELISA. n=6-8 
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Figure 4.3 Allergen-induced pulmonary inflammatory cells in mice exposed to 
filtered air or diesel exhaust with or without OVA. Mice were exposed to filtered air 
or DE at a particle concentration of 500 or 2000 µg/m3 on days 0-4 for 4 hr/day, 
intranasally instilled with OVA or saline on days 0, 1, 2, 18, challenged with OVA on 
day 28, and necropsied 18, 48, and 96 hrs later. Data is shown for 48 hr time point only. 
Eosinophils (A), Neutrophils (B), and lymphocytes (C) were measured in BALF. n=6-8; 
Significantly different from saline control: +p<0.05; ++ p<0.01. Significantly different 
from OVA control: *p<0.05; **p<0.01; ***p<0.001. 
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Figure 4.4 Quantification of IL-6 and IL-10 protein levels. Mice were exposed to 
filtered air or DE at a particle concentration of 500 or 2000 µg/m3on days 0-4 for 4 
hr/day, intranasally instilled with OVA or saline on days 0, 1, 2, 18, challenged with 
OVA on day 28, and necropsied 18, 48, and 96 hrs later.  IL-6 (A) and IL-10 (B) protein 
levels were measured by ELISA in the BALF of the same mice as described in Figure 1. 
n= 6-8; Significantly different from OVA control: **p<0.01. 
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Figure 4.5 Principle component analysis plot from microarray data.  Mice were 
necropsied 4 hours after the last diesel exposure on Day 4. RNA was isolated from the 
lungs and hybridized to Affymetrix Mouse 430A gene chips (n=4).  PCA plots were 
created in Rosetta Resolver. Each plot contains gene chips from all mice and each dot 
represents a gene chip. Gene chips were highlighted according to the immunization 
protocol (blue-OVA treatment or red-saline treatment) (A) or the diesel concentration 
(blue- air/saline and air/OVA, red-500 µg DE/m3/saline and 500 µg DE/m3/OVA, green- 
2000 µg DE/m3/saline and 2000 µg DE/m3/OVA) (B). 
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Figure 4.6 Heat map of top 50 genes associated with high DE in non-allergic mice.  
In the heat map, expression values for the top 50 genes in each chip is represented as a 
color, where the range of colors (red, pink, light blue, dark blue) shows the range of 
expression values (high, moderate, low, lowest). Lanes 1-4 are high DE/saline and 5-8 
are air/saline.  
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Figure 4.7 Heat map of top 50 genes associated with high DE in OVA-allergic mice.  
In the heat map, expression values for the top 50 genes in each chip is represented as a 
color, where the range of colors (red, pink, light blue, dark blue) shows the range of 
expression values (high, moderate, low, lowest). Lanes 1-4 are high DE/OVA and 5-8 are 
air/OVA.  
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Over the past several decades the prevalence, morbidity, and mortality of asthma 
has been increasing at an alarming rate, making it a major public health concern. 
Increases in ambient particulate matter (PM) have been correlated with a rise in 
hospitalization associated with respiratory illnesses such as asthma [118, 183]. Diesel 
exhaust particles (DEP) are a major constituent of ambient particulate matter in urban 
environments and occupational settings. Several studies in humans and animals have 
shown that diesel exhaust (DE) as well as DEP can act as an immunological adjuvant to 
increase the severity of allergen induced asthma [114, 115, 123, 128, 134, 184-186]. 
However, there is still a fundamental lack of understanding as to what component or 
components are responsible for these effects and the underlying mechanisms through 
which they act. The purpose of this research was to investigate the relative adjuvant 
potency of 3 chemically distinct DEP given with an allergen, and to identify the cellular 
mechanisms responsible for this effect.  
The heterogeneous nature of DEP samples adds to the difficulty in determining 
what effects are common among all DEP exposures versus specific characteristics of a 
particular sample. Several studies investigating the adjuvant potential of the particle itself 
have demonstrated its ability to induce antigen-specific IgE antibodies when given with 
antigen [194, 195, 262]. Nygaard et al. [262] studied the adjuvant effect of polystyrene 
particles (PSP) of various sizes (0.0588 to 11.14 µm), carbon black (CB; 0.035 µm), and 
DEP (0.030 µm) in mice. The results demonstrated the smaller PSP (0.0588 and 0.202 
µm), CB, and DEP increased allergen-specific IgE serum levels. Furthermore linear 
regression analysis indicated particle diameter and surface area were predictive of IgE 
response [262].   Another body of evidence supports the notion that adsorbed chemical 
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substances found on the particles such as polycyclic aromatic hydrocarbons (PAHs) can 
induce allergic adjuvancy [191-195].  Most of the mechanistic studies have focused on 
the role of oxidative stress and the generation of reactive oxygen species (ROS) from 
organic rich DEP or DEP extracts.  The present work investigated the relative adjuvant 
potency of three different DEP samples, N-DEP, A-DEP, and C-DEP which differed in 
the percentage of dichloromethane (DCM) extractable organic material (EOM) (1.5%, 
68.6%, and 18.9%, respectively) in a mucosal sensitization model adopted from 
Steerenberg et al. [199].  
Results of this research show that DEP induces asthma-like parameters of 
antigen-specific IgG1, airway hyperresponsiveness (AHR) and inflammation, as well as 
alterations in local lung cytokine levels and increases in lung permeability. In addition, 
on a comparative mass basis, the three samples induced a gradation of post-challenge 
adjuvancy and this was not solely dependent on the organic content. Immune and 
inflammatory endpoints demonstrate C-DEP/OVA ≈ A-DEP/OVA >> N-DEP/OVA with 
respect to post-challenge adjuvancy as measured by eosinophilic inflammation and TH2 
cytokines in the BALF, serum OVA-specific IgG1 antibodies, and airway 
hyperresponsiveness. 
Human and rodent studies have shown DEP induced allergic asthma is 
characterized by recruitment of T helper 2 (TH2) lymphocytes and subsequent production 
of TH2 cytokines like IL-4, IL-5, IL-10, and IL-13, which perpetuate the inflammatory 
response.  The importance of TH2 cells in allergic asthma is underlined by a study in 
which adoptive transfer of these cells into naïve mice led to an allergic asthma phenotype 
[205]. Conversely, removal of these cells prevented induction of asthma in sensitized 
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mice. Thymus activation regulated chemokine (TARC), mainly produced by dendritic 
cells, selectively induces the migration of CCR4-expressing TH2 cells [206, 207] and is 
thought to play a crucial role in allergic asthma. In the present study, TARC levels post-
challenge in the BALF were significantly increased in C-DEP + OVA exposed mice 
compared to all groups and this was accompanied by a significant increase in 
lymphocytes.  
While most reports on PM-induced adjuvancy have focused on immune effects 
post-challenge, we were also interested in assessing early signaling events caused by 
DEP in the context of antigen sensitization. C-DEP/OVA, consistent with the strong 
degree of adjuvancy post-challenge, increased the influx of eosinophils, neutrophils, and 
lymphocytes, increased the production of TH2 cytokines, and decreased the production of 
the TH1 cytokine IL-12 in the BALF, 18 hrs after sensitization. On the other hand, post-
sensitization differential cell counts and production of TH1 and TH2 cytokines were not 
significantly different for the organic rich A-DEP/OVA compared to OVA control 
although this group induced a strong adjuvant effect post-challenge suggesting the 
kinetics of the response may be different. The elemental carbon rich N-DEP/OVA 
exposures induced a mild TH2 phenotype post-sensitization followed by a mild adjuvant 
effect post-challenge.  
There is much evidence that the organic chemical compounds, such as PAHs, 
quinones, and nitro-PAHs, absorbed on the surface of DEP play a role in ROS production 
which in turn causes oxidative stress. If the level of oxidative stress exceeds the cells 
natural antioxidant defense mechanisms then inflammatory cytokines and chemokines, 
 130 
which may contribute to the adjuvant effect of DEP, are produced. The amount of DCM 
extractable organic material present in the A-DEP sample was about 3.5 times greater 
than C-DEP; however, both samples when given with allergen induced similar degrees of 
adjuvancy post challenge. One possible explanation is the adjuvant response was 
saturated. In other words the A-DEP sample may produce the same degree of adjuvancy 
at a lower dose than the C-DEP. An alternate explanation for these effects induced by 
exposure to the different DEP samples is the presence of particular species of compounds 
in the organic fraction, rather than the overall amount, could be responsible for the toxic 
effects. Xia et al [165] demonstrated the quinone-enriched polar fraction of DEP was 
more potent than the PAH-enriched aromatic fraction in ROS production suggesting a 
greater ability to cause oxidative stress. Therefore, it is possible that C-DEP contains a 
more potent compound. Complete chemical analysis of the compounds present in the 
fractionated DCM EOM of the DEP samples may be informative in further examination 
of this hypothesis. 
To elucidate possible mechanisms and biomarkers for these effects, early 
signaling events and global gene expression changes in the lung were assessed. Certain 
exposures to DEP induce lung inflammation. DE and DEP have been shown to induce 
pulmonary inflammation manifested by neutrophil infiltration and elevated levels of total 
protein, albumin, LDH, and ROS in the lung as well as up-regulation of inflammatory 
pathways [201, 217, 219, 223, 224]. Based on these observations, it was no surprise that 
the cytokine-cytokine receptor pathway was a significantly altered pathway common to 
all DEP/saline exposures. The genes in this pathway included inflammatory, TH1, and 
TH2 cytokines and chemokines, but the majority of them were associated with neutrophil 
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signaling in the DEP/saline exposures. In agreement with these findings, all three 
DEP/saline samples induced an increase in neutrophils in the BALF at this time point, 
although the increase was not significant [219].  
  Toll-like receptor signaling was also altered in all DEP/saline exposures. Toll-like 
receptors (TLRs) play important roles in the initiation of both innate and adaptive 
immune responses [225, 226]. Their activation is usually associated with viral or bacterial 
exposure; however, TLRs can also signal in response to endogenous molecules and 
environmental pollutants.  NO2 adjuvant effects are dependent on TLR2 [227] and airway 
hyperresponsiveness, induced by chronic ozone exposure, is dependent on TLR4 [228]. 
In addition, Zhou et al. [229] reported heat shock induced increases in TLR2 and TLR4 
mRNA and protein expression in monocytes. Furthermore, DEP has been shown to 
induce TLR4 expression in the lung [230] and TLR4 deficient mice develop airway 
inflammation to a lesser degree in response to DEP compared to control [231]. Our 
results demonstrated that the toll-like receptor interaction pathway was altered by all 
three DEP/saline exposures, providing further evidence that the TLR pathway is involved 
in DEP induced inflammatory responses.  
The cytokine-cytokine receptor interaction and toll-like receptor signal pathways 
were also common pathways associated with all three DEP/OVA exposures but with a 
greater enrichment of genes in both pathways. In addition, GeneGo pathway analysis 
revealed significantly altered immune response, inflammatory, and apoptosis pathways. 
We have previously shown all three DEP/OVA exposures induced allergic adjuvancy 
after antigen challenge suggesting the pathways presented here may be important early 
signaling pathways in DEP induced allergic disease.   
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Li et al. [174] proposed a hierarchical oxidative stress model to explain DEP 
induced effects whereby low levels of oxidative stress induce antioxidant defense 
mechanisms to restore redox balance in the cell (tier 1). Intermediate levels of oxidative 
stress (tier 2) activate MAPK and NF-κB cascades, which induce inflammation, while 
high levels of oxidative stress (tier 3) activate apoptosis and apoptosis/necrosis 
pathways[174].  
The study presented in chapter 3 demonstrated altered transcription of genes in all 
three tiers simultaneously with DEP/OVA exposure in vivo.  Antioxidant transcription 
factor and enzymes such as Nrf2, heme oxygenase 1 (HO-1), and superoxide dismutase 2 
(SOD2) were up-regulated in response to all three DEP/OVA exposures indicative of low 
oxidative stress levels according to the tiered model. The tier 2 responses were also up-
regulated in the lungs of mice exposed to all three DEP samples when given with OVA 
(i.e. MAPKs, NF-κB, as well as inflammatory, TH1, and TH2 cytokines and chemokines). 
In addition, A- and C-DEP/OVA exposures altered apoptosis (tier 3) pathways; however, 
C-DEP/OVA significantly altered the greatest number of these pathways. Furthermore, 
the apoptosis pathway representation appears to coincide with the combined phenotypic 
allergic responses of the three DEP/OVA. Although ROS production was not measured, 
the results suggest that C-DEP/OVA, according to the hierarchical stress model, induced 
high levels of oxidative stress. 
While the hierarchical oxidative stress model suggests a dose-dependent response, 
because we were examining whole lungs rather than individual cell lines it is possible the 
discrepancy seen in this study was due to cell turnover rates, varying concentration of 
DEP throughout the lung, as well as differences in the response of different cell types to 
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DEP.  
It has been established that DEP organic compounds can generate reactive oxygen 
species (ROS) [232] and excessive ROS production can lead to a variety of cellular 
responses including DNA damage [233]. In fact, oxidative DNA damage has been 
detected in mouse lung DNA after DEP exposure [234].  Although the A-DEP sample 
contained the greatest amount of DCM EOM, in the present study, C-DEP/OVA 
exposure was unique in significantly altering cell cycle and DNA damage pathways.  
Global transcriptional analysis of lung tissue revealed up-regulation of cell cycle control 
genes including 6 cyclin genes, 7 cell division cycle genes, 7 members of the family of 
MAP kinases, 2 cyclin-dependent kinases, RAS p21 protein activator 3 (Rasa3),  and 5 
other RAS related proteins.  This suggests the amount of DCM EOM does not directly 
relate to the ability of the sample to generate ROS.  
In addition to the role of oxidative stress, the cytotoxicity and immune-
modulating effects of DEP have been examined in a number of studies. DEP has been 
shown to induce the degranulation of eosinophils and enhance their adhesiveness to 
epithelial cells [263]. Also, DEP exposure may disrupt the epithelial barrier, which would 
further increase the cell’s response to increased levels of proinflammatory cytokines 
[264] and allow antigens like OVA to become more easily available to antigen-presenting 
dendritic cells thus increasing adjuvancy [265]. The pathology results presented in 
chapter 2 demonstrate C-DEP/OVA exposure to induce the greatest amount peribronchial 
and perivascular inflammation. 
All DEP samples with or without OVA had altered cytokine and toll-like receptor 
pathways suggesting these responses are a DEP chemical class signature rather than an 
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effect of a particular component of DEP (i.e. the percentage of DCM EOM). All 
DEP/OVA exposures increased transcription of genes involved in each tier of the 
hierarchical stress response model described by Li et al. [166, 174, 175]. CDEP/OVA 
exposure significantly altered the most number of apoptosis pathways as well as cell 
cycle and DNA damage pathways suggesting the C-DEP is the most bioactive sample. 
This comprehensive approach using gene expression analysis to examine pathway 
changes at a transcriptional level provides a clearer picture of the events occurring in the 
lung after DEP exposure in the presence or absence of antigen. Genomic analysis 
revealed a wide range of altered pathways suggesting this method may be more sensitive 
and can be used for identifying mechanisms involved in adverse effects of inhaled 
pollutants. 
In conclusion the data suggest that three DEP samples appear to have signature 
responses. For example the C-DEP/OVA treatment increased eosinophil and lymphocyte 
lung infiltration, TARC, MCP-1, IL-4, and IL-5 production in the BALF, and altered 
transcription of immune, inflammation, protein degradation, cell adhesion, DNA damage, 
and cell cycle networks. These post-sensitization responses were associated with a strong 
adjuvant response after antigen challenge. A-DEP/OVA exposure induced transcriptional 
changes in networks associated with immune responses, inflammation, and cell adhesion 
but to a less extent than C-DEP/OVA. This exposure also resulted in a strong degree of 
adjuvancy post-challenge. The N-DEP/OVA exposure increased TARC and IL-5 
production in the BALF and altered transcription of immune, inflammation, and cell 
adhesion networks post-sensitization. This response was associated with mild adjuvancy 
post-challenge.   An in-depth analysis of the particle chemistry for each sample would 
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provide a means to relate chemical compounds with allergic potential.  
In addition, this work also explored immune responses in mice acutely exposed to 
moderate doses of DE in an OVA mucosal sensitization model and identified possible 
mechanisms using genomics. Many studies have used instillation boluses of DEP or DEP 
extracts to explore the mechanisms of diesel enhanced allergic immune responses. While 
these methods are simpler and cheaper than inhalation, and can be used for hazard 
identification, they are less representative of real world exposures than inhalation 
exposures.  Previous inhalation studies have used chronic exposures, between 5-34 
weeks, and antigen administration has often been systemic or in combination with 
adjuvants such as alum.  These studies have shown increases in neutrophils and 
eosinophils in the BALF [14, 252] but it is not clear if short term, moderate dose 
exposures would have the same effect on mucosal immunization. Moreover, these 
inhalation studies have not investigated the signaling mechanisms responsible for 
increased immunity and clinical disease.  
The study described in chapter 4, exposed mice to DE generated from an engine 
used to power an air compressor. This is the same engine and operation procedures used 
to generate the C-DEP sample. The two goals of this study were: 1) to investigate the 
adjuvant effects, post antigen challenge, of a short term inhalation exposure to moderate 
doses (500 and 2000 µg/m3) of DE; and 2) to identify global gene changes associated 
with altered immune function.  Our data demonstrate for the first time that even short 
term inhalation exposure to moderate concentrations of DE, when given with an antigen, 
can induce allergic lung disease after antigen challenge.  Furthermore, these adjuvant 
effects were associated with changes in gene expression 4 hrs after DE exposure in mice 
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given antigen that were distinct from changes in animals exposed to DE alone.  
The post-challenge results demonstrate DE exposure with antigen resulted in mild 
adjuvancy as evidenced by significant increases in eosinophils, neutrophils, lymphocytes, 
and IL-6 in the BALF. Saline and OVA control mice did not induce an asthma phenotype 
after the 2° OVA challenge and DE alone only increased neutrophils, indicating the 
combination exposure of DE and antigen was essential to promote the development of 
allergic lung disease.  
For the second goal, transcriptional analysis of RNA isolated from whole lung 
tissue of mice 4 hrs after the last DE exposure was assessed. GSEA was applied to 
identify pathway level changes associated with DE and DE + OVA exposures.  DE 
inhalation has been shown to induce lung inflammation in humans [253] and in mice [14, 
254]. In agreement with these studies, the DE exposures caused an up-regulation of 
neutrophil homing chemokines genes (CCL4, CXCL1, -5, and -6) and inflammatory 
cytokines (IL-1β, CXCL2 [mouse equivalent to IL-8], and GMCSF) as well as 32 other 
signaling molecules including numerous interleukins and TNF subtypes, and an array of 
CC and CXC chemokines. Similar pathways were altered with the C-DEP instillation 
exposures.  
Cell cycle control genes such as cyclin E2, cell division cycle associated 7, 
cyclin-dependent kinase 8, E2F transcription factor 5, mitogen-activated protein kinase 
kinase kinase 5 (MAP3K5), and mitogen-activated protein kinase 6 (MAPK6), 
retinoblastoma 1 (Rb1) were increased with DE inhalation and also in the C-DEP/OVA 
exposure. In addition, we observed in both exposure systems, an up-regulation of several 
genes up-stream of this pathway such as Jun-B oncogene (JunB), trans-acting 
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transcription factor 1 (Sp1), and early growth response 1 (Egr1) that could be driving this 
proliferative response.   
Global transcriptional analysis of lung tissue from mice in the high DE/OVA 
treatment group expressed increased transcription of 45 genes involved in the NADH and 
FADH2  respiratory chain located in the inner membrane of the mitochondria.  These 
include 6 ATP synthases, 6 ATPases, 8 cytochrome c oxidases, 20 NADH 
dehydrogenases, and 2 ubiquinol-cytochrome c reductases, the majority of which were 
up-regulated.  The genomic profile for the DEP/OVA group also altered a significant 
number of genes reflecting phase I metabolism, including cytochrome P450s, 
dehydrogenases, carboxylesterases, and reductases, and a consistent induction of phase II 
transferases. This was very similar to the pathways up-regulated in the C-DEP/OVA 
exposures. These data confirm in vitro findings that have shown polycyclic aromatic 
hydrocarbons (PAH) induce oxidative stress indirectly, through biotransformation by 
cytochrome P450, expoxide hydrolase, and dihydrodiol dehydrogenase to generate redox 
active quinones [261]. 
In conclusion, mice exposed to high DE and C-DEP altered inflammatory and cell 
cycle control pathways post-sensitization. Consistent with the Li et al premise, DE and 
C-DEP exposure in the context of antigen immunization induced oxidative stress 
pathways, possibly through disruption of the inner mitochondrial membrane. These 
effects were associated with adjuvancy post-challenge. Genomic alterations in lung 
tissues after both high DE/saline and high DE/OVA exposures are more likely to reflect 
molecular changes within the resident lung cell population rather than the infiltration of 
new cells because the cell differential counts were unchanged compared to saline and 
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OVA controls at that time point; however a significant influx of eosinophils, neutrophils 
and lymphocytes were present in the lung post-sensitization for the C-DEP/OVA 
exposure.  
This comprehensive approach using gene expression analysis to examine changes 
at a cellular and molecular level combined with more traditional immunotoxicity 
endpoints provide a clearer picture of the events occurring in the lung after DE and DEP 
exposure in the presence or absence of antigen. Genomic analysis revealed a wide range 
of altered pathways suggesting this method may be more sensitive and can be used for 
identifying mechanisms involved in adverse effects of inhaled pollutants. 
TH2 cells play a crucial role in the initiation, progression, and persistence of 
allergic asthma. While previous studies have suggested that a disturbance in balance 
between TH1 and TH2 cells underlies the allergic response to otherwise harmless antigen, 
the data presented here indicates other immuno-modulating mechanisms may be 
responsible for the adjuvant effect of DE and DEP + OVA exposure in mice. Regulatory 
T (Treg) cells are capable of preventing allergic sensitization and progression of allergic 
responses. Down-regulation or apoptosis of these cells is a possible mechanism by which 
DEP may induce adjuvany. A- and C-DEP/OVA exposures led to a strong allergic 
response after antigen challenge. The genomic data presented in chapter 3 indicated 
altered expression of apoptosis pathways after sensitization was unique to these 
exposures. Cell death of Treg cells may provide an explanation for the DEP induced 
adjuvant effect. Investigation of Treg cell numbers in the lung after DEP/OVA exposures 
as well as the relative susceptibility of this cell population to the cytotoxic effects of DEP 
ex vivo, may be informative in further examination of this hypothesis.  
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Appendix 1 
 
Significantly altered gene sets by N-DEP/saline compared to saline 
 
NAME SIZE ES NES FDR q-val 
CARIES_PULP_HIGH_UP 68 0.81 2.85 < 1.00E-06 
LAL_KO_3MO_UP 46 0.84 2.80 < 1.00E-06 
FLECHNER_KIDNEY_TRANSPLANT_ 
REJECTION_UP 72 0.78 2.79 < 1.00E-06 
LINDSTEDT_DEND_8H_VS_48H_UP 58 0.81 2.78 < 1.00E-06 
LAL_KO_6MO_UP 58 0.80 2.75 < 1.00E-06 
WIELAND_HEPATITIS_B_INDUCED 71 0.77 2.71 < 1.00E-06 
GALINDO_ACT_UP 75 0.74 2.66 < 1.00E-06 
YANG_OSTECLASTS_SIG 39 0.84 2.61 < 1.00E-06 
NAKAJIMA_MCS_UP 85 0.70 2.55 < 1.00E-06 
BLEO_HUMAN_LYMPH_HIGH_24HRS_UP 86 0.69 2.54 < 1.00E-06 
BASSO_GERMINAL_CENTER_CD40_UP 82 0.69 2.54 < 1.00E-06 
HINATA_NFKB_UP 89 0.69 2.52 < 1.00E-06 
NADLER_OBESITY_UP 57 0.73 2.51 < 1.00E-06 
SANA_TNFA_ENDOTHELIAL_UP 61 0.72 2.50 < 1.00E-06 
NEMETH_TNF_UP 82 0.69 2.49 < 1.00E-06 
MUNSHI_MM_VS_PCS_UP 64 0.67 2.34 < 1.00E-06 
MUNSHI_MM_UP 57 0.69 2.34 7.18E-05 
NI2_MOUSE_UP 40 0.74 2.33 6.78E-05 
TNFA_NFKB_DEP_UP 17 0.86 2.33 6.43E-05 
SHIPP_FL_VS_DLBCL_DN 30 0.74 2.24 6.11E-05 
LINDSTEDT_DEND_UP 44 0.69 2.23 5.81E-05 
TAVOR_CEBP_UP 42 0.69 2.22 5.55E-05 
HOUSTIS_ROS 32 0.73 2.21 5.31E-05 
MARTINELLI_IFNS_DIFF 16 0.83 2.19 5.09E-05 
ZUCCHI_EPITHELIAL_DN 36 0.68 2.19 4.88E-05 
TPA_SENS_MIDDLE_UP 55 0.64 2.17 1.39E-04 
ROSS_CBF_MYH 38 0.70 2.17 2.21E-04 
CROONQUIST_IL6_RAS_UP 18 0.81 2.15 2.99E-04 
ZHAN_MULTIPLE_MYELOMA_VS_ 
NORMAL_DN 33 0.71 2.15 2.89E-04 
NAKAJIMA_MCSMBP_MAST 37 0.69 2.14 3.19E-04 
ABBUD_LIF_UP 45 0.66 2.14 3.09E-04 
KNUDSEN_PMNS_UP 65 0.62 2.14 2.99E-04 
JECHLINGER_EMT_UP 56 0.63 2.12 4.73E-04 
DAC_BLADDER_UP 23 0.76 2.12 4.59E-04 
DAC_IFN_BLADDER_UP 16 0.82 2.12 4.46E-04 
PEART_HISTONE_DN 63 0.61 2.11 4.34E-04 
RADAEVA_IFNA_UP 38 0.67 2.10 4.22E-04 
ZELLER_MYC_UP 23 0.73 2.10 4.11E-04 
CANCER_UNDIFFERENTIATED_META_ 
UP 62 0.61 2.10 4.62E-04 
MARSHALL_SPLEEN_BAL 25 0.74 2.09 4.50E-04 
PROTEASOMEPATHWAY 21 0.73 2.09 4.69E-04 
TNFALPHA_ALL_UP 66 0.59 2.08 5.41E-04 
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EMT_UP 55 0.60 2.08 5.29E-04 
SCHUMACHER_MYC_UP 47 0.63 2.07 5.17E-04 
PASSERINI_INFLAMMATION 23 0.73 2.07 5.05E-04 
APPEL_IMATINIB_UP 29 0.70 2.07 4.94E-04 
MYC_TARGETS 39 0.65 2.07 4.84E-04 
ADIP_DIFF_CLUSTER4 31 0.68 2.07 4.99E-04 
CMV_24HRS_UP 61 0.61 2.06 4.89E-04 
OXIDATIVE_PHOSPHORYLATION 55 0.61 2.06 5.28E-04 
CMV_ALL_UP 81 0.57 2.05 6.36E-04 
HOFMANN_MDS_CD34_LOW_AND_ 
HIGH_RISK 31 0.68 2.05 7.14E-04 
FERRANDO_MLL_T_ALL_DN 71 0.57 2.03 9.73E-04 
IFNALPHA_NL_UP 19 0.74 2.01 1.16E-03 
ERM_KO_SERTOLI_DN 17 0.77 2.01 1.18E-03 
AGED_MOUSE_NEOCORTEX_UP 60 0.59 2.01 1.16E-03 
INOS_ALL_UP 47 0.61 2.01 1.16E-03 
CANTHARIDIN_DN 45 0.61 2.00 1.22E-03 
COLLER_MYC_UP 17 0.77 2.00 1.43E-03 
ROS_MOUSE_AORTA_DN 68 0.57 2.00 1.40E-03 
PROTEASOME 17 0.75 2.00 1.38E-03 
NKTPATHWAY 28 0.67 1.99 1.53E-03 
HADDAD_CD45CD7_PLUS_VS_MINUS_ 
UP 52 0.58 1.99 1.51E-03 
IL6_FIBRO_UP 35 0.63 1.99 1.48E-03 
HEARTFAILURE_VENTRICLE_DN 56 0.59 1.99 1.55E-03 
APOPTOSIS 64 0.56 1.98 1.84E-03 
TAKEDA_NUP8_HOXA9_3D_DN 20 0.71 1.97 1.85E-03 
LIAN_MYELOID_DIFF_GRANULE 28 0.67 1.96 2.33E-03 
HADDAD_HSC_CD7_UP 52 0.58 1.96 2.39E-03 
ST_TUMOR_NECROSIS_FACTOR_ 
PATHWAY 28 0.67 1.96 2.56E-03 
MOOTHA_VOXPHOS 73 0.55 1.95 2.71E-03 
CHAUHAN_2ME2 42 0.60 1.95 2.76E-03 
RIBOSOMAL_PROTEINS 78 0.54 1.95 2.77E-03 
TNFALPHA_4HRS_UP 34 0.63 1.94 2.91E-03 
LEE_MYC_TGFA_UP 54 0.57 1.94 2.89E-03 
MOREAUX_TACI_HI_IN_PPC_UP 43 0.59 1.94 2.97E-03 
BHATTACHARYA_ESC_UP 57 0.57 1.94 3.07E-03 
BRCA_BRCA1_POS 68 0.56 1.94 3.09E-03 
IFNALPHA_HCC_UP 23 0.70 1.94 3.13E-03 
DSRNA_UP 32 0.64 1.94 3.09E-03 
PROTEASOME_DEGRADATION 32 0.64 1.93 3.26E-03 
BENNETT_SLE_UP 19 0.70 1.93 3.39E-03 
TARTE_PC 65 0.55 1.93 3.58E-03 
CMV_HCMV_TIMECOURSE_12HRS_ 
UP 21 0.69 1.93 3.58E-03 
TNFALPHA_30MIN_UP 37 0.61 1.92 3.71E-03 
UVB_NHEK3_C0 73 0.54 1.92 3.89E-03 
GOLDRATH_CYTOLYTIC 24 0.67 1.92 3.84E-03 
LIAN_MYELOID_DIFF_RECEPTORS 33 0.61 1.92 3.84E-03 
PARK_RARALPHA_UP 34 0.61 1.91 4.34E-03 
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IL2PATHWAY 21 0.68 1.90 4.71E-03 
STEMCELL_COMMON_DN 54 0.56 1.90 4.66E-03 
AGED_MOUSE_CEREBELLUM_UP 58 0.55 1.89 5.69E-03 
DER_IFNG_UP 54 0.56 1.88 6.10E-03 
CCR5PATHWAY 18 0.70 1.87 7.21E-03 
HALMOS_CEBP_UP 41 0.57 1.86 8.29E-03 
ZHAN_MM_CD138_MF_VS_REST 30 0.62 1.85 8.56E-03 
HOHENKIRK_MONOCYTE_DEND_ 
UP 85 0.51 1.85 8.52E-03 
ST_GAQ_PATHWAY 24 0.65 1.85 8.95E-03 
PHOTOSYNTHESIS 21 0.67 1.85 9.02E-03 
IFN_GAMMA_UP 35 0.59 1.84 9.97E-03 
IFNA_UV-CMV_COMMON_HCMV_6HRS_ 
UP 20 0.67 1.84 9.88E-03 
 
ES = enrichment score; NES = normalized enrichment score; FDR = false discovery rate  
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Appendix 2 
 
Significantly altered gene sets by A-DEP/saline compared to saline 
 
NAME SIZE ES NES FDR q-val 
CARIES_PULP_HIGH_UP 68 0.77 2.89 < 1.00E-06 
LAL_KO_3MO_UP 46 0.78 2.73 < 1.00E-06 
LAL_KO_6MO_UP 58 0.73 2.65 < 1.00E-06 
DNA_REPLICATION_REACTOME 41 0.75 2.55 < 1.00E-06 
ELECTRON_TRANSPORT_CHAIN 86 0.65 2.55 < 1.00E-06 
CANCER_UNDIFFERENTIATED_META_UP 62 0.69 2.51 < 1.00E-06 
MOOTHA_VOXPHOS 73 0.67 2.48 < 1.00E-06 
YANG_OSTECLASTS_SIG 39 0.74 2.45 < 1.00E-06 
MANALO_HYPOXIA_DN 73 0.65 2.44 < 1.00E-06 
CANCER_NEOPLASTIC_META_UP 59 0.68 2.44 < 1.00E-06 
YU_CMYC_UP 37 0.72 2.38 < 1.00E-06 
GALINDO_ACT_UP 75 0.62 2.37 < 1.00E-06 
OXIDATIVE_PHOSPHORYLATION 55 0.66 2.36 < 1.00E-06 
FLECHNER_KIDNEY_TRANSPLANT_ 
REJECTION_UP 72 0.62 2.34 < 1.00E-06 
LINDSTEDT_DEND_8H_VS_48H_UP 58 0.65 2.32 < 1.00E-06 
CANTHARIDIN_DN 45 0.66 2.31 < 1.00E-06 
SERUM_FIBROBLAST_CELLCYCLE 88 0.58 2.30 < 1.00E-06 
FERRANDO_MLL_T_ALL_DN 71 0.61 2.30 < 1.00E-06 
SCHUMACHER_MYC_UP 47 0.66 2.29 < 1.00E-06 
WIELAND_HEPATITIS_B_INDUCED 71 0.62 2.29 < 1.00E-06 
ADIP_DIFF_CLUSTER4 31 0.72 2.28 < 1.00E-06 
P21_ANY_DN 27 0.74 2.28 < 1.00E-06 
HOUSTIS_ROS 32 0.71 2.27 < 1.00E-06 
PEART_HISTONE_DN 63 0.62 2.27 < 1.00E-06 
IDX_TSA_UP_CLUSTER3 81 0.60 2.26 4.59E-05 
NEMETH_TNF_UP 82 0.59 2.25 4.42E-05 
CMV_IE86_UP 42 0.67 2.24 4.25E-05 
BLEO_HUMAN_LYMPH_HIGH_24HRS_UP 86 0.57 2.21 4.10E-05 
INOS_ALL_UP 47 0.64 2.21 3.96E-05 
MENSSEN_MYC_UP 30 0.70 2.21 3.83E-05 
UVB_NHEK2_UP 55 0.61 2.17 2.29E-04 
NI2_MOUSE_UP 40 0.64 2.16 2.97E-04 
PROTEASOME_DEGRADATION 32 0.67 2.15 4.35E-04 
RIBOSOMAL_PROTEINS 78 0.56 2.15 4.57E-04 
BHATTACHARYA_ESC_UP 57 0.59 2.12 5.44E-04 
HG_PROGERIA_DN 24 0.71 2.12 5.29E-04 
NAKAJIMA_MCS_UP 85 0.55 2.12 5.47E-04 
COLLER_MYC_UP 17 0.76 2.10 6.62E-04 
HEARTFAILURE_VENTRICLE_DN 56 0.58 2.09 6.74E-04 
OLDAGE_DN 45 0.61 2.09 6.58E-04 
BASSO_GERMINAL_CENTER_CD40_UP 82 0.54 2.07 9.37E-04 
DOX_RESIST_GASTRIC_UP 30 0.65 2.06 1.26E-03 
ZELLER_MYC_UP 23 0.69 2.04 1.70E-03 
UVB_NHEK1_C1 41 0.60 2.03 1.69E-03 
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MOREAUX_TACI_HI_IN_PPC_UP 43 0.60 2.03 1.70E-03 
RIBAVIRIN_RSV_UP 18 0.72 2.01 2.22E-03 
P21_P53_ANY_DN 35 0.62 2.01 2.17E-03 
BREAST_DUCTAL_CARCINOMA_GENES 19 0.71 2.01 2.30E-03 
CMV_24HRS_UP 61 0.55 2.00 2.42E-03 
REN_E2F1_TARGETS 37 0.60 2.00 2.52E-03 
IDX_TSA_UP_CLUSTER5 82 0.52 2.00 2.49E-03 
CROONQUIST_IL6_STARVE_UP 32 0.62 1.99 2.51E-03 
TNFALPHA_ALL_UP 66 0.53 1.99 2.60E-03 
TSA_CD4_UP 24 0.65 1.99 2.55E-03 
PYRIMIDINE_METABOLISM 55 0.55 1.98 2.90E-03 
HINATA_NFKB_UP 89 0.51 1.97 3.15E-03 
MYC_TARGETS 39 0.59 1.96 3.66E-03 
ADIP_DIFF_CLUSTER5 34 0.59 1.95 4.09E-03 
SHIPP_FL_VS_DLBCL_DN 30 0.61 1.95 4.06E-03 
TNFA_NFKB_DEP_UP 17 0.71 1.95 4.23E-03 
ATP_SYNTHESIS 20 0.67 1.95 4.18E-03 
TNFALPHA_30MIN_UP 37 0.58 1.95 4.12E-03 
HPV31_DN 37 0.58 1.94 4.28E-03 
P21_P53_MIDDLE_DN 17 0.71 1.94 4.23E-03 
TAVOR_CEBP_UP 42 0.57 1.93 4.64E-03 
PHOTOSYNTHESIS 21 0.67 1.93 4.74E-03 
PROTEASOMEPATHWAY 21 0.65 1.92 5.43E-03 
TARTE_PC 65 0.52 1.91 5.70E-03 
TYPE_III_SECRETION_SYSTEM 20 0.67 1.91 5.66E-03 
CMV_ALL_UP 81 0.50 1.91 5.88E-03 
UEDA_MOUSE_SCN 86 0.49 1.91 5.82E-03 
G1_TO_S_CELL_CYCLE_REACTOME 65 0.51 1.90 6.40E-03 
STRESS_TPA_SPECIFIC_UP 34 0.59 1.90 6.36E-03 
CELL_CYCLE 71 0.50 1.90 6.42E-03 
FLAGELLAR_ASSEMBLY 20 0.67 1.89 6.60E-03 
ABBUD_LIF_UP 45 0.54 1.89 7.01E-03 
KNUDSEN_PMNS_UP 65 0.51 1.88 7.46E-03 
TPA_SENS_MIDDLE_UP 55 0.53 1.88 7.62E-03 
CARBON_FIXATION 18 0.66 1.88 7.67E-03 
MMS_HUMAN_LYMPH_HIGH_24HRS_UP 18 0.69 1.88 7.58E-03 
ZHAN_MM_CD138_PR_VS_REST 28 0.62 1.87 7.97E-03 
ZUCCHI_EPITHELIAL_DN 36 0.58 1.87 8.21E-03 
TIS7_OVEREXP_DN 17 0.67 1.87 8.23E-03 
ZHAN_MULTIPLE_MYELOMA_VS_ 
NORMAL_DN 33 0.58 1.87 8.23E-03 
ROS_MOUSE_AORTA_DN 68 0.50 1.87 8.17E-03 
BRENTANI_DNA_METHYLATION_AND_ 
MODIFICATION 23 0.63 1.86 8.83E-03 
NADLER_OBESITY_UP 57 0.52 1.86 8.73E-03 
BLEO_MOUSE_LYMPH_LOW_24HRS_DN 24 0.63 1.86 8.70E-03 
ET743_SARCOMA_UP 56 0.51 1.86 8.63E-03 
UVB_NHEK3_C6 25 0.61 1.85 9.32E-03 
 
ES = enrichment score; NES = normalized enrichment score; FDR = false discovery rate  
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Appendix 3 
 
Significantly altered gene sets by C-DEP/saline compared to saline 
 
NAME SIZE ES NES FDR q-val 
CARIES_PULP_HIGH_UP 68 0.77 2.90 < 1.00E-06 
GALINDO_ACT_UP 75 0.72 2.79 < 1.00E-06 
YANG_OSTECLASTS_SIG 39 0.79 2.74 < 1.00E-06 
LINDSTEDT_DEND_8H_VS_48H_UP 58 0.70 2.69 < 1.00E-06 
HINATA_NFKB_UP 89 0.65 2.64 < 1.00E-06 
NAKAJIMA_MCS_UP 85 0.65 2.58 < 1.00E-06 
NEMETH_TNF_UP 82 0.64 2.57 < 1.00E-06 
LAL_KO_6MO_UP 58 0.68 2.57 < 1.00E-06 
WIELAND_HEPATITIS_B_INDUCED 71 0.66 2.53 < 1.00E-06 
LAL_KO_3MO_UP 46 0.73 2.52 < 1.00E-06 
HOUSTIS_ROS 32 0.75 2.49 < 1.00E-06 
SANA_TNFA_ENDOTHELIAL_UP 61 0.66 2.48 < 1.00E-06 
FLECHNER_KIDNEY_TRANSPLANT_ 
REJECTION_UP 72 0.64 2.47 < 1.00E-06 
BLEO_HUMAN_LYMPH_HIGH_24HRS_UP 86 0.61 2.45 < 1.00E-06 
NADLER_OBESITY_UP 57 0.66 2.45 < 1.00E-06 
ADIP_DIFF_CLUSTER4 31 0.74 2.44 < 1.00E-06 
MYC_TARGETS 39 0.71 2.44 < 1.00E-06 
TNFA_NFKB_DEP_UP 17 0.86 2.42 < 1.00E-06 
NI2_MOUSE_UP 40 0.71 2.41 < 1.00E-06 
INOS_ALL_UP 47 0.68 2.39 < 1.00E-06 
TPA_SENS_MIDDLE_UP 55 0.66 2.38 < 1.00E-06 
TSA_CD4_UP 24 0.76 2.35 < 1.00E-06 
CANCER_UNDIFFERENTIATED_META_UP 62 0.62 2.35 < 1.00E-06 
ZELLER_MYC_UP 23 0.76 2.33 < 1.00E-06 
ZUCCHI_EPITHELIAL_DN 36 0.70 2.33 < 1.00E-06 
CMV_IE86_UP 42 0.66 2.26 5.58E-05 
CMV_24HRS_UP 61 0.59 2.26 5.37E-05 
MUNSHI_MM_UP 57 0.59 2.24 1.03E-04 
DAC_BLADDER_UP 23 0.74 2.23 1.47E-04 
PASSERINI_INFLAMMATION 23 0.71 2.19 3.21E-04 
BASSO_GERMINAL_CENTER_CD40_UP 82 0.56 2.19 3.11E-04 
IDX_TSA_UP_CLUSTER3 81 0.56 2.18 4.32E-04 
MARTINELLI_IFNS_DIFF 16 0.79 2.18 4.19E-04 
CMV_ALL_UP 81 0.54 2.17 4.47E-04 
P21_ANY_DN 27 0.69 2.16 4.73E-04 
MANALO_HYPOXIA_DN 73 0.55 2.16 4.97E-04 
MUNSHI_MM_VS_PCS_UP 64 0.58 2.15 5.20E-04 
FERRANDO_MLL_T_ALL_DN 71 0.56 2.15 5.06E-04 
SHIPP_FL_VS_DLBCL_DN 30 0.66 2.14 5.30E-04 
MMS_HUMAN_LYMPH_HIGH_24HRS_UP 18 0.76 2.14 5.16E-04 
DAC_IFN_BLADDER_UP 16 0.78 2.14 5.37E-04 
DNA_REPLICATION_REACTOME 41 0.62 2.13 5.24E-04 
PROTEASOME_DEGRADATION 32 0.66 2.13 5.43E-04 
ROSS_CBF_MYH 38 0.61 2.12 7.18E-04 
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HG_PROGERIA_DN 24 0.70 2.11 7.33E-04 
ROS_MOUSE_AORTA_DN 68 0.55 2.10 8.96E-04 
OLDAGE_DN 45 0.60 2.09 1.05E-03 
COLLER_MYC_UP 17 0.76 2.09 1.14E-03 
KNUDSEN_PMNS_UP 65 0.55 2.08 1.29E-03 
TARTE_PC 65 0.54 2.07 1.37E-03 
PROTEASOME 17 0.75 2.07 1.37E-03 
DER_IFNG_UP 54 0.56 2.06 1.37E-03 
CANCER_NEOPLASTIC_META_UP 59 0.55 2.06 1.40E-03 
CHAUHAN_2ME2 42 0.60 2.06 1.48E-03 
SCHUMACHER_MYC_UP 47 0.60 2.06 1.45E-03 
UVB_NHEK2_UP 55 0.57 2.06 1.50E-03 
NKTPATHWAY 28 0.65 2.06 1.50E-03 
MENSSEN_MYC_UP 30 0.64 2.06 1.52E-03 
SERUM_FIBROBLAST_CELLCYCLE 88 0.52 2.05 1.54E-03 
TAVOR_CEBP_UP 42 0.59 2.05 1.58E-03 
PROTEASOMEPATHWAY 21 0.69 2.04 1.71E-03 
IFNALPHA_NL_UP 19 0.71 2.04 1.68E-03 
JECHLINGER_EMT_UP 56 0.55 2.04 1.70E-03 
ABBUD_LIF_UP 45 0.59 2.04 1.76E-03 
IL6_FIBRO_UP 35 0.60 2.03 1.79E-03 
PEART_HISTONE_DN 63 0.53 2.02 2.33E-03 
AS3_FIBRO_DN 26 0.65 2.01 2.34E-03 
YU_CMYC_UP 37 0.59 2.01 2.34E-03 
P21_P53_MIDDLE_DN 17 0.71 2.01 2.31E-03 
STRESS_TPA_SPECIFIC_UP 34 0.61 2.01 2.40E-03 
DSRNA_UP 32 0.60 2.00 2.60E-03 
ERM_KO_SERTOLI_DN 17 0.71 1.99 2.64E-03 
RADAEVA_IFNA_UP 38 0.59 1.99 2.73E-03 
TNFALPHA_4HRS_UP 34 0.60 1.99 2.90E-03 
CANTHARIDIN_DN 45 0.55 1.98 2.97E-03 
IFN_GAMMA_UP 35 0.59 1.98 3.04E-03 
HOFMANN_MDS_CD34_LOW_AND_ 
HIGH_RISK 31 0.61 1.97 3.31E-03 
ADIP_DIFF_CLUSTER5 34 0.59 1.97 3.27E-03 
TIS7_OVEREXP_DN 17 0.69 1.97 3.22E-03 
LIAN_MYELOID_DIFF_RECEPTORS 33 0.59 1.97 3.36E-03 
MARSHALL_SPLEEN_BAL 25 0.63 1.95 4.34E-03 
NAKAJIMA_MCSMBP_MAST 37 0.58 1.94 4.80E-03 
TAKEDA_NUP8_HOXA9_3D_DN 20 0.67 1.93 5.19E-03 
PYRIMIDINE_METABOLISM 55 0.52 1.93 5.34E-03 
TNFALPHA_ALL_UP 66 0.51 1.92 6.17E-03 
CMV_HCMV_TIMECOURSE_12HRS_UP 21 0.65 1.92 6.12E-03 
HEARTFAILURE_VENTRICLE_DN 56 0.52 1.92 6.14E-03 
IFNALPHA_HCC_UP 23 0.64 1.91 6.44E-03 
HYPOXIA_REVIEW 68 0.50 1.91 6.64E-03 
LINDSTEDT_DEND_UP 44 0.54 1.91 6.87E-03 
CROONQUIST_IL6_RAS_UP 18 0.67 1.90 7.79E-03 
LEE_MYC_TGFA_UP 54 0.51 1.89 7.81E-03 
EMT_UP 55 0.51 1.89 8.20E-03 
LEE_ACOX1_UP 58 0.51 1.89 8.21E-03 
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BENNETT_SLE_UP 19 0.65 1.88 8.45E-03 
ZHAN_MMPC_SIMAL 41 0.55 1.88 8.40E-03 
P21_P53_ANY_DN 35 0.57 1.88 8.63E-03 
BREAST_DUCTAL_CARCINOMA_ 
GENES 19 0.65 1.88 8.74E-03 
 
ES = enrichment score; NES = normalized enrichment score; FDR = false discovery rate  
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Appendix 4 
 
Significantly altered gene sets by N-DEP/OVA compared to OVA 
 
NAME SIZE ES NES FDR q-val 
CARIES_PULP_HIGH_UP 68 0.81 2.76 < 1.00E-06 
LAL_KO_3MO_UP 46 0.83 2.61 < 1.00E-06 
LAL_KO_6MO_UP 58 0.79 2.60 < 1.00E-06 
NEMETH_TNF_UP 82 0.74 2.59 < 1.00E-06 
WIELAND_HEPATITIS_B_INDUCED 71 0.74 2.54 < 1.00E-06 
NADLER_OBESITY_UP 57 0.76 2.51 < 1.00E-06 
YANG_OSTECLASTS_SIG 39 0.82 2.50 < 1.00E-06 
LINDSTEDT_DEND_8H_VS_48H_UP 58 0.73 2.45 < 1.00E-06 
NAKAJIMA_MCS_UP 85 0.69 2.44 < 1.00E-06 
SANA_TNFA_ENDOTHELIAL_UP 61 0.71 2.41 < 1.00E-06 
BASSO_GERMINAL_CENTER_CD40_UP 82 0.69 2.40 < 1.00E-06 
GALINDO_ACT_UP 75 0.69 2.40 < 1.00E-06 
FLECHNER_KIDNEY_TRANSPLANT_ 
REJECTION_UP 72 0.69 2.39 < 1.00E-06 
HINATA_NFKB_UP 89 0.64 2.26 < 1.00E-06 
NI2_MOUSE_UP 40 0.70 2.16 3.02E-04 
BLEO_HUMAN_LYMPH_HIGH_24HRS_UP 86 0.60 2.14 2.83E-04 
GOLDRATH_CYTOLYTIC 24 0.77 2.14 3.32E-04 
BRENTANI_IMMUNE_FUNCTION 42 0.68 2.13 3.75E-04 
JECHLINGER_EMT_UP 56 0.64 2.11 5.30E-04 
ADIP_DIFF_CLUSTER3 28 0.73 2.10 5.03E-04 
TNFA_NFKB_DEP_UP 17 0.80 2.09 5.83E-04 
YU_CMYC_DN 53 0.65 2.09 5.57E-04 
YAGI_AML_PROGNOSIS 31 0.70 2.07 7.26E-04 
ROSS_MLL_FUSION 60 0.62 2.05 1.12E-03 
LIAN_MYELOID_DIFF_RECEPTORS 33 0.69 2.03 1.47E-03 
EMT_UP 55 0.61 2.02 1.50E-03 
PASSERINI_INFLAMMATION 23 0.74 2.01 1.69E-03 
APPEL_IMATINIB_UP 29 0.70 2.01 1.96E-03 
ABBUD_LIF_UP 45 0.64 2.01 1.89E-03 
TAKEDA_NUP8_HOXA9_3D_DN 20 0.74 2.01 1.86E-03 
LINDSTEDT_DEND_DN 53 0.61 2.01 1.87E-03 
CMV_ALL_UP 81 0.56 2.01 1.81E-03 
TAVOR_CEBP_UP 42 0.63 1.99 2.34E-03 
STEMCELL_COMMON_DN 54 0.60 1.98 2.89E-03 
SCHUMACHER_MYC_UP 47 0.61 1.97 3.54E-03 
ERM_KO_SERTOLI_DN 17 0.75 1.96 3.66E-03 
DAC_IFN_BLADDER_UP 16 0.77 1.95 4.26E-03 
SANA_IFNG_ENDOTHELIAL_UP 45 0.62 1.95 4.26E-03 
WANG_HOXA9_VS_MEIS1_UP 25 0.68 1.94 4.75E-03 
LIAN_MYELOID_DIFF_GRANULE 28 0.68 1.93 5.19E-03 
CMV_24HRS_UP 61 0.58 1.93 5.58E-03 
MARTINELLI_IFNS_DIFF 16 0.75 1.93 5.45E-03 
TARTE_PC 65 0.56 1.92 5.48E-03 
MYC_TARGETS 39 0.63 1.92 5.46E-03 
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WANG_MLL_CBP_VS_GMP_UP 42 0.61 1.91 6.10E-03 
XU_CBP_UP 25 0.68 1.91 6.53E-03 
LOTEM_LEUKEMIA_UP 22 0.69 1.91 6.39E-03 
LINDSTEDT_DEND_UP 44 0.61 1.90 6.60E-03 
LU_IL4BCELL 62 0.56 1.90 6.79E-03 
ZELLER_MYC_UP 23 0.69 1.90 6.99E-03 
CASPASEPATHWAY 20 0.69 1.90 6.89E-03 
ROSS_CBF_MYH 38 0.62 1.90 6.76E-03 
CMV_8HRS_UP 27 0.66 1.88 8.38E-03 
TPA_SENS_MIDDLE_UP 55 0.57 1.88 8.27E-03 
DSRNA_UP 32 0.63 1.87 8.52E-03 
NAKAJIMA_MCSMBP_MAST 37 0.61 1.87 8.37E-03 
CROONQUIST_IL6_RAS_UP 18 0.72 1.87 8.38E-03 
GENOTOXINS_ALL_24HRS_REG 22 0.68 1.87 8.26E-03 
HOHENKIRK_MONOCYTE_DEND_UP 85 0.53 1.87 8.40E-03 
SHIPP_FL_VS_DLBCL_DN 30 0.63 1.87 8.34E-03 
 
ES = enrichment score; NES = normalized enrichment score; FDR = false discovery rate  
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Appendix 5 
 
Significantly altered gene sets by A-DEP/OVA compared to OVA 
 
NAME SIZE ES NES FDR q-val 
YANG_OSTECLASTS_SIG 39 0.86 2.84 < 1.00E-06 
LAL_KO_6MO_UP 58 0.74 2.59 < 1.00E-06 
NAKAJIMA_MCS_UP 85 0.68 2.58 < 1.00E-06 
LINDSTEDT_DEND_8H_VS_48H_UP 58 0.73 2.58 < 1.00E-06 
LAL_KO_3MO_UP 46 0.76 2.56 < 1.00E-06 
NADLER_OBESITY_UP 57 0.72 2.56 < 1.00E-06 
GALINDO_ACT_UP 75 0.70 2.54 < 1.00E-06 
SANA_TNFA_ENDOTHELIAL_UP 61 0.71 2.52 < 1.00E-06 
CARIES_PULP_HIGH_UP 68 0.70 2.50 < 1.00E-06 
NEMETH_TNF_UP 82 0.66 2.43 < 1.00E-06 
JECHLINGER_EMT_UP 56 0.67 2.32 < 1.00E-06 
HINATA_NFKB_UP 89 0.60 2.29 < 1.00E-06 
TNFA_NFKB_DEP_UP 17 0.85 2.29 < 1.00E-06 
NI2_MOUSE_UP 40 0.70 2.26 7.14E-05 
ERM_KO_SERTOLI_DN 17 0.83 2.25 6.67E-05 
BASSO_GERMINAL_CENTER_CD40_UP 82 0.61 2.24 6.25E-05 
WIELAND_HEPATITIS_B_INDUCED 71 0.62 2.22 5.88E-05 
EMT_UP 55 0.63 2.21 5.56E-05 
PASSERINI_INFLAMMATION 23 0.75 2.19 5.26E-05 
NAKAJIMA_MCSMBP_MAST 37 0.68 2.17 5.00E-05 
TPA_SENS_MIDDLE_UP 55 0.62 2.16 4.76E-05 
LIAN_MYELOID_DIFF_RECEPTORS 33 0.69 2.14 1.40E-04 
BENNETT_SLE_UP 19 0.77 2.13 2.24E-04 
TGFBETA_C2_UP 17 0.79 2.12 2.14E-04 
TAKEDA_NUP8_HOXA9_3D_DN 20 0.76 2.12 2.48E-04 
RADAEVA_IFNA_UP 38 0.65 2.10 3.19E-04 
IL1_CORNEA_UP 53 0.60 2.08 5.72E-04 
DAC_BLADDER_UP 23 0.72 2.08 5.89E-04 
DAC_IFN_BLADDER_UP 16 0.79 2.08 6.03E-04 
MARTINELLI_IFNS_DIFF 16 0.77 2.07 6.89E-04 
TAVOR_CEBP_UP 42 0.62 2.06 7.32E-04 
AS3_FIBRO_DN 26 0.70 2.05 7.74E-04 
HEARTFAILURE_VENTRICLE_DN 56 0.59 2.03 1.03E-03 
CANCER_UNDIFFERENTIATED_META_UP 62 0.56 2.01 1.43E-03 
FLECHNER_KIDNEY_TRANSPLANT_ 
REJECTION_UP 72 0.55 2.01 1.39E-03 
ADIP_DIFF_CLUSTER4 31 0.64 2.01 1.38E-03 
KNUDSEN_PMNS_UP 65 0.56 2.00 1.39E-03 
AGED_MOUSE_CEREBELLUM_UP 58 0.58 1.99 1.66E-03 
CMV_ALL_UP 81 0.54 1.98 1.90E-03 
BLEO_HUMAN_LYMPH_HIGH_24HRS_UP 86 0.52 1.98 2.06E-03 
MATRIX_METALLOPROTEINASES 24 0.69 1.98 2.04E-03 
DORSEY_DOXYCYCLINE_UP 23 0.68 1.96 2.53E-03 
PASSERINI_EM 34 0.62 1.96 2.56E-03 
TSA_CD4_UP 24 0.66 1.95 2.62E-03 
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CROONQUIST_IL6_RAS_UP 18 0.70 1.95 2.70E-03 
ZUCCHI_EPITHELIAL_DN 36 0.60 1.94 3.52E-03 
CMV_8HRS_UP 27 0.64 1.93 4.18E-03 
IFNALPHA_HCC_UP 23 0.66 1.92 4.21E-03 
SANA_IFNG_ENDOTHELIAL_UP 45 0.58 1.92 4.35E-03 
APPEL_IMATINIB_UP 29 0.63 1.92 4.30E-03 
SHEPARD_POS_REG_OF_CELL_ 
PROLIFERATION 85 0.52 1.92 4.22E-03 
CROONQUIST_IL6_STROMA_UP 34 0.60 1.92 4.34E-03 
SERUM_FIBROBLAST_CELLCYCLE 88 0.50 1.91 4.61E-03 
DSRNA_UP 32 0.61 1.91 4.91E-03 
MYC_TARGETS 39 0.58 1.90 5.89E-03 
INSULIN_NIH3T3_UP 15 0.72 1.89 6.12E-03 
CHAUHAN_2ME2 42 0.56 1.89 6.17E-03 
CAMPTOTHECIN_PROBCELL_DN 21 0.66 1.89 6.08E-03 
LINDSTEDT_DEND_DN 53 0.55 1.89 6.21E-03 
LEE_DENA_UP 55 0.54 1.88 6.31E-03 
ROSS_MLL_FUSION 60 0.53 1.88 6.51E-03 
CCR5PATHWAY 18 0.68 1.88 6.64E-03 
PEART_HISTONE_DN 63 0.52 1.88 6.61E-03 
IRITANI_ADPROX_DN 45 0.55 1.87 7.03E-03 
ABBUD_LIF_UP 45 0.56 1.87 7.16E-03 
MUNSHI_MM_UP 57 0.53 1.87 7.10E-03 
ZHAN_MULTIPLE_MYELOMA_VS_ 
NORMAL_DN 33 0.61 1.87 7.10E-03 
NKTPATHWAY 28 0.62 1.85 9.28E-03 
 
ES = enrichment score; NES = normalized enrichment score; FDR = false discovery rate  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 151 
Appendix 6 
 
Significantly altered gene sets by C-DEP/OVA compared to OVA 
 
NAME SIZE ES NES FDR q-val 
CARIES_PULP_HIGH_UP 68 0.80 2.94 < 1.00E-06 
WIELAND_HEPATITIS_B_INDUCED 71 0.76 2.83 < 1.00E-06 
NEMETH_TNF_UP 82 0.73 2.77 < 1.00E-06 
YANG_OSTECLASTS_SIG 39 0.82 2.73 < 1.00E-06 
LINDSTEDT_DEND_8H_VS_48H_UP 58 0.76 2.73 < 1.00E-06 
FLECHNER_KIDNEY_TRANSPLANT_ 
REJECTION_UP 72 0.73 2.71 < 1.00E-06 
IFNA_HCMV_6HRS_UP 38 0.80 2.64 < 1.00E-06 
LAL_KO_6MO_UP 58 0.76 2.64 < 1.00E-06 
GALINDO_ACT_UP 75 0.71 2.62 < 1.00E-06 
LAL_KO_3MO_UP 46 0.77 2.60 < 1.00E-06 
SANA_TNFA_ENDOTHELIAL_UP 61 0.73 2.59 < 1.00E-06 
CMV_ALL_UP 81 0.67 2.50 < 1.00E-06 
SANA_IFNG_ENDOTHELIAL_UP 45 0.74 2.50 < 1.00E-06 
RADAEVA_IFNA_UP 38 0.76 2.49 < 1.00E-06 
CMV_8HRS_UP 27 0.81 2.48 < 1.00E-06 
BASSO_GERMINAL_CENTER_CD40_UP 82 0.66 2.48 < 1.00E-06 
NAKAJIMA_MCS_UP 85 0.65 2.46 < 1.00E-06 
DER_IFNA_UP 53 0.69 2.45 < 1.00E-06 
CANCER_NEOPLASTIC_META_UP 59 0.69 2.45 < 1.00E-06 
DER_IFNB_UP 76 0.65 2.41 < 1.00E-06 
HINATA_NFKB_UP 89 0.63 2.41 < 1.00E-06 
CMV_HCMV_TIMECOURSE_12HRS_UP 21 0.82 2.39 < 1.00E-06 
CANCER_UNDIFFERENTIATED_META_UP 62 0.66 2.34 < 1.00E-06 
CMV_24HRS_UP 61 0.66 2.34 < 1.00E-06 
MANALO_HYPOXIA_DN 73 0.62 2.33 < 1.00E-06 
NADLER_OBESITY_UP 57 0.66 2.32 < 1.00E-06 
IFNA_UV-CMV_COMMON_HCMV_6HRS_UP 20 0.81 2.32 < 1.00E-06 
SCHUMACHER_MYC_UP 47 0.68 2.32 < 1.00E-06 
DER_IFNG_UP 54 0.66 2.28 < 1.00E-06 
IFN_ANY_UP 71 0.61 2.27 < 1.00E-06 
PEART_HISTONE_DN 63 0.63 2.26 < 1.00E-06 
IFN_BETA_UP 55 0.64 2.26 < 1.00E-06 
ADIP_DIFF_CLUSTER4 31 0.72 2.25 < 1.00E-06 
IFNALPHA_NL_UP 19 0.80 2.25 < 1.00E-06 
IFN_GAMMA_UP 35 0.69 2.23 < 1.00E-06 
GOLDRATH_CYTOLYTIC 24 0.75 2.21 < 1.00E-06 
IFNALPHA_HCC_UP 23 0.74 2.20 < 1.00E-06 
CANTHARIDIN_DN 45 0.65 2.20 < 1.00E-06 
MOREAUX_TACI_HI_IN_PPC_UP 43 0.66 2.19 < 1.00E-06 
DAC_IFN_BLADDER_UP 16 0.82 2.19 < 1.00E-06 
BENNETT_SLE_UP 19 0.79 2.18 < 1.00E-06 
STRESS_TPA_SPECIFIC_UP 34 0.69 2.17 2.91E-05 
TNFA_NFKB_DEP_UP 17 0.81 2.17 2.84E-05 
TARTE_PC 65 0.60 2.17 2.77E-05 
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BLEO_HUMAN_LYMPH_HIGH_24HRS_UP 86 0.57 2.17 2.71E-05 
DSRNA_UP 32 0.69 2.16 2.65E-05 
TSA_CD4_UP 24 0.73 2.15 5.32E-05 
JECHLINGER_EMT_UP 56 0.61 2.14 1.30E-04 
INOS_ALL_UP 47 0.62 2.14 1.27E-04 
IFN_ALL_UP 16 0.79 2.14 1.25E-04 
IFN_ALPHA_UP 34 0.67 2.13 1.95E-04 
LIAN_MYELOID_DIFF_RECEPTORS 33 0.67 2.13 1.91E-04 
BRCA_BRCA1_POS 68 0.58 2.13 2.11E-04 
ERM_KO_SERTOLI_DN 17 0.78 2.12 2.07E-04 
COLLER_MYC_UP 17 0.78 2.12 2.03E-04 
AMINOACYL_TRNA_BIOSYNTHESIS 18 0.75 2.10 4.86E-04 
PROTEASOMEPATHWAY 21 0.73 2.09 5.20E-04 
HSC_INTERMEDIATEPROGENITORS_ADULT 88 0.54 2.09 5.11E-04 
PASSERINI_INFLAMMATION 23 0.70 2.08 6.52E-04 
LINDSTEDT_DEND_DN 53 0.59 2.07 6.83E-04 
ROSS_CBF_MYH 38 0.63 2.07 7.52E-04 
LU_IL4BCELL 62 0.57 2.06 7.81E-04 
DNA_REPLICATION_REACTOME 41 0.64 2.06 7.68E-04 
STRESS_GENOTOXIC_SPECIFIC_DN 36 0.63 2.06 9.11E-04 
SERUM_FIBROBLAST_CELLCYCLE 88 0.54 2.05 9.35E-04 
YAGI_AML_PROGNOSIS 31 0.65 2.05 9.21E-04 
EMT_UP 55 0.58 2.05 9.07E-04 
PROTEASOME_DEGRADATION 32 0.65 2.05 9.12E-04 
NI2_MOUSE_UP 40 0.62 2.05 9.88E-04 
HSC_INTERMEDIATEPROGENITORS_SHARED 80 0.54 2.05 9.74E-04 
LINDSTEDT_DEND_UP 44 0.61 2.04 1.05E-03 
TRNA_SYNTHETASES 17 0.75 2.03 1.19E-03 
SHIPP_FL_VS_DLBCL_DN 30 0.66 2.02 1.29E-03 
INSULIN_ADIP_INSENS_UP 17 0.73 2.02 1.36E-03 
PROTEASOME 17 0.74 2.01 1.46E-03 
GOLDRATH_CELLCYCLE 28 0.65 2.01 1.52E-03 
ZHAN_MULTIPLE_MYELOMA_SUBCLASSES_ 
DIFF 26 0.67 2.01 1.68E-03 
YU_CMYC_DN 53 0.58 2.00 1.72E-03 
UV-CMV_UNIQUE_HCMV_6HRS_UP 83 0.53 2.00 1.72E-03 
CHOLESTEROL_BIOSYNTHESIS 15 0.76 2.00 1.69E-03 
TAKEDA_NUP8_HOXA9_3D_DN 20 0.70 2.00 1.69E-03 
YU_CMYC_UP 37 0.61 1.99 1.77E-03 
UEDA_MOUSE_SCN 86 0.53 1.98 2.20E-03 
APOPTOSIS 64 0.55 1.98 2.34E-03 
ZELLER_MYC_UP 23 0.68 1.96 3.06E-03 
DAC_BLADDER_UP 23 0.67 1.96 3.11E-03 
MYC_TARGETS 39 0.58 1.94 3.99E-03 
BLEO_MOUSE_LYMPH_HIGH_24HRS_DN 32 0.62 1.94 3.97E-03 
CMV_HCMV_6HRS_UP 19 0.70 1.94 3.99E-03 
HDACI_COLON_CUR24HRS_UP 28 0.63 1.94 3.96E-03 
UNDERHILL_PROLIFERATION 18 0.69 1.93 4.03E-03 
MENSSEN_MYC_UP 30 0.63 1.93 4.16E-03 
IL1_CORNEA_UP 53 0.55 1.93 4.15E-03 
FASPATHWAY 25 0.65 1.93 4.18E-03 
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MUNSHI_MM_UP 57 0.54 1.92 5.04E-03 
IDX_TSA_UP_CLUSTER3 81 0.51 1.92 5.09E-03 
ST_TUMOR_NECROSIS_FACTOR_PATHWAY 28 0.64 1.91 5.10E-03 
PYRIMIDINE_METABOLISM 55 0.54 1.91 5.39E-03 
KNUDSEN_PMNS_UP 65 0.53 1.91 5.40E-03 
NFKBPATHWAY 23 0.65 1.90 5.53E-03 
HEARTFAILURE_VENTRICLE_DN 56 0.53 1.90 5.62E-03 
CMV_UV-CMV_COMMON_HCMV_6HRS_UP 17 0.70 1.90 6.00E-03 
ABBUD_LIF_UP 45 0.56 1.88 7.06E-03 
HPV31_DN 37 0.57 1.88 7.03E-03 
LOTEM_LEUKEMIA_UP 22 0.65 1.88 7.17E-03 
TPA_SENS_MIDDLE_UP 55 0.54 1.88 7.59E-03 
CASPASEPATHWAY 20 0.67 1.88 7.62E-03 
UVC_HIGH_D3_DN 35 0.59 1.87 7.75E-03 
WANG_MLL_CBP_VS_GMP_UP 42 0.56 1.87 8.33E-03 
MARSHALL_SPLEEN_BAL 25 0.62 1.86 9.11E-03 
XU_CBP_UP 25 0.61 1.86 9.64E-03 
MUNSHI_MM_VS_PCS_UP 64 0.51 1.86 9.70E-03 
GENOTOXINS_ALL_24HRS_REG 22 0.64 1.86 9.65E-03 
 
ES = enrichment score; NES = normalized enrichment score; FDR = false discovery rate  
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Appendix 7 
 
Significantly altered gene sets by high DE/saline compared to air/saline 
 
NAME SIZE ES NES NOM p-val 
WANG_MLL_CBP_VS_GMP_UP 42 0.5829 1.8836 < 1.00E-06 
HSC_MATURE_SHARED 169 0.4647 1.8517 < 1.00E-06 
CARIES_PULP_HIGH_UP 68 0.5137 1.8385 < 1.00E-06 
HSC_MATURE_ADULT 232 0.4448 1.8207 < 1.00E-06 
NEMETH_TNF_DN 26 0.5976 1.7882 0.00430 
SA_MMP_CYTOKINE_CONNECTION 15 0.6905 1.7827 0.00938 
UVB_NHEK3_C2 35 0.5643 1.7761 0.00546 
GSK3PATHWAY 26 0.5953 1.7462 0.00147 
ZHAN_PCS_MULTIPLE_MYELOMA_SPKD 20 0.6155 1.7248 0.00436 
TAKEDA_NUP8_HOXA9_16D_DN 126 0.4403 1.7221 < 1.00E-06 
CORDERO_KRAS_KD_VS_CONTROL_DN 48 0.5109 1.7068 < 1.00E-06 
LE_MYELIN_UP 91 0.4602 1.6978 0.00122 
NI2_MOUSE_UP 40 0.5196 1.6940 0.00409 
YANG_OSTECLASTS_SIG 39 0.5290 1.6935 0.00955 
IGF1MTORPATHWAY 19 0.6039 1.6913 0.01351 
CHEN_HOXA5_TARGETS_UP 135 0.4345 1.6912 < 1.00E-06 
UVB_NHEK3_C5 30 0.5573 1.6886 0.00980 
HOHENKIRK_MONOCYTE_DEND_DN 100 0.4442 1.6822 0.00122 
TENEDINI_MEGAKARYOCYTIC_GENES 47 0.5038 1.6754 0.00530 
HCC_SURVIVAL_GOOD_VS_POOR_DN 118 0.4318 1.6661 0.00118 
 
ES = enrichment score; NES = normalized enrichment score; NOM p-val = nominal p-
value  
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Appendix 8 
 
Significantly altered gene sets by high DE/OVA compared to air/OVA 
 
NAME SIZE ES NES NOM p-val 
ELECTRON_TRANSPORT_CHAIN 86 0.5388 1.8950 < 1.00E-06 
MOOTHA_VOXPHOS 73 0.5432 1.8901 < 1.00E-06 
CANTHARIDIN_DN 45 0.5841 1.8698 < 1.00E-06 
WANG_MLL_CBP_VS_GMP_UP 42 0.5782 1.8590 < 1.00E-06 
FETAL_LIVER_VS_ADULT_LIVER_GNF2 53 0.5481 1.8214 < 1.00E-06 
LVAD_HEARTFAILURE_DN 33 0.5996 1.8206 < 1.00E-06 
MITOCHONDRIA 355 0.4661 1.7823 < 1.00E-06 
GLUTATHIONE_METABOLISM 28 0.5990 1.7704 0.0012 
FLECHNER_KIDNEY_TRANSPLANT_ 
REJECTION_UP 72 0.5018 1.7340 < 1.00E-06 
CMV_HCMV_TIMECOURSE_14HRS_UP 33 0.5748 1.7278 0.0012 
WIELAND_HEPATITIS_B_INDUCED 71 0.4953 1.7061 < 1.00E-06 
INNEREAR_UP 34 0.5598 1.7037 0.0012 
HUMAN_MITODB_6_2002 352 0.4416 1.7015 < 1.00E-06 
ROSS_MLL_FUSION 60 0.5003 1.6858 0.0022 
AMINOACYL_TRNA_BIOSYNTHESIS 18 0.6183 1.6649 0.0076 
PYRIMIDINE_METABOLISM 55 0.5008 1.6546 0.0011 
FATTY_ACID_DEGRADATION 23 0.5875 1.6440 0.0036 
OXIDATIVE_PHOSPHORYLATION 55 0.4895 1.6302 0.0011 
ABBUD_LIF_UP 45 0.5048 1.6222 0.0045 
ROS_MOUSE_AORTA_UP 23 0.5807 1.6160 0.0086 
 
ES = enrichment score; NES = normalized enrichment score; NOM p-val = nominal p-
value 
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